A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Reference |
|---|
| "End-stage human heart failure is the common final manifestation of a group of heterogeneous diseases, and it is usually accompanied by myocardial hypertrophy." | ( Eschenhagen, T; Mende, U; Schmitz, W; Scholz, H, 1992) |
| "Congestive heart failure is a syndrome common in the United States, especially in elderly patients." | ( Parmley, WW, 1992) |
| "Congestive heart failure is the most common cause of death in young adults with thalassaemia major." | ( Bellone, P; Derchi, G; Forni, GL; Jappelli, S; Lupi, G; Randazzo, M; Vecchio, C; Zino, V, 1992) |
| "Heart failure is associated with poor prognosis, but recent large-scale investigations have generated valuable and practical information to help improve clinical management and patient survival." | ( Oldershaw, PJ, 1992) |
| "Congestive heart failure is a condition associated with increased plasma norepinephrine levels." | ( D'Onofrio, F; De Riu, S; Marrazzo, G; Paolisso, G; Varricchio, M; Verza, M, 1991) |
| "The prognosis of heart failure is severe and approximately half of the patients die suddenly." | ( Storstein, L, 1990) |
| "Severe congestive heart failure is a fatal illness." | ( Yancy, CW, 1991) |
| "Heart failure is known to impair arterial baroreceptor control of heart rate." | ( Ferraro, N; Frey, MJ; Lanoce, V; Wilson, JR, 1990) |
| "Congestive heart failure is characterized by excessive neuro-humoral excitation as evidenced by direct recordings of sympathetic activity and by increased plasma levels of catecholamines, renin, angiotensin II and arginine vasopressin." | ( Shepherd, JT, 1990) |
| "Common causes of heart failure are coronary artery disease, hypertension, cardiomyopathies, valvular heart diseases and congenital heart diseases, for the incidence of which coronary artery disease is most frequently responsible." | ( Rudolph, W, 1990) |
| "The pathogenesis of heart failure is not yet fully understood." | ( Belch, JJ; Bridges, A; Chopra, M; McLay, J; McMurray, J; Scott, N; Smith, WE, 1990) |
| "Congestive heart failure is characterized by both disturbances in electrolyte homeostasis and neuro-hormonal regulation." | ( Francis, GS, 1990) |
| "Heart failure is an additional cause of raised serum concentration of C-reactive protein but the pathological importance of this feature is not yet known." | ( Cobbe, SM; Pye, M; Rae, AP, 1990) |
| "Heart failure is a complex cardiovascular syndrome affording many pharmacotherapeutic targets." | ( Taylor, SH, 1989) |
| "Congestive heart failure is a complex clinical syndrome characterized by circulatory and metabolic abnormalities." | ( Francis, GS, 1989) |
| "1." | ( Gurné, O; Hanet, C; Pouleur, H; Rousseau, MF, 1989) |
| "Congestive heart failure is a common clinical syndrome, with a relatively poor prognosis in its advanced stages." | ( Parmley, WW, 1989) |
| "Heart failure is a common cardiovascular disorder that increases in prevalence with age." | ( Fisher, MB; Giles, TD; Rush, JE, 1988) |
| "Congestive heart failure is the most arrhythmogenic disorder in cardiovascular medicine." | ( Gottlieb, SS; Kessler, PD; Packer, M, 1986) |
| "Congestive heart failure is a complex clinical syndrome characterized by striking abnormalities of the autonomic nervous system." | ( Cohn, JN; Francis, GS, 1986) |
| "Heart failure is characterized by hyperactivity of sympathetic pathways and parasympathetic withdrawal." | ( Giles, TD; Quiroz, AC; Sander, GE; Thomas, MG, 1986) |
| "Congestive heart failure is an especially disabling consequence in up to 49% of the age-class 75 to 80 years." | ( Bertel, O; Marx, B; Nägeli, B, 1989) |
| "Heart failure is characterized by a reduction in atrial ANF and an increase in ventricular ANF." | ( Ackermann, DM; Burnett, JC; Edwards, BS; Lee, ME; Reeder, GS; Wold, LE, 1988) |
| "Congestive heart failure is characterized by increased circulating levels of ANF; however, there appears to be an attenuation in the renal response to the hormone." | ( Burnett, JC; Edwards, BS; Zimmerman, RS, 1987) |
| "Congestive heart failure is an unusual complication of the hyperreninemia of Wilms' tumors." | ( Goertz, KK; Lowman, JT; Poisner, AM; Stine, KC, 1986) |
| "Congestive heart failure is a clinical syndrome with inadequate cardiac output and increased venous pressure, characterized by hyperfunction of the sympatho-neuro-endocrine system, favoring maximal vasoconstriction in non-essential organs and retention of salt and water." | ( Rutishauser, W, 1986) |
| "Congestive heart failure is a complex physiopathological state where both myocardial hypo-contraction and excessive peripheral vasoconstriction lead to lower cardiac output." | ( Hannedouche, T; Saoudi, N, 1987) |
| "Congestive heart failure is associated with hypoperfusion to various organs including the sites of drug clearance, i." | ( Dickstein, K; Shammas, FV, 1988) |
| "Congestive heart failure is a serious health-care problem that is associated with a high mortality." | ( DiBianco, R, 1988) |
| "Usually congestive heart failure is considered to develop as a vicious cycle in which impaired cardiac output, increased peripheral resistance, decreased renal blood flow, increased renin release and further increased peripheral resistance and decreased cardiac output are important constituents." | ( Wennmalm, A, 1986) |
| "Congestive heart failure is characterized by peripheral circulatory abnormalities including arterial and venous vasoconstriction and redistribution of regional blood flow." | ( Fournier, JF; Hannedouche, T, 1987) |
| "Heart failure is a major health problem, particularly among the elderly who experience the long term consequence of coronary artery disease." | ( Blakeley, C; Heaney, L; Hughes, J; Manglal-Lan, E; Pacholik, C; Weber, KT, 1987) |
| "Congestive heart failure is accompanied by a number of compensatory mechanisms that may overshoot the mark." | ( Parmley, WW, 1985) |
| "Chronic congestive heart failure is a frequently occurring disease associated with an impaired quality of life and significant mortality rate." | ( Applefeld, MM, 1986) |
| "Chronic congestive heart failure is a state with reduced digoxin clearance by the kidney, which could lead to digoxin intoxication not explicable by overdose, reduced renal function or the effect of interacting drugs." | ( Koorevaar, G; Naafs, MA; Schopman, W; Silberbusch, J; van der Hoek, C; van Duin, S, 1985) |
| "Congestive heart failure is frequently associated with elevated systemic vascular resistance." | ( Sullivan, JM, 1983) |
| "Signs of congestive heart failure are absent." | ( Ebrecht, G; Jacob, R; Jörg, E; Kissling, G; Rupp, H; Takeda, N, 1984) |
| "Finally chronic heart failure is a terminal condition of relatively short duration so that clinical trials designed to test the efficacy of a drug treatment will fail if they are continued for more than a brief period, as all patients will die." | ( Storstein, L; Taylor, SH, 1983) |
| "Congestive heart failure is a serious pathological heart state which is manifested by cardiorespiratory signs and symptoms." | ( Duncklee, JE, 1984) |
| "Congestive heart failure is usually accompanied by cardiovascular signs of an increased sympathetic and a decreased parasympathetic efferent activity." | ( Malliani, A; Pagani, M, 1983) |
| "Heart failure is associated with a reduction in tissue norepinephrine concentration, catecholamine fluorescence, and tyrosine hydroxylase activity." | ( Burgess, JH; Cousineau, D; Rose, CP, 1983) |
| "Heart failure is a syndrome with distinct clinical signs and symptoms." | ( Andrews, V; Janicki, JS; Weber, KT, 1982) |
| "Chronic heart failure is associated with neurohumoral activation and alterations of the peripheral circulation and skeletal muscle." | ( Drexler, H; Hornig, B; Jeserich, M; Kurz, S; Münzel, T, 1995) |
| "Congestive heart failure is the end product of a progressive series of events resulting from acute myocardial damage." | ( Dzau, VJ; Gibbons, GH; Pratt, R, 1994) |
| "Congestive heart failure is a debilitating disease characterized by impaired cardiac function with accompanying activation of a variety of neural and hormonal counter-regulatory systems." | ( Cox, HS; Esler, MD; Jennings, GL; Kaye, DM; Lambert, GW; Lefkovits, J; Turner, AG, 1995) |
| "Chronic heart failure is associated simultaneously with impairment of endothelium-dependent vasodilatation and with excess production of NO via the inducible NO synthase (iNOS), although it is unclear whether the latter ameliorates or exacerbates ventricular dysfunction." | ( Dusting, GJ; Macdonald, PS, 1995) |
| "The development of heart failure is associated with a remarkable increase in the expression of a local RAS in the heart, which may contribute to the pathogenesis of this clinical syndrome." | ( Abassi, ZA; Keiser, HR; Pieruzzi, F, 1995) |
| "Since congestive heart failure is characterized by abnormal intracellular Ca2+ homeostasis, we sought to delineate MRPES behavior before and after the production of heart failure to obtain insights into the relation between altered mechanical performance and Ca2+ handling." | ( Freeman, GL; Prabhu, SD, 1995) |
| "Congestive heart failure is characterized by a clear-cut impairment of arterial compliance of medium-sized arteries, but whether this alteration is irreversible or can be favorably affected by cardiovascular drugs currently used in congestive heart failure treatment is unknown." | ( Carugo, S; Failla, M; Giannattasio, C; Grassi, G; Mancia, G; Mangoni, AA; Pozzi, M; Stella, ML; Turrini, D, 1995) |
| "Heart failure is commonly associated with high plasma concentrations of endothelin-1, a powerful vasoconstrictor produced by endothelium." | ( Bertel, O; Hunziker, P; Jones, R; Kim, J; Kiowski, W; Müller, P; Oechslin, E; Schmitt, R; Sütsch, G, 1995) |
| "Patients with heart failure are known to demonstrate periodic respiration during sleep." | ( Andreas, S; Kreuzer, H; Mohr, FW, 1995) |
| "Chronic congestive heart failure is one of the risk groups of acquired hypercoagulant and hyperviscous state." | ( Mayer, J; Novotný, J; Spinar, J; Spinarová, L; Vítovec, J, 1995) |
| "The term "heart failure" is used to describe the pathophysiological state in which an abnormality of cardiac function is responsible for failure of the heart to pump blood at a rate commensurate with the requirements of the metabolizing tissues, or to do so only from an elevated filling pressure." | ( Kitabatake, A, 1995) |
| "Congestive heart failure is characterized by avid sodium retention and a blunted renal response to exogenous and endogenous atrial natriuretic peptide." | ( Abassi, ZA; Golomb, E; Keiser, HR; Kotob, S; Pieruzzi, F, 1995) |
| "Congestive heart failure is closely related to myocardial sympathetic nerve function." | ( Azuma, A; Ito, K; Kohno, Y; Miyao, K; Nakagawa, M; Ohtsuki, K; Shiga, K; Sugihara, H; Taniguchi, Y; Terada, K, 1995) |
| "Heart failure is a major and increasing public health problem." | ( Ghali, JK, 1995) |
| "Congestive heart failure is associated with chronotropic and inotropic hyporesponsiveness to adrenergic stimulation." | ( Bilezikian, JP; Goldsmith, RL; Gratch, M; Horn, EM; Kukin, ML; McCarty, M; Medina, N; Neuberg, GW; Packer, M; Yushak, M, 1995) |
| "Chronic heart failure is characterized by increased sympathetic activity and decreased parasympathetic activity." | ( Bigger, JT; Goldsmith, RL; Krum, H; Packer, M, 1995) |
| "Heart failure is a pathophysiological state resulting from disturbed cardiac function." | ( André, C; Barros, F; Campos, PM; Centeno, AM; Costa, P; Fernandes, SV; Godinho, F; Pinto, S; Reis-Santos, K; Serra, D, 1994) |
| "Heart failure is today one of the most serious health problems of modern industrialized societies." | ( Dessì-Fulgheri, P; Paci, MV; Rappelli, A, 1994) |
| "Congestive heart failure is characterized by profound alterations in systemic haemodynamics as well as in neurohumoral profile with activation of the sympathetic nervous system, reninangiotensin axis, plasma vasopressin and atrial natriuretic peptides, i." | ( Grassi, G; Mancia, G, 1994) |
| "The signs of heart failure are tachycardia, tachypnea and hepatomegaly." | ( Stocker, F; Wyler, F, 1994) |
| "Congestive heart failure is a complex disorder with a poor long-term prognosis." | ( Miller, MM, 1994) |
| "Heart failure is a syndrome characterized by the activation of neurohumoral mechanisms (sympathoadrenergic, renin-angiotensin, vasopressin) which cause peripheral vasoconstriction, sodium retention and myocardial hypertrophy." | ( Dei Cas, L; Metra, M; Visioli, O, 1993) |
| "Although heart failure is generally accompanied by sympathoexcitation, the integrity of cardiac sympathetic nerve function in heart failure remains controversial, particularly in relation to nerve firing activity and to the capacity of sympathetic nerves to recapture norepinephrine." | ( Esler, MD; Jennings, G; Kaye, DM; Lambert, GW; Lefkovits, J; Morris, M, 1994) |
| "Congestive heart failure is a condition associated with increased plasma norepinephrine levels, which have been demonstrated to impair glucose handling." | ( D'Amore, A; D'Onofrio, F; Galzerano, D; Gambardella, A; Paolisso, G; Rubino, P; Teasuro, P; Varricchio, M; Verza, M, 1994) |
| "Chronic heart failure is associated with a poor prognosis and reduced survival rates." | ( Eagle, KA; Kuntz, KM; Paul, SD; Weinstein, MC, 1994) |
| "Congestive heart failure is associated with impaired hemodynamic performance and reduced mechanical efficiency." | ( Bersin, RM; Chatterjee, K; de Marco, T; Henderson, GN; Khorrami, P; Klinski, C; Kwasman, M; Lau, D; Tanaka, K; Wolfe, C, 1994) |
| "Heart failure is associated with severe cardiac adrenergic dysfunction manifested by reduced MIBG activity and increased heterogeneity in the LV distribution of MIBG." | ( Armstrong, PW; Freeman, MR; Grima, EA; Hsia, TW; Simmons, WW, 1994) |
| "Heart failure is usually characterized by a relative insensitivity to atrial natriuretic factor (ANF)." | ( Barthelemy, C; Bouanani, N; Carayon, A; Crozatier, B; Eurin, J; Isnard, R; Komajda, M; Legrand, JC; Maistre, G, 1993) |
| "Patients with heart failure are less able than normal subjects to increase blood pressure during arterial baroreceptor unloading, but they can reduce blood pressure appropriately during baroreceptor stimulation." | ( Creager, MA; Creager, SJ, 1994) |
| "The onset of heart failure is associated with complex neurohumoral, cardiac, and vascular changes." | ( Auzépy, P; Depret, J; Giudicelli, JF; Richard, C; Thuillez, C, 1993) |
| "Congestive heart failure is a clinical syndrome characterized by increased cardiac volume and pressure overload with an inability to excrete a sodium load, which is associated with increased activity of systemic neurohumoral and local autocrine and paracrine mechanisms." | ( Brandt, RR; Burnett, JC; Redfield, MM; Wright, RS, 1993) |
| "The term heart failure is a complex of clinical syndromes caused by "neuroendocrine" compensatory responses that are renal, neural, hormonal and hemodynamic in nature." | ( Rosenfeld, JB; Sclarovsky, S; Shmuely, H, 1993) |
| "Congestive heart failure is a clinical syndrome characterized by neuroendocrine activation." | ( Cohn, JN; Francis, GS; Goldman, S; Johnson, G; Rector, TS; Simon, A, 1993) |
| "Congestive heart failure is a condition often requiring repeated admission to hospital." | ( Levinoff Roth, SN; Moe, G, 1993) |
| "Progressive heart failure is a further manifestation of established septic shock." | ( Brady, AJ, 1995) |
| "Chronic heart failure is associated with endothelial dysfunction including impaired endothelium-mediated, flow-dependent dilation (FDD)." | ( Drexler, H; Hornig, B; Maier, V, 1996) |
| "Heart failure is a physiopathological condition, with an increasing incidence and prevalence, involving the action of a series of mechanisms known as 'compensators', which are phylogenetically ready to normalize minute volume and blood pressure." | ( Cosín Aguilar, J; Cruz Fernández, JM; de Teresa Galván, E; Ferreira Montero, IJ; López-Sendón, J; Soler Soler, J; Tamargo Menéndez, J, 1996) |
| "Heart failure is a common clinical syndrome in which left ventricular dysfunction results in vasoconstriction, volume overload, activity intolerance, reduced quality of life, and high mortality." | ( Moser, DK, 1996) |
| "Symptomatic heart failure is accompanied by diastolic ventricular dysfunction due largely to an extensive reactive and reparative fibrosis." | ( Campbell, SE; Sun, Y; Weber, KT, 1995) |
| "Human heart failure is associated with prolonged relaxation and prolonged Ca2+ transients which indicates an impaired function of the sarcoplasmic reticulum (SR) and may be detrimental for cardiac function." | ( Bokník, P; Eschenhagen, T; Jones, LR; Linck, B; Müller, FU; Neumann, J; Nose, M; Schmitz, W; Scholz, H, 1996) |
| "Congestive heart failure is a frequent disorder with an estimated prevalence of 0." | ( Buser, P; Osswald, S; Pfisterer, M; Rickenbacher, P, 1996) |
| "Heart failure is at the same time a muscular and a neurohormonal disease." | ( Perrenoud, JJ, 1996) |
| "Congestive heart failure is a frequent cardiovascular disease with a poor prognosis in advanced stages." | ( Binggeli, C; Noll, G; Wenzel, RR, 1996) |
| "Heart failure is a physiopathological condition, with an increasing incidence and prevalence, involving the action of a series of mechanisms known as "compensators", which are phylogenetically ready to normalize minute volume and blood pressure." | ( Cosín Aguilar, J; Cruz Fernández, JM; de Teresa Galván, E; Ferreira Montero, IJ; López-Sendón, J; Soler Soler, J; Tamargo Menéndez, J, 1996) |
| "Heart failure is a physiopathological condition, with an increasing incidence and prevalence, involving the action of a series of mechanisms known as "compensators", which are phylogenetically ready to normalize minute volume and blood pressure." | ( Cosín Aguilar, J; Cruz Fernández, JM; de Teresa Galván, E; Ferreira Montero, IJ; López-Sendón, J; Soler Soler, J; Tamargo Menéndez, J, 1996) |
| "Chronic heart failure is associated both with impairment of endothelium-dependent vasodilatation and with excess production of NO via the inducible NO synthase (iNOS), although it is unclear whether the latter assists or compromises ventricular contractile performance under these conditions." | ( Dusting, GJ, 1996) |
| "Congestive heart failure is the final common pathway of diverse etiologies that result in impaired systolic and diastolic function, deleterious activation of neurohumoral pathways, and high morbidity and mortality." | ( Wagoner, LE; Walsh, RA, 1996) |
| "Congestive heart failure is characterized by contractile dysfunction and frequent complex ventricular ectopy." | ( Adams, KF; Patterson, JH; Sueta, CA, 1995) |
| "Heart failure is a problem of increasing importance in cardiovascular medicine." | ( Koch, WJ; Lefkowitz, RJ; Milano, CA; Rockman, HA, 1996) |
| "Heart failure is common in the elderly and is associated with a significant morbidity and mortality." | ( King, D, 1996) |
| "Congestive heart failure is a major public health problem in Western countries." | ( Doughty, RN; Sharpe, N, 1997) |
| "Severe heart failure is associated with an intense sympathetic nerve hyperactivity." | ( Bergmann-Sverrisdottir, Y; Casale, R; Elam, M; Friberg, P; Mortara, A; Rundqvist, B, 1997) |
| "Congestive heart failure is a clinical syndrome in which the capacity of the heart to maintain cardiac output is impaired." | ( Ceconi, C; Confortini, R; Curello, S; Ferrari, F; Ferrari, R; Pepi, P; Visioli, O, 1996) |
| "Two signatures of heart failure are activation of the sympathetic nervous system and catecholamine desensitization." | ( Asai, K; Ghaleh-Marzban, B; Kudej, RK; Mirsky, I; Patrick, TA; Sato, N; Shannon, RP; Shen, YT; Uechi, M; Vatner, DE; Vatner, SF, 1997) |
| "Heart failure is associated with pathobiochemical changes that can reduce the responsiveness of the myocardium to positive inotropic agents." | ( Erdmann, E, 1997) |
| "Since chronic heart failure is a state of impaired oxidative metabolism, we sought to determine whether serum uric acid concentrations correlate with measures of functional capacity and disease severity." | ( Anker, S; Chua, TP; Coats, AJ; Godsland, IF; Leyva, F; Stevenson, JC; Swan, JW; Wingrove, CS, 1997) |
| "Heart failure is often preceded by isolated systolic hypertension, but the effectiveness of antihypertensive treatment in preventing heart failure is not known." | ( Applegate, WB; Berge, KG; Berkson, DM; Black, HR; Blaufox, MD; Cohen, JD; Curb, JD; Cutler, J; Davis, BR; Grimm, RH; Kostis, JB; Lacy, CR; McDonald, R; Perry, HM; Schron, E; Smith, WM; Wassertheil-Smoller, S, 1997) |
| "Patients with heart failure are particularly susceptible to the negative effects of calcium channel blockers because the failing heart demonstrates a defect in the delivery of calcium to the contractile proteins, and an attenuation of the normal sympathetic reflexes." | ( Dickstein, K; Gundersen, T; Hole, T; Kjekshus, J; Myhre, ES; Rønnevik, PK; Westheim, AS, 1997) |
| "Chronic heart failure is associated with loss of muscle bulk that may be related to alteration of the balance between catabolism and anabolism." | ( Anker, SD; Clark, AL; Coats, AJ; Hellewell, PG; Kemp, M; Salsbury, C; Teixeira, MM, 1997) |
| "Heart failure is a common problem associated with considerable mortality and morbidity." | ( Birks, EJ; Yacoub, MH, 1997) |
| "Symptoms of heart failure are commonly managed with the use of diuretics, vasodilators, and positive inotropes or digoxin." | ( Cohn, JN, 1997) |
| "The heart failure is associated with reduced myocardial energy stores and absence of cardiac hypertrophy." | ( Armstrong, PW; Grima, EA; Howard, RJ; Moe, GW, 1995) |
| "Heart failure is associated with an increase in plasma nitrate levels, and yet most experimental evidence demonstrates a reduction in endothelial nitric oxide production during heart failure." | ( Bernstein, RD; Forfia, P; Hintze, TH; Ochoa, F; Ochoa, M; Tuzman, J; Vogel, T; Zhang, X; Zhao, G, 1997) |
| "Chronic heart failure is a complex syndrome: as such it may perhaps be too simplistic to expect any single parameter to be universally predictive of drug effects on mortality, especially when each drug works by different mechanisms." | ( Struthers, AD; Yee, KM, 1997) |
| "Congestive heart failure is a clinical condition associated with alterations in the normal balance of neurohumoral agents and factors acting on the vascular wall." | ( Altieri, PI; Crespo, MJ; Escobales, N, 1997) |
| "The cause of heart failure is usually coronary sclerosis and, less often, hypertension or a valvular defect." | ( Düren, DR; Lie, KI; Tukkie, R; van den Brink, RB, 1997) |
| "The progression of heart failure is related to activation of neuroendocrine hormone systems." | ( Pieske, B, 1998) |
| "Heart failure is defined as a malfunction of the cardiac muscle." | ( Pacher, R, 1998) |
| "Heart failure is a challenge for modern cardiology, Common, disabling, lethal, this condition represents a major economic burden for Public Health." | ( Kulbertus, H, 1998) |
| "Heart failure is a major medical problem in the elderly." | ( Boomsma, F; Crijns, HJ; de Kam, PJ; Hampton, JR; Lie, KI; Man in't Veld, AJ; van Veldhuisen, DJ, 1998) |
| "Heart failure is associated with activation of cytokines and expression of inducible nitric oxide synthase (NOS II), which generates NO from L-arginine." | ( Brodde, OE; Drexler, H; Hasenfuss, G; Kästner, S; Strobel, A; Studer, R, 1998) |
| "As a consequence, heart failure is nowadays considered as a complex disease, not merely characterized by haemodynamic disturbances." | ( Brutsaert, DL; De Keulenaer, GW, 1998) |
| "Given that chronic heart failure is a hypercatabolic state, we sought to determine whether congestive heart failure involves elevations in plasma leptin levels." | ( Anker, SD; Coats, AJ; Egerer, K; Kox, WJ; Leyva, F; Stevenson, JC, 1998) |
| "Heart failure is a common clinical problem in patients with cardiovascular disease." | ( Fowler, MB, 1998) |
| "Chronic heart failure is associated with hyperuricaemia and elevations in circulating markers of inflammation." | ( Anker, SD; Coats, AJ; Godsland, IF; Hellewell, PG; Kox, WJ; Leyva, F; Poole-Wilson, PA; Teixeira, M, 1998) |
| "Chronic congestive heart failure is a common, often lethal disorder of cardiac contractility." | ( Altschuld, RA; Hashimoto, K; Marbán, E; McCune, S; Pérez, NG, 1999) |
| "Heart failure is a physiologically delicate condition that can decompensate with excess dietary salt intake or over diuresis, or compensate with cautious therapy designed to block the sodium retention and simultaneously interrupt excessively activated neurohumoral mechanisms." | ( Hall, WD, 1999) |
| "Heart failure is a clinical syndrome that is predominantly caused by cardiovascular disorders such as coronary heart disease and hypertension." | ( Feenstra, J; Grobbee, DE; Remme, WJ; Stricker, BH, 1999) |
| "Heart failure is characterized by increased vascular resistance and water retention." | ( Dietz, R; Krause, EG; Pagel, I; Scheuermann, M; Willenbrock, R, 1999) |
| "Chronic heart failure is one of a number of disorders associated with the development of a wasting syndrome." | ( Anker, SD; Clark, AL; Coats, AJ; Hellewell, PG; Hooper, J; Kemp, M; Leyva, F; Ponikowski, PP; Poole-Wilson, PA; Rauchhaus, M; Teixeira, MM, 1999) |
| "Chronic heart failure is characterized by a selective potentiation of ventilatory and sympathetic responses to central chemoreceptor activation by hypercapnia." | ( Kato, M; Narkiewicz, K; Pesek, CA; Somers, VK; van de Borne, PJ, 1999) |
| "Chronic heart failure is associated with impaired renal function, which may worsen during therapy." | ( Chertow, GM; Stevenson, LW; Weinfeld, MS, 1999) |
| "Heart failure is a major and still growing medical and epidemiological problem, but in the last 10-20 years great progress has been made in its treatment." | ( van Veldhuisen, DJ, 1999) |
| "Heart failure is associated with increased sympathetic nerve activity." | ( Edvinsson, L; Feng, Q; Hedner, T; Lu, X; Sun, X, 1999) |
| "Heart failure is a common and increasing public problem." | ( Halawa, B; Jołda-Mydłowska, B; Mazurek, W, 1999) |
| "Since congestive heart failure is associated with various metabolic abnormalities including a deficiency of carnitine, we examined the effects of propionyl L-carnitine, a carnitine derivative, in animals with congestive heart failure." | ( Dhalla, KS; Dhalla, NS; Ferrari, R; Ganguly, PK; Sethi, R, 1999) |
| "Human heart failure is associated with a disturbed intracellular calcium (Ca2+) homeostasis." | ( Bieligk, U; Dieterich, S; Hasenfuss, G; Prestle, J; Preuss, M, 1999) |
| "Congestive heart failure is characterized by a skeletal muscle myopathy with muscle bulk loss." | ( Ambrosio, GB; Libera, LD; Sandri, M; Vescovo, G; Zennaro, R, 1999) |
| "Heart failure is increasing in both incidence and prevalence and is associated with a high mortality." | ( Parmley, WW, 2000) |
| "Heart failure is a condition of increased neurohormonal stimulation the level of which is affected by both the rate of clinical advancement of the disease and by the manner of its treatment." | ( Jabłecka, A, 1999) |
| "Heart failure is associated with abnormal endothelium-dependent vasodilation." | ( Bank, AJ; Kubo, SH; Lee, PC, 2000) |
| "Chronic heart failure is accompanied by autonomic impairment and analysis of heart rate variability can be used to examine autonomic modulation of heart rate." | ( Brouwer, J; Crijns, HJ; de Kam, PJ; Haaksma, J; Tjeerdsma, G; van Veldhuisen, DJ, 2000) |
| "Heart failure is a highly complex, progressive and deadly disease." | ( Stanek, B, 2000) |
| "Heart failure is becoming the most prevalent cardiovascular disorder in the older population, in part as a consequence of the declining fatality rate of hypertension, myocardial infarction and ictus, resulting in progressive increment of older subjects at increased risk of developing heart failure." | ( Rossi, G, 2000) |
| "Congestive heart failure is associated with cardiac adrenergic nerve terminal changes and beta-adrenoceptor density downregulation." | ( Armstrong, J; Dong, E; Hagen, J; Kawai, H; Liang, CS; Mohan, A; Stevens, SY, 2000) |
| "Heart failure is regularly associated with excessive elevation of Nt-proANP in plasma." | ( Hall, C; Holmström, H; Stokke, TO; Thaulow, E, 2000) |
| "Heart failure is common, causes major disability and often shortens life." | ( , 2000) |
| "Chronic heart failure is associated with a significant increase in plasma big endothelin-1 and C-terminal fragment immunoreactivity." | ( Davenport, AP; Ferro, CJ; Haynes, WG; Love, MP; McMurray, JJ; Plumpton, C; Webb, DJ, 2000) |
| "Heart failure is no longer conceptualized as a hemodynamic disorder resulting from changes in renal and hormonal function." | ( Jarvis, C; Kim, SD; Piano, MR, 2000) |
| "This subset of heart failure is most commonly associated with concentric left ventricular hypertrophy and ischemic states." | ( Beattie, S, 2000) |
| "Heart failure is a symptom complex of varied etiology associated with substantial mortality." | ( Behmer-Miller, KA; Hilleman, DE; Skrabal, MZ; Stading, JA, 2000) |
| "Heart failure is a common cause of hospitalization and death across the industrialized world." | ( Booth, RJ; Campbell, DJ; Mitchelhill, KI; Schlicht, SM, 2000) |
| "Congestive heart failure is a progressive disease with significant morbidity and mortality." | ( Haji, SA; Movahed, A, 2000) |
| "Congestive heart failure is a complex syndrome and one of the major cardiological problems of our time." | ( Avendaño, C; Gutiérrez-Iñiguez, MA; Marín, E; Marín, J; Rodríguez-Martínez, MA, 2000) |
| "Chronic heart failure is an increasing cause of hospital admission in the Netherlands and Belgium." | ( Missault, LH; van Veldhuisen, DJ, 2000) |
| "Heart failure is a leading cause of morbidity and mortality." | ( Lloyd, SJ; Mauro, VF, 2000) |
| "Acute heart failure is a common cause of referral and admission to hospital." | ( McMurray, JJ; Murdoch, DR, 2000) |
| "Congestive heart failure is a most arrhythmogenic disease that is responsible for many unexpected sudden deaths." | ( Seelig, MS, 2000) |
| "Chronic heart failure is associated with a decreased responsiveness of the heart to beta-adrenergic receptor agonists." | ( Baltus, D; Kübler, W; Lutz, S; Movsesian, M; Mura, R; Niroomand, F, 2001) |
| "Congestive heart failure is associated with impaired endothelial function in the peripheral systemic vasculature and with systemic release of inflammatory cytokines." | ( Dimmeler, S; Freyssinet, JM; Haendeler, J; Hugel, B; Mallat, Z; Rössig, L; Tedgui, A; Zeiher, AM, 2000) |
| "Heart failure is associated with an increase in plasma nitrate and nitrite (NOx)." | ( Hintze, TH; Laycock, S; Ochoa, M; Osorio, JC; Vogel, T; Xu, X, 2001) |
| "Development of heart failure is associated with an impairment of intracellular calcium handling." | ( Angelillo, N; Casaburi, C; Cittadini, A; De Simone, G; Di Rella, F; Ettari, G; Fazio, S; Longobardi, S; Morgan, JP; Riccio, G; Troise, A, 2000) |
| "Heart failure is widely prevalent and continues to be associated with high morbidity and mortality, even with currently recommended care." | ( Rivey, MP; Struckman, DR, 2001) |
| "Heart failure is emerging as a major component of the public health problem of cardiovascular disease as we move into the twenty-first century." | ( Adams, KF, 2001) |
| "Heart failure is a changing paradigm." | ( Francis, GS, 2001) |
| "Advanced chronic heart failure is a hypercatabolic state with an imbalance between anabolic and catabolic metabolism and finally progressive loss of both muscle mass and adipose tissue." | ( Figulla, HR; Gastmann, A; Krack, A; Küthe, F; Lotze, U; Richartz, BM, 2001) |
| "Heart failure is associated with reduction of exercise capacity that cannot be solely ascribed to reduced maximal oxygen uptake (VdotO2max)." | ( Lunde, PK; Schiøtz Thorud, HM; Sejersted, OM; Sjaastad, I, 2001) |
| "Chronic heart failure is characterized as a clinical disorder by exercise intolerance." | ( Ambrosio, GB; Dalla Libera, L; Vescovo, G, 2001) |
| "Heart failure is a common and growing public health problem, with increasing incidence and prevalence over the last 2 decades." | ( Castellanos, A; de Marchena, E; Lopera, G, 2001) |
| "Congestive heart failure is characterized by high levels of norepinephrine which is considered to be arrhythmogenic." | ( Baartscheer, A; de Bakker, JM; de Jonge, N; Opthof, T; Schumacher, C; van Ginneken, AC; Veldkamp, MW; Verkerk, AO, 2001) |
| "Heart failure is associated with a decreased variability in circadian systolic blood pressure." | ( Giles, TD; Given, MB; Hutchinson, H; Jones, R; Kerut, EK; Roffidal, LE; Tresznewsky, O, 2001) |
| "The course of heart failure is characterized by progressive LV deterioration associated with an increase in cardiac (natriuretic peptides) and predominantly extracardiac (norepinephrine, big endothelin [big ET]) hormone plasma levels." | ( Berger, R; Bergler-Klein, J; Bojic, A; Frey, B; Hartter, E; Hülsmann, M; Moser, P; Pacher, R; Stanek, B; Strametz-Juranek, J; Sturm, B, 2001) |
| "Mild heart failure is characterized by increases in atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) in the absence of activation of the renin-angiotensin-aldosterone system (RAAS)." | ( Burnett , JC; Chen, HH; Harty, GJ; Lainchbury, JG; Matsuda, Y, 2001) |
| "Congestive heart failure is characterized by a sympathetic activation that is coupled with a baroreflex impairment." | ( Bertinieri, G; Grassi, G; Mancia, G; Pierini, A; Seravalle, G; Turri, C, 2001) |
| "Heart failure is characterized by the inability of the myocardium to shorten sufficiently or to eject an adequate stroke volume to maintain normal perfusion of both the cardiac and the extracardiac organs." | ( Strauer, BE, 1990) |
| "Human congestive heart failure is characterized by complex neurohumoral activation associated with the up-regulation of vasoconstricting and salt-retaining mediators and the compensatory rise of counter-regulatory hormones." | ( Armbruster, FP; Bartsch, C; Baumann, G; Dschietzig, T; Laule, M; Richter, C; Stangl, K, 2001) |
| "Patients with heart failure are characterised by a disturbed sympathovagal balance, as could be shown by analyses of heart rate variability and baroreflexsensitivity." | ( Hennersdorf, MG; Hillebrand, S; Perings, C; Strauer, BE, 2001) |
| "Heart failure is characterized by neurohumoral alterations, such as activation of the sympathetic nervous system, stimulation of the renin-angiotensin system, increased activity of the endothelin system, increased production of norepinephrine, and increased circulating levels of cytokines." | ( Casado, S; López Farré, A, 2001) |
| "Heart failure is a leading cause of morbidity and mortality." | ( Cadnapaphornchai, MA; Gurevich, AK; Schrier, RW; Weinberger, HD, 2001) |
| "Congestive heart failure is characteristically associated with systemic vasoconstriction and impaired vasodilatory capacity, leading to decreased peripheral perfusion." | ( Akhter, W; Elkayam, U; Mehdi, S; Nikitina, A; Prakash, M; Subbiah, S, 2001) |
| "Heart failure is unique among the major cardiovascular disorders in that it alone is increasing in prevalence while there has been a striking decrease in other conditions." | ( Greenberg, B, 2001) |
| "Heart failure is associated with alterations in contractile parameters and accompanied by abnormalities in intracellular calcium homeostasis." | ( Bøkenes, J; Christensen, G; Hoen, IB; Holt, E; Lunde, PK; Sande, JB; Sjaastad, I; Tønnessen, T, 2002) |
| "Heart failure is a major and increasing cause of death and disability and accounts for significant resource use." | ( Cole, J; Tooley, JF; Weintraub, WS, 2002) |
| "Heart failure is not a simple defect in the pumping function of cardiac muscle, but rather a complex systemic inflammatory disease affecting many organ systems." | ( Farmer, JA; Koerner, MM; Lisman, KA; Stetson, SJ; Torre-Amione, G, 2002) |
| "Heart failure is one of the most common diagnoses and reason for hospitalization in the United States." | ( Capriotti, T, 2002) |
| "Congestive heart failure is a major health problem in the diabetic." | ( Lopaschuk, GD, 2002) |
| "Acute heart failure is a life-threatening medical emergency, most commonly occurring as an immediate or delayed complication of acute myocardial infarction (AMI), or resulting from severe hypertension or valvular defects (stenosis or incompetence)." | ( Chapman, PJ, 2002) |
| "Heart failure is a substantial cause of increased morbidity and mortality in the African-American population, with poorer prognosis versus white patients." | ( Ferdinand, DP; Ferdinand, KC; Serrano, CC, 2002) |
| "Heart failure is the number one hospital discharge diagnosis of older Americans." | ( Ahmed, A, 2002) |
| "Management of heart failure is estimated to consume 1% to 2% of total healthcare resources and recent data from the UK suggests this may be as high as 4% with hospital admissions accounting for approximately 70% of this expenditure." | ( Barry, M, 2002) |
| "Heart failure is characterized by a disturbed contractility and activation of neurohumoral mechanisms." | ( Beuckelmann, DJ, 2002) |
| "Congestive heart failure is associated with hyperuricemia and elevations in the levels of circulating markers for inflammation." | ( Gonsorcík, J; Kisel'ová, J; Olejníková, M; Olexa, P; Olexová, M; Tkác, I, 2002) |
| "Because heart failure is a progressive disease that often evolves from hypertrophy, we analyzed the RyR2 macromolecular complex in several animal models of cardiomyopathy that lead to heart failure, including hypertrophy, and at different stages of disease progression." | ( Burkhoff, D; D'Armiento, J; Gaburjakova, M; Gomez, AM; Guatimosim, S; Lederer, WJ; Marks, AR; Reiken, S; Vassort, G; Wang, J, 2003) |
| "Progression of heart failure is related to ventricular remodeling, a process associated to neurohormonal activation." | ( Anand, I; de Angelis, N; Latini, R; Masson, S, 2002) |
| "Heart failure is a common clinical problem, affecting at least 5 million Americans." | ( Keown, ML; Rahko, PS, 2002) |
| "Systolic heart failure is the most common cause of CHF presentations." | ( Gould, PA; Kaye, DM, 2002) |
| "Chronic heart failure is associated with high mortality and morbidity." | ( Frick, M; Gouya, G; Hügel, H; Pachinger, O; Pölzl, G; Ulmer, H, 2002) |
| "Heart failure is characterized by sodium and fluid retention, sympathetic overactivity, parasympathetic withdrawal, vasoconstrictor activation and cytokine elevation." | ( Aronson, D; Burger, AJ; Burger, MR, 2002) |
| "The development of heart failure is tightly correlated with a decrease in the stoichiometric ratio for FKBP12." | ( Doi, M; Hisaoka, T; Kobayashi, S; Kohno, M; Matsuzaki, M; Obayashi, M; Ohkusa, T; Okuda, S; Suetsugu, M; Tokuhisa, T; Yano, M, 2003) |
| "Chronic heart failure is characterised by functional deficiencies of the myocardium." | ( Becker, M; Henkel, T; Hoffmann, A; Kirsch, T; Leclair, S; Navé, BT; Roenicke, V; Stoss, O; Szado, T, 2003) |
| "Heart failure is known for alteration of cardiac catecholamine responsiveness involving adrenergic receptor (AR) down-regulation." | ( Bescond-Jacquet, A; Grynberg, A; Helies-Toussaint, C; Lucien, A; Morin, D; Tabbi-Anneni, I, 2003) |
| "Heart failure is the term used for a cardiovascular syndrome whose definition lacks uniform criteria." | ( Breithardt, G; Eckardt, L; Haverkamp, W, 2002) |
| "Since chronic heart failure is accompanied not only by endothelial dysfunction, but also by pro-inflammatory cytokine activation and enhanced formation of oxygen free radicals, it is tempting to speculate that statins might be an ideal candidate to treat certain features of this disease." | ( Anker, SD; Bassenge, E; von Haehling, S, 2003) |
| "Patients with heart failure are characterized by impaired nitric oxide-dependent endothelial vasodilation and, in addition, by reduced renal perfusion." | ( Bode-Böger, SM; Fliser, D; Graf, S; Haller, H; Kielstein, JT; Klein, G, 2003) |
| "Infarct-induced heart failure is usually associated with cardiac hypertrophy and decreased -adrenergic responsiveness." | ( Chedid, NG; Díaz G, LE; Masuda, MO; Quintero H, CC; Saraiva, RM, 2003) |
| "Heart failure is a common, lethal condition whose pathogenesis is poorly understood." | ( Armstrong, RC; Chandra, M; Factor, SM; Garantziotis, S; Kitsis, RN; Miao, W; Nguyen, K; Shirani, J; Wencker, D, 2003) |
| "Ischemic heart failure is induced by myocardial ischemia, which is probably the commonest cause of left ventricular systolic dysfunction." | ( Hori, M; Inoue, K, 2003) |
| "Ischemic heart failure is a significant source of morbidity and mortality, yet it has an unclear treatment strategy." | ( Borges-Neto, S; Bourque, JM; O'Connor, CM; Shaw, LK; Velazquez, EJ; Whellan, DJ, 2003) |
| "Heart failure is often treated with ACE inhibitors and diuretics although diuretic treatment could activate the renin-angiotensin system (RAS)." | ( Böhm, M; Itter, G; Jockenhövel, F; Kouchi, I; Linz, W; Seeland, U; Zolk, O, 2003) |
| "Congestive heart failure is extremely common in octogenarians and is associated with severe fatigue, shortness of breath, recurrent hospitalizations, and death." | ( Blum, M; Iaina, A; Keren, G; Schwartz, D; Sheps, D; Silverberg, DS; Wexler, D, 2003) |
| "Heart failure is a major health problem of epidemic proportions." | ( Ahokas, RA; Gerling, IC; Guntaka, RV; Kiani, MF; Postlethwaite, AE; Sun, Y; Warrington, KJ; Weber, KT, 2003) |
| "In most cases, heart failure is caused by left ventricular dysfunction due to coronary heart disease." | ( Jung, J; Schreiber, JU, 2003) |
| "Heart failure is associated with Cheyne-Stokes breathing, which fragments patients' sleep." | ( Crosthwaite, N; Davies, RJ; Jones, DR; Langford-Wiley, BA; Maskell, NA; Pepperell, JC; Stradling, JR, 2003) |
| "Heart failure is a common medical condition affecting nearly 5 million people each year in the United States, of whom 500,000 are newly diagnosed." | ( Baran, DA; Galin, I, 2003) |
| "Heart failure is the leading cause for hospitalization in the United States, resulting in over $8 billion in costs annually." | ( Gordon, C; Rempher, KJ, 2003) |
| "Heart failure is increasing in incidence and prevalence and is predominantly a condition of the elderly, which confers significant morbidity and mortality risks and places an enormous economic burden on the health care system and society." | ( Gaulden, L, 2003) |
| "Heart failure is also a major cause of hospital admissions; its amelioration and, as far as possible, prevention is therefore important in terms not only of morbidity and premature mortality for the individual patient, but also containment of healthcare costs." | ( Funder, JW, 2003) |
| "Congestive heart failure is a major public health problem in the United States, Canada, and other Western countries." | ( Collins, JF; Egan, D; Garg, R; Geller, N; Williford, WO; Yusuf, S, 2003) |
| "Chronic heart failure is widely recognised as a common and escalating problem that causes major disability and often shortens life." | ( Cowley, AJ; McKenzie, DB, 2003) |
| "Heart failure is characterized by sodium and fluid retention, sympathetic overactivation, parasympathetic withdrawal, vasoconstrictor activation and cytokine elevation." | ( Andréka, P; Kónya, L; Nádházi, Z; Szánthó, G; Takács, E; Tulassay, Z; Vándor, L, 2003) |
| "Heart failure is accompanied by stereotypic alterations in cardiac gene expression." | ( El-Armouche, A; Eschenhagen, T; Rau, T; Zolk, O, 2003) |
| "Heart failure is associated with increased sympathetic nervous stimulation that results in down-regulation of myocardial beta-1 receptors." | ( Ahmed, A, 2003) |
| "Diastolic heart failure is predominantly a disease of the elderly: at the age of 70 years, almost half of all patients with heart failure have diastolic heart failure." | ( Bronzwaer, JG; Kamp, O; Smulders, YM; Stehouwer, CD, 2003) |
| "Heart failure is a serious disorder associated with substantial morbidity and mortality." | ( Fung, JW; Kum, LC; Sanderson, JE; Yip, GW; Yu, CM, 2003) |
| "Heart failure is a leading cause of morbidity and mortality, but there are no reliable models based on readily available clinical variables to predict outcomes in patients taking angiotensin-converting enzyme (ACE) inhibitors." | ( Brophy, JM; Dagenais, GR; McSherry, F; Williford, W; Yusuf, S, 2004) |
| "The heart failure is a common, costly, disabling and fatal cardiac disorder with high mortality and a continuously growing health problem in the population." | ( Cserhalmi, L, 2003) |
| "Heart failure is the most common malignant disease in the developed world." | ( Cleland, JG; McGowan, J; Nikitin, N, 2004) |
| "Chronic heart failure is a multifactorial, progressive disease of many causes and is associated with complex ventricular remodeling." | ( Arusoglu, L; Becker, G; Böthig, D; El Banayosy, A; Heimann, P; Jacob, M; Kassner, A; Körfer, R; Mannherz, HG; Meyer, HE; Milting, H; Morshuis, M, 2004) |
| "Heart failure is a major and growing public health problem with a high mortality rate." | ( Akiyama, H; Arimoto, T; Fukui, A; Hirono, O; Kubota, I; Minamihaba, O; Miyamoto, T; Nitobe, J; Nozaki, N; Okada, A; Okuyama, M; Tachibana, H; Takahashi, H; Takahashi, K; Takeishi, Y; Yamauchi, S, 2004) |
| "Because heart failure is also associated with attenuated response to catecholamines, we examined the effects of propionyl L-carnitine (PLC) (a carnitine derivative) therapy on the beta-adrenoceptor (beta-AR) signal transduction in the failing heart." | ( Dhalla, NS; Ferrari, R; Sethi, R; Wang, X, 2004) |
| "Congestive heart failure is found in about one-quarter of cases of chronic kidney disease." | ( Blum, M; Iaina, A; Schwartz, D; Silverberg, D; Wexler, D, 2004) |
| "Heart failure is defined as the inability of the heart to pump blood at an amount sufficient to meet the metabolic needs of the body." | ( McBride, BF; White, CM, 2004) |
| "Congestive heart failure is a syndrome that is usually initiated by a reduction in pump function of the heart, i." | ( Gao, L; Qian, ZM; Tan, W; Wang, W; Zhu, GQ, 2004) |
| "Chronic congestive heart failure is associated with abnormal HRT." | ( Chan, HL; Du, CC; Hwang, JJ; Lai, LP; Lin, JL; Lin, LY; Tseng, YZ, 2004) |
| "Congestive heart failure is a common condition with a poor prognosis." | ( Feldman, AM, 2004) |
| "Heart failure is a growing public health problem in the United States, and the approach to the treatment of heart failure has undergone a radical transformation in the past decade." | ( Bauman, JL; Talbert, RL, 2004) |
| "Congestive heart failure is associated with a loss of circadian and short-term variability in blood pressure and heart rate." | ( Engelhardt, S; Janssen, BJ; Lemmer, B; Lohse, M; Witte, K, 2004) |
| "Although heart failure is common among women with coronary disease, the risk factors for developing heart failure have not been well studied." | ( Barrett-Connor, E; Bibbins-Domingo, K; Grady, D; Hulley, SB; Lin, F; Shlipak, MG; Vittinghoff, E, 2004) |
| "Heart failure is an independent risk factor for overanticoagulation." | ( Bleumink, GS; Hofman, A; Stricker, BH; Trienekens, PH; Visser, LE; Vulto, AG, 2004) |
| "Patients with heart failure are at increased risk of sudden death and death attributed to progressive pump failure." | ( Finn, P; Granger, CB; McMurray, JJ; Michelson, EL; Pfeffer, MA; Pocock, S; Skali, H; Solomon, SD; Swedberg, K; Wang, D; Yusuf, S; Zornoff, L, 2004) |
| "The diagnosis of heart failure is difficult, with both overdiagnosis and underdiagnosis occurring commonly in practice." | ( Dobson, AJ; Doust, JA; Glasziou, PP; Pietrzak, E, 2004) |
| "Heart failure is the leading cause of hospitalizations in the USA, and is associated with significant morbidity, mortality and resource utilization." | ( Tsao, L; Wylie, JV, 2004) |
| "for heart failure are metoprolol succinate and carvedilol." | ( Talbert, RL, 2004) |
| "Heart failure is a highly prevalent disease in aging western populations, associated with a substantially increased risk of thromboembolic events, not only in severe but even in mild to moderate stages." | ( Bauersachs, J; Schäfer, A, 2004) |
| "Since heart failure is also associated with attenuated responses to catecholamines, we examined the effects of imidapril, an ACE inhibitor, on the beta-adrenoceptor (beta-AR) signal transduction in the failing heart." | ( Dhalla, NS; Ren, B; Saini, HK; Sethi, R; Shao, Q; Takeda, N, 2004) |
| "Heart failure is often accompanied by psychiatric disorders." | ( Aizawa, Y; Fujita, S; Hanawa, H; Hayashi, M; Kato, K; Kodama, M; Komura, S; Kondo, D; Minagawa, S; Ohno, Y; Okura, Y; Sato, A, 2004) |
| "Heart failure is a major public health problem in the Western world." | ( Bhatia, GS; Davis, RC; Lip, GY; Sosin, MD, 2004) |
| "Since heart failure is an inadequacy of function, these results strongly support the notion that N-BNP is a useful blood test in estimating the extent of cardiac pump dysfunction and helpful in establishing positive diagnosis of heart failure." | ( Ng, LL; O'Brien, RJ; Tan, LB; Taylor, S; Williams, SG; Wright, DJ, 2004) |
| "Heart failure is a major public health problem and despite significant advances in treatment remains the only cardiovascular disease still on the rise." | ( Berkowitz, R, 2004) |
| "Heart failure is a severe pathology, which has displayed a dramatic increase in the occurrence of patients with chronic heart disease in developed countries, as a result of increases in the population's average age and in survival time." | ( Cynober, L; Grynberg, A; Héliès-Toussaint, C; Moinard, C; Rasmusen, C; Tabbi-Anneni, I, 2005) |
| "Advanced congestive heart failure is associated with activation of the renin-angiotensin system and skeletal muscle wasting." | ( Delafontaine, P; Du, J; Li, Y; Mitch, WE; Rosenthal, N; Song, YH, 2005) |
| "Heart failure is an important cause of morbidity and mortality." | ( Liu, PP; Yan, AT; Yan, RT, 2005) |
| "Chronic heart failure is associated with increased levels of hypoxanthine and decreased levels of nitrite." | ( Böger, R; Clark, AL; Coats, AJ; Niebauer, J; Webb-Peploe, KM, 2005) |
| "Today heart failure is understood as a complex interplay of hemodynamic and neurohormonal factors." | ( Hoch, M; Netz, H, 2005) |
| "Heart failure is rarely observed in patients experiencing hypocalcemia." | ( Baggs, D; Hurley, K, 2005) |
| "Heart Failure is a syndrome describing a pathophysiological state with diverse etiologies." | ( Dickstein, K, 2005) |
| "The prognosis of heart failure is worse than that of most cancers, but new therapeutic interventions using stem and other cell-based therapies are succeeding in the fight against it, and old drugs, with new twists, are making a comeback." | ( Benjamin, IJ; Schneider, MD, 2005) |
| "Chronic heart failure is a common condition with high mortality." | ( Adlam, D; Silcocks, P; Sparrow, N, 2005) |
| "Heart failure is a leading cause of morbidity and mortality." | ( Bunney, EB; Prendergast, HM, 2005) |
| "Heart failure is the major cause of mortality in Western countries." | ( Chachques, JC; Monnet, E, 2005) |
| "Heart failure is common in the elderly population and carries a serious prognosis." | ( Alehagen, U; Dahlström, U; Levin, LA; Lindstedt, G, 2005) |
| "Heart failure is characterized by limited exercise tolerance and by a skeletal muscle myopathy with atrophy and shift toward fast fibres." | ( Angelini, A; Dalla Libera, L; Danieli Betto, D; Germinario, E; Gobbo, V; Ravara, B; Vescovo, G, 2005) |
| "Heart failure is commonly associated with vascular diseases and a high rate of athero-thrombotic events, but the risks and benefits of antithrombotic therapy are unknown." | ( De Lorenzo, F; Kakkar, VV, 2005) |
| "Congestive heart failure is a leading cause of morbidity and mortality throughout the world and is now the leading cause of hospitalizations in adults over 65 years of age with an estimated annual expenditure in excess of USD 20 billion." | ( Januzzi, JL; O'Donoghue, M, 2005) |
| "Heart failure is associated with a high rate of hospitalization and poor prognosis." | ( Balk, AH; Cleland, JG; Janssens, U; Louis, AA; Rigby, AS, 2005) |
| "Heart failure is associated with reduced function of sarcoplasmic reticulum (SR) Ca2+-ATPase (SERCA2a) but increased function of sarcolemmal Na+/Ca2+ exchanger (NCX), leading to decreased SR Ca2+ content and loss of frequency-potentiation of contractile force." | ( Dybkova, N; Franz, WM; Horn, W; Maier, LS; Müller, OJ; Näbauer, M; Pagel, C; Pieske, B; Wagner, S; Wahl-Schott, C; Weichert, S, 2005) |
| "Diastolic heart failure is a frequent entity but difficult to diagnose." | ( Gaub, R; Kasner, M; Poller, WC; Schultheiss, HP; Tschöpe, C; Westermann, D, 2005) |
| "The prevalence of heart failure is not decreasing, and heart failure is currently a cause for hospitalization in >25% of admissions to internal medicine and cardiology departments." | ( Flugelman, MY; Halon, DA; Jaffe, R; Karkabi, B; Lewis, BS; Yuval, R, 2005) |
| "Heart failure is a very common clinical pathology." | ( Reingardiene, D, 2005) |
| "Chronic heart failure is associated with maladaptive and prolonged neurohormonal and pro-inflammatory cytokine activation causing a metabolic shift favouring catabolism, vasodilator incapacity, and loss of skeletal muscle bulk and function." | ( Channer, KS; Jones, TH; Malkin, CJ; Pugh, PJ; van Beek, EJ; West, JN, 2006) |
| "Heart failure is a widespread and costly malady." | ( Cerulli, A; Frech, FH; Smith, DG, 2005) |
| "Heart failure is a major cause of morbidity all over the world." | ( Gupta, S; Sen, S, 2005) |
| "Chronic heart failure is associated with reduced FMD; the prognostic impact of this observation is unknown." | ( Berger, R; Hülsmann, M; Kulemann, V; Meyer, B; Mörtl, D; Neunteufl, T; Pacher, R; Strecker, K, 2005) |
| "Heart failure is analysed following the recent classification (prognostic and symptomatic: 4 stages) proposed by the American Heart Association (AHA)." | ( Camici, M, 2005) |
| "Heart failure is a disease of epidemic proportions." | ( Collins, SP; Hinckley, WR; Storrow, AB, 2005) |
| "Chronic heart failure is also associated with a decrease in NO synthesis in the brain as indicated by a reduction in the mRNA for the neuronal isoform (nNOS)." | ( Liu, JL; Zucker, IH, 2000) |
| "Chronic heart failure is accompanied by a sustained elevation in sympathetic nerve traffic, which is thought to be an important component in the pathophysiology and progression of the disease." | ( Schultz, HD; Sun, SY, 2000) |
| "Heart failure is characterized by an elevation in sympathetic tone." | ( Ma, R; Wang, W, 2000) |
| "Symptoms of heart failure are common in patients with pacemakers." | ( Anderson, A; Clark, AL; Cleland, JG; Ghosh, J; Goode, K; Nikitin, N; Rigby, A; Thackray, SD; Witte, K, 2006) |
| "Chronic heart failure is a disease syndrome characterized in its advanced stages by a poor quality of life, frequent hospitalizations, and a high risk of mortality." | ( Bristow, MR; Demets, DL; Eichhorn, E; Evans, G; Feldman, AM; Freytag, JW; Gerber, MJ; Gorczynski, R; Hartman, C; Liard, JF; Linseman, JV; Lowes, BD; Metra, M; Robertson, AD; Roecker, EB; Shakar, SF; Stewart, J, 2005) |
| "The evaluation of heart failure is routinely based on subjective patient symptoms and physician examination." | ( Gennings, C; Hess, ML; Hogan, CJ; Ward, KR, 2005) |
| "Although congestive heart failure is rare in the case of drug-induced hypereosinophilia, it is one of life-threatening complications." | ( Akiyama, O; Hagiwara, K; Matsuno, H; Sato, T, 2005) |
| "Pharmacotherapy for heart failure is complex and, due to polypharmacy, is associated with a large risk of potential drug-drug interactions (DDIs)." | ( Krähenbühl, S; Schlienger, RG; Straubhaar, B, 2006) |
| "Although diastolic heart failure is clinically and radiographically indistinguishable from systolic heart failure, normal ejection fraction and abnormal diastolic function in the presence of symptoms and signs of heart failure confirm diastolic heart failure." | ( Barone, E; Mishra, TK; Satpathy, C; Satpathy, HK; Satpathy, R, 2006) |
| "Heart failure is a common disorder that is associated with significant mortality and morbidity." | ( Moe, GW, 2006) |
| "(1) Heart failure is diagnosed on the basis of both clinical symptoms and evaluation of cardiac function (preferably measured by echocardiography)." | ( , 2006) |
| "Congestive heart failure is increasing in prevalence and represents a major public health problem." | ( Akao, M; Delafontaine, P, 2006) |
| "Heart failure is responsible for a huge burden in hospital care." | ( Bian, WY; Huang, J; Li, W; Li, YS; Pang, HM; Wang, F; Wang, L; Wang, Y; Xu, ZM, 2006) |
| "Although heart failure is a final common consequence of various heart diseases and is a leading cause of mortality worldwide, the precise molecules and signaling pathways that mediate heart failure progression are largely undefined." | ( Komuro, I; Shiojima, I, 2006) |
| "Chronic left heart failure is the result of the activation of pathophysiological mechanisms which over time lead to progressive deterioration of the cardiac function." | ( Haghfelt, TH; Novosel, MK, 2006) |
| "Heart failure is a growing epidemic, with systemic hypertension a major risk factor for development of disease." | ( Behfar, A; Dyer, RB; Hodgson, DM; Kane, GC; Liu, XK; Miki, T; O'Cochlain, DF; Reyes, S; Seino, S; Terzic, A, 2006) |
| "Chronic left-heart failure is often associated with the development of pulmonary venous hypertension." | ( Braun, S; Schmeisser, A; Schrötter, H; Strasser, RH, 2007) |
| "Heart failure is correlated with attenuation of parasympathetic nervous function and enhanced sympathetic activity." | ( Kang, XQ; Li, M; Lu, J; Xu, XL; Yu, XJ; Zang, WJ, 2006) |
| "Heart failure is a major cause of cardiovascular morbidity and mortality and its incidence is on the increase." | ( Ferro, A; Odedra, K, 2006) |
| "Briefly, heart failure is unlikely when BNP is below 100 pg/ml (NT-proBNP<500 pg/ml), and very likely when BNP is higher than 400 pg/ml (or NT-proBNP>2000 pg/ml)." | ( Lefort, Y; Ray, P, 2006) |
| "Heart failure is associated with downregulation of the fatty acid oxidation pathway in the ventricular myocardium." | ( Aasum, E; Larsen, TS; Lerch, R; Montessuit, C; Papageorgiou, I; Pedrazzini, T; Pellieux, C, 2006) |
| "Acute decompensated heart failure is a growing public health care problem worldwide." | ( Munger, MA, 2006) |
| "Doxorubicin-induced heart failure is a rare but serious illness due to the well-known treatment difficulties." | ( Autschbach, R; Christiansen, S, 2006) |
| "Diastolic heart failure is a common form of congestive heart failure that is responsible for significant morbidity and mortality." | ( Khan, NU; Movahed, A; Nekkanti, R; Shammas, RL, 2007) |
| "Heart failure is a major health problem, and is one of the few cardiovascular diseases that increased its prevalence over the last decade." | ( Mulder, P; Thuillez, C, 2006) |
| "Heart failure is associated with increased risk of venous thromboembolism, stroke, and sudden death." | ( Chung, I; Lip, GY, 2006) |
| "Decompensated heart failure is reported to increase response to warfarin, but documentation is limited." | ( Oliphant, CS; Reaves, AB; Sands, C; Self, TH, 2006) |
| "The development of heart failure is uncommon in patients with stable angina, and even less so in the absence of an obvious precipitating factor." | ( de Brouwer, S; Erik Otterstad, J; Kirwan, BA; Lubsen, J; Poole-Wilson, PA; Sutton, GC; Vokó, Z, 2007) |
| "Heart failure is a growing major cause of human morbidity and mortality worldwide." | ( Chien, KR; Hoshijima, M; Knöll, R; Pashmforoush, M, 2006) |
| "Heart failure is a prominent problem of public health, requiring innovating methods of health services organization." | ( Baccichetto, R; Barro, S; Calderan, A; Carbonieri, E; Chiatto, M; Chinellato, M; Corazza, F; D'Atri, M; D'Eri, A; Drigo, R; Fabris, S; Gelli, GF; Lo Giudice, A; Milani, L; Noventa, F; Pollon, A; Santin, P; Valle, R; Zanardi, F, 2006) |
| "Heart failure is associated with increased free radical production, which leads to a state of oxidative stress." | ( Bertomeu, V; Cortés, R; García de Burgos, F; Jordán, A; Marín, F; Martínez-Dolz, L; Miró, V; Payá, R; Pérez-Boscá, JL; Portolés, M; Rivera, M; Roselló-Lletí, E; Salvador, A; Sogorb, F; Valero, R, 2006) |
| "Heart failure is thought to be more common and of greater severity in African-Americans (AAs)." | ( Arroyo, M; Bhattacharya, SK; Carbone, LD; Johnson, PL; Laguardia, SP; Nelson, MD; Newman, KP; Weber, KT, 2006) |
| "Chronic heart failure is an increasingly frequent clinical syndrome, characterized by reduced physical performance, dyspnea and an adverse prognosis." | ( Angermann, CE; Ertl, G, 2007) |
| "Heart failure is associated with a skeletal muscle myopathy with cellular and extracellular alterations." | ( Carvalho, RF; Cicogna, AC; Dal Pai-Silva, M; Dariolli, R; Felisbino, SL; Justulin Junior, LA; Politi Okoshi, M; Sugizaki, MM, 2006) |
| "Heart failure is common, yet it is difficult to treat." | ( Arnold, JM; Dorian, P; Ducharme, A; Giannetti, N; Haddad, H; Heckman, GA; Howlett, JG; Ignaszewski, A; Isaac, D; Jong, P; Liu, P; Mann, E; McKelvie, RS; Moe, GW; O'Halloran, K; Parker, JD; Rao, V; Ross, HJ; Sequeira, EJ; Svendsen, AM; Tsuyuki, RT; White, M, 2007) |
| "Systolic heart failure is a condition that exerts a devastating toll on those affected." | ( Flack, JM, 2007) |
| "Heart failure is a relatively important public health problem due to its increasing incidence, poor prognosis, and frequent need of re-hospitalization." | ( Cam, N; Kasikcioglu, HA, 2006) |
| "Congestive heart failure is a pathologic condition characterized by progressive decrease in left ventricular contractility and consequent decline of cardiac output." | ( Aras, O; Dilsizian, V; Eckelman, WC; Messina, SA; Shirani, J, 2007) |
| "Congestive heart failure is increasing in prevalence in the United States, and associated morbidity and mortality remain high." | ( Abraham, WT; Hiestand, B, 2007) |
| "Acute decompensated heart failure is the most common cause for hospitalization among patients over 65 years of age." | ( Dec, GW, 2007) |
| "End-stage heart failure is believed to involve depressed cardiomyocyte contractility and Ca2+ transients." | ( Louch, WE; Mørk, HK; Periasamy, M; Sande, JB; Sejersted, OM; Sjaastad, I, 2007) |
| "Acute heart failure is a disease with various etiologies that is difficult to treat and has a poor prognosis." | ( Spinar, J; Vítovec, J, 2007) |
| "Chronic heart failure is known to be an important risk factor for adverse perioperative outcome in patients undergoing non-cardiac surgery." | ( Huschak, G; Rüffert, H; Schmidt-Runke, H, 2007) |
| "Heart failure is one of the leading death reasons in the world." | ( Acikel, M; Arslan, S; Bozkurt, E; Erol, MK; Gundogdu, F; Gurlertop, Y; Senocak, H; Sevimli, S; Yilmaz, M, 2007) |
| "Heart failure is a heterogeneous disease, the development and pathophysiology of which involves complex interactions between genetic and environmental factors." | ( Johnson, BD; Olson, TP; Snyder, EM, 2007) |
| "Chronic heart failure is a multisystem disorder in which intestinal morphology, permeability, and absorption are modified." | ( Anker, SD; Bauditz, J; Buhner, S; Doehner, W; Karhausen, T; Lochs, H; Poole-Wilson, P; Rauchhaus, M; Sandek, A; Schroedl, W; Swidsinski, A; Volk, HD; von Haehling, S; Weber-Eibel, J, 2007) |
| "Heart failure is a cause of pulmonary vasoconstriction and remodelling, leading to pulmonary hypertension (PH) and decreased survival." | ( Hadad, I; Jespers, P; Mahmoudabady, M; Mathieu, M; McEntee, K; Motte, S; Naeije, R; Pensis, A; Peters, IR; Ray, L, 2008) |
| "Congestive heart failure is the most common cause of death in patients with thalassemia, as chronic accumulation of iron due to regular blood transfusions leads to biventricular systolic dysfunction and death at a very young age." | ( Davison, G; Jabbar, DA; Muslin, AJ, 2007) |
| "Congestive heart failure is a growing public health problem worldwide, particularly in the elderly population, in whom it has a substantial impact on quality of life and survival." | ( Brunner-La Rocca, HP; Leibundgut, G; Pfisterer, M, 2007) |
| "Heart failure is associated with reversal to a fetal gene expression pattern of contractile and metabolic genes." | ( Brieke, A; Bristow, MR; Calalb, M; Cleveland, J; Geraci, M; Gray, N; Lindenfeld, J; Lowes, BD; Minobe, W; Reed, M; Shakar, SF; Wolfel, EE; Zolty, R, 2007) |
| "Heart failure is one of the leading causes of hospitalizations in the United States." | ( Greene, EL; Liang, KV; Redfield, MM; Williams, AW, 2008) |
| "Heart failure is characterised by decreased cardiac output, which results in the development of both peripheral hypoperfusion and pulmonary congestion and can lead to the development of acute pulmonary edema." | ( Antoniades, C; Koumallos, N; Shirodaria, C; Stefanadis, C; Tousoulis, D, 2006) |
| "Heart failure is a major healthcare problem and leading cause of death in Western countries." | ( Ishikawa, Y; Iwatsubo, K, 2008) |
| "Therapy of heart failure is more difficult when renal function is impaired." | ( Miracle, C; Thomson, S; Vallon, V, 2008) |
| "Heart failure is a condition that affects nearly 5 million people in the United States and costs the nation an estimated $35 billion a year." | ( Bart, BA, 2008) |
| "Heart failure is a very serious cardiovascular disease that affects more than five million people in North America." | ( El-Kadi, AO; Zordoky, BN, 2008) |
| "Heart failure is a major problem in the Unites States." | ( Gallegos, PJ; Haase, KK; Maclaughlin, EJ, 2008) |
| "Heart failure is associated with decreased myocardial fatty acid oxidation capacity and has been likened to energy starvation." | ( Chandler, MP; Foster, AB; Fujioka, H; Hoit, BD; Hoppel, CL; McElfresh, TA; Minkler, PE; Okere, IC; Patel, HV; Patel, KK; Rennison, JH; Stoll, MS; Young, ME, 2008) |
| "End-stage heart failure is characterized by a number of abnormalities at the cellular level, which include changes in excitation-contraction coupling, alterations in contractile proteins and activation/deactivation of signaling pathways." | ( Del Monte, F; Hajjar, RJ, 2008) |
| "The heart failure is one of the pathologies with major social and economic impact in the western world." | ( Dequarti, MC; Poggio, L; Vanoli, E, 2007) |
| "Common causes of heart failure are associated with derangements in myocardial fuel utilization." | ( Kelly, DP; Madrazo, JA, 2008) |
| "Heart failure is common in Hong Kong, and is associated with significant morbidity and mortality." | ( Liu, PT; Maurellet, JD, 2008) |
| "Acute decompensated heart failure is the most common cause of hospitalization for patients older than 65 years of age." | ( Lepage, S, 2008) |
| "Heart failure is end-stage cardiac disease, developing in 46% of women within 6 years of having a myocardial infarction, and is the leading cause of all hospitalizations and readmissions in women over the age of 65 years." | ( Pruitt, AL, 2008) |
| "Heart failure is a major public health problem." | ( Artigou, JY; de Groote, P; Diévart, F; Galinier, M; Habib, G; Hanon, O; Herpin, D; Juillière, Y; Komajda, M; Neuder, Y; Roudaut, R; Trochu, JN, 2008) |
| "Heart failure is characterised by depressed myocyte contractility and is considered to involve a complex malfunction of adrenergic regulation, Ca2+-handling and the contractile apparatus." | ( de Tombe, PP; Marston, SB, 2008) |
| "Heart failure is a pathological substrate permissive to drug-induced torsades de pointes." | ( Hamlin, RL; Kijtawornrat, A, 2008) |
| "Heart failure is a condition in which the heart cannot supply enough blood to the body's organs, and is a final common consequence of various heart diseases." | ( Komuro, I; Oka, T, 2008) |
| "Hypertension and heart failure are worldwide health problems of ever-increasing proportions." | ( Simpson, RU; Weber, KT; Weglicki, WB, 2009) |
| "Acute heart failure is associated with dyspnea that is usually defined as difficulty in breathing that is accompanied by an element of distress." | ( Kappagoda, T; Ravi, K, 2009) |
| "Chronic heart failure is common and can be described as a syndrome characterized by impairment of cardiac function associated with a maladaptive metabolic and neurohormonal axis." | ( Channer, K; Jones, T; Malkin, C, 2009) |
| "Heart failure is a global health problem, appearing most commonly in patients with previous myocardial infarction (MI)." | ( Sun, Y, 2009) |
| "In the elderly, heart failure is often accompanied by concomitant conditions that often make diagnosis and treatment of chronic heart disease difficult." | ( Nessler, J; Skrzypek, A, 2008) |
| "Congestive heart failure is associated with a decrease in LZ+ MYPT1 expression, which results in a decrease in the sensitivity to cGMP-mediated smooth muscle relaxation." | ( Brozovich, FV; Ogut, O, 2008) |
| "Heart failure is a highly prevalent disease, the prognosis of which depends on different predictive factors." | ( Del Carlo, CH; Oliveira Junior, MT; Pereira Barretto, AC; Ramirez, JA; Scipioni, A; Silva, CP; Strunz-Cassaro, C, 2008) |
| "Heart failure is an established diagnosis." | ( Köhler, D, 2009) |
| "Acute heart failure is a common clinical problem faced in cardiac surgery operating rooms and intensive care units." | ( Tagarakis, GI; Tsilimingas, NB, 2009) |
| "Heart failure is a life-threatening complication of high-dose cyclophosphamide (CTX) chemotherapy, and the present study aimed at identifying the mechanism involved in mice." | ( Wang, X; Xu, T; Zhang, J, 2009) |
| "Chronic heart failure is very common in hemodialyzed patients due to several factors such as intermittent volume overload, anemia, and hypertension." | ( Chytilova, E; Holaj, R; Krupickova, Z; Malík, J; Slavikova, M; Tuka, V, 2009) |
| "Because heart failure is a syndrome and not a disease, an underlying Etiology must be sought and determined." | ( Ahmed, A, 2009) |
| "Acute heart failure is the most frequent cause of acute dyspnea in geriatric patients." | ( Legrain, S; Ray, P; Teixeira, A, 2009) |
| "DOX-induced heart failure is thought to be caused by reduction/oxidation cycling of DOX to generate oxidative stress and cardiomyocyte cell death." | ( Bennett, JA; Danz, ED; Henry, N; Keller, RS; Skramsted, J, 2009) |
| "Thermal therapy for heart failure is recognized to improve clinical symptoms." | ( Hashimoto, S; Hashimura, K; Higashi, H; Kato, TS; Kitakaze, M; Kitamura, S; Komamura, K; Mano, A; Nakatani, T; Oda, N; Shishido, T; Wada, K; Yanase, M, 2009) |
| "Congestive heart failure is a risk factor for ischemic stroke." | ( Aoki, J; Iguchi, Y; Kimura, K; Okada, Y; Shibazaki, K; Terasawa, Y, 2009) |
| "Generally chronic heart failure is a clinical diagnosis verified by blood tests like NT-proBNP and cardiac ultrasound." | ( Clodi, M; Hülsmann, M; Pacher, R; Resl, M, 2009) |
| "Heart failure is associated with impairment in nitric oxide (NO) mediated vasodilatation, which has been demonstrated to result from a reduction in the relative expression of the leucine zipper positive (LZ+) isoform of the myosin targeting subunit (MYPT1) of myosin light chain phosphatase." | ( Ararat, E; Brozovich, FV, 2009) |
| "Heart failure is an example of this entity: when congestive heart failure becomes refractory, ultrafiltration by various modes of dialysis is needed." | ( Ait-Oile, F; Bellavia, S; Bovy, P; Chachati, A; Godon, E, 2009) |
| "The prevalence of heart failure is ever increasing around the world, particularly due to aging populations." | ( Baguet, JP; Barone-Rochette, G; Neuder, Y, 2009) |
| "Heart failure is known as a predisposition for atrial fibrillation (AF)." | ( Grove, R; Kranig, W; Lüdorff, G; Schütte, F; Thale, J, 2009) |
| "Anemia in heart failure is related to advanced New York Heart Association classes, severe systolic dysfunction, and reduced exercise tolerance." | ( Calabrò, A; Campagna, MS; Franci, B; Nuti, R; Palazzuoli, A; Quatrini, I; Silverberg, DS; Spinelli, T, 2009) |
| "Heart failure is a complex clinical syndrome that manifests itself with signs and symptoms which are neither sensitive nor specific for the diagnosis of heart failure." | ( Betihavas, V; Macdonald, P; Newton, PJ, 2009) |
| "Heart failure is a major cause of mortality in diabetes and may be causally associated with altered metabolism." | ( Chan, SY; Jones, KE; Jun, JY; Jung, DY; Kim, JK; Ko, HJ; Ma, Z; Zhang, Z, 2009) |
| "Heart failure is accompanied by electrolyte disturbance including reduced calcium and sodium in the extracellular milieu but increased calcium within cells, a phenomenon called "calcium paradox"." | ( Abdallah, Y; Schlüter, KD; Schreckenberg, R; Tastan, I; Wenzel, S, 2010) |
| "Acute heart failure is a potentially fatal manifestation of viral myocarditis." | ( Kytö, V; Latva-Hirvelä, J; Levijoki, J; Saraste, A; Saukko, P; Vuorinen, T, 2009) |
| "Heart failure is an important cause of cardiovascular morbidity and mortality." | ( Davies, M; Davis, R; Freemantle, N; Gill, PS; Lip, GY, 2009) |
| "Heart failure is common, causes major disability and often shortens life." | ( , 2009) |
| "Heart failure is a rare but life-threatening manifestation of cardiac involvement in SLE." | ( Bax, JJ; Boumpas, DT; Huizinga, TW; Kritikos, H; Mollema, SA; Schoe, A; van der Laan-Baalbergen, NE; van Laar, JM, 2009) |
| "Heart failure is a syndrome characterized initially by left ventricular dysfunction that triggers countermeasures aimed to restore cardiac output." | ( Butler, J; Giamouzis, G; Karayannis, G; Louridas, G; Skoularigis, J; Triposkiadis, F, 2009) |
| "Heart failure is increasingly prevalent worldwide and is associated with significant morbidity and mortality." | ( Moe, GW; Tu, J, 2010) |
| "Heart failure is more prevalent in aboriginal than in the nonaboriginal counterparts." | ( Moe, GW; Tu, J, 2010) |
| "Heart failure is a serious condition, and it is, therefore, important to identify patients at high risk as early as possible in order to initiate appropriate treatment." | ( Alehagen, U; Dahlström, U; Lindahl, TL, 2010) |
| "Doxorubicin-induced heart failure is a rare, but serious illness and is well-known to be difficult to treat." | ( Christiansen, S, 2010) |
| "Acute decompensated heart failure is a common clinical problem with associated poor outcomes." | ( DeWald, TA; Hernandez, AF, 2010) |
| "Heart failure is an important cardiac disease with an increasing prevalence in Western societies." | ( Berghöfer, A; Reinhold, T; Willich, SN, 2010) |
| ""End stage" heart failure is unresponsive to conventional pharmacological and non pharmacological treatments and has a bad prognosis either regarding survival or quality-of-life; besides cardiac transplantation is limited by organ shortage." | ( Bonacchi, M; Burgisser, C; Cellai, T; Fattirolli, F; Francini, S; Gensini, GF; Sani, G; Valente, S, 2009) |
| "Hospitalization for heart failure is a major health problem with high in-hospital and postdischarge mortality and morbidity." | ( Boccanelli, A; Brandimarte, C; Brandimarte, F; Cacciatore, G; Fedele, F; Gheorghiade, M; Mureddu, GF, 2010) |
| "Heart failure is one of the main causes of mortality in developed countries and is frequently associated with cardiac hypertrophy." | ( Condorelli, G; Papait, R, 2010) |
| "Congestive heart failure is a syndrome characterized by decreased cardiac output with consequent neurohormonal activation leading to water and salt retention." | ( Torre-Amione, G; Youker, K, 2009) |
| "CHF (chronic heart failure) is associated with a prolonged recovery of skeletal muscle energy stores following submaximal exercise, limiting the ability to perform repetitive daily activities." | ( De Vries, WR; Doevendans, PA; Kemps, HM; Nicolay, K; Prompers, JJ; Schep, G; Thijssen, EJ; Wessels, B; Zonderland, ML, 2009) |
| "Heart failure is a major public health problem in developed countries including Japan, therefore it is important to estimate the future risk in patients with heart failure." | ( Aihara, K; Daida, H; Iwama, Y; Takagi, A; Yamada, A, 2010) |
| "Heart failure is a progressive disease, leading to reduced quality of life and premature death." | ( De Keulenaer, GW; De Meyer, GR; Martinet, W, 2010) |
| "Heart failure is a progressive disease affecting millions of people worldwide." | ( Agarwal, M; Naghi, J; Phan, A; Philip, K; Schwarz, ER; Willix, RD, 2010) |
| "Chronic heart failure is associated with elevated blood serum concentration of neopterin." | ( Bogdański, P; Chmara, E; Jabłecka, A; Kazmierczak, M; Korzeniowska, K; Musialik, K; Wetlicka, I, 2010) |
| "Heart failure is an important cause of disease burden in aging societies." | ( Strandberg, TE, 2010) |
| "Heart failure is a significant medical problem affecting more than five million people in the USA alone." | ( Ashley, EA; Ho, M; Knowles, JW; Pavlovic, A; Wheeler, MT, 2008) |
| "Heart failure is a significant public health problem." | ( Burton, P; Cheng, M; Griffin, G; Lee, MS; Oppenheimer, L; Plotnikov, AN; Weinstein, R; Yuan, Z; Zhang, J; Zolynas, R, 2010) |
| "Heart failure is one of the most serious complications in Duchenne muscular dystrophy (DMD)." | ( Kawai, M; Kikuchi, Y; Kuru, S; Matsumura, T; Tamura, T, 2010) |
| "Heart failure is highly prevalent in type 2 diabetes mellitus (T2DM), but associations of BNP to left ventricular (LV) mass and function in individuals with a different glucose status have not been compared." | ( Alssema, M; Boomsma, F; Dekker, JM; Diamant, M; Heine, RJ; Henry, RM; Kamp, O; Nijpels, G; Paulus, WJ; Stehouwer, CD; van den Hurk, K, 2010) |
| "Heart failure is characterised by reduced expression of sarcoplasmic reticulum calcium-ATPase (SERCA) and increased expression of B-type natriuretic peptide (BNP)." | ( Hasenfuss, G; Kögler, H; Kuhn, M; Teucher, N; Toischer, K; Unsöld, B, 2010) |
| "Chronic heart failure is associated with high mortality and morbidity." | ( Böhm, M; Borer, JS; Dubost-Brama, A; Ford, I; Komajda, M; Lerebours, G; Swedberg, K; Tavazzi, L, 2010) |
| "Heart failure is a major source of cardiovascular morbidity, including acute decompensations requiring hospitalization." | ( Goonewardena, SN; Spencer, KT, 2010) |
| "Heart failure is a complex syndrome with multiple risk factors involved in its genesis, making its prevention and management difficult to achieve." | ( Corrêa, Kde S; Nogueira, PR; Rassi, S, 2010) |
| "Heart failure is the common and final pathway of all the cardiovascular diseases." | ( Isnard, R, 2010) |
| "The diagnosis of heart failure is based on strict process using clinical examination as well as other tests." | ( Logeart, D, 2010) |
| "Left heart failure is characterized by alterations in metabolic substrate utilization, and metabolic modulation may be a future strategy in the management of heart failure." | ( Aung, M; Beanlands, RS; Birnie, D; Burwash, I; DaSilva, JN; Davies, RA; deKemp, RA; Guo, A; Haddad, H; Mielniczuk, LM; Tang, AT; Ukkonen, H; Williams, K; Ziadi, MC, 2011) |
| "Heart failure is a common cardiovascular disease with high morbidity and mortality." | ( Bahl, A; Reddy, S; Talwar, KK, 2010) |
| "Chronic heart failure is a substantial public health problem." | ( Anker, SD; Jankowska, EA; Ponikowski, P; von Haehling, S, 2011) |
| "Doxorubicin-induced heart failure is a rare but serious illness due to the well-known treatment difficulties." | ( Christiansen, S, 2011) |
| "The diagnosis of heart failure is essentially based upon the presence of typical symptoms and signs of congestion or a low cardiac output as well as the objective evidence of cardiac dysfunction." | ( Maeder, MT; Rickli, H, 2011) |
| "Advanced HF (heart failure) is associated with altered substrate metabolism." | ( Benada, O; Benes, J; Cervenka, L; Drahota, Z; Houstek, J; Kazdova, L; Kolar, M; Kopecky, J; Kovarova, N; Medrikova, D; Melenovsky, V; Petrak, J; Sedmera, D; Skaroupkova, P; Strnad, H; Vrbacky, M, 2011) |
| "Heart failure is a progressive deterioration in heart function associated with overactivity of the sympathetic nervous system." | ( Abdel Rahman, AA; Aceros, H; Mukaddam-Daher, S; Noiseux, N; Stabile, AM; Stockmeyer, K, 2011) |
| "Congestive heart failure is a major cause of morbidity and mortality in diabetes." | ( Andrén, B; Berne, C; Holst, JJ; Ingelsson, E; Lind, L; Nathanson, D; Nyström, T; Zethelius, B, 2011) |
| "Acute decompensated heart failure is one of the most important causes of hospitalisation worldwide." | ( Di Somma, S; Ferri, E; Magrini, L, 2011) |
| "Heart failure is one of the most frequent cardiac complications in patients with end-stage renal disease receiving long-term hemodialysis or peritoneal dialysis and is associated strongly with a poor prognosis." | ( Sanderson, JE; Wang, AY, 2011) |
| "Early, slow-onset heart failure is difficult to diagnose from just signs and symptoms." | ( Cramer, MJ; Grobbee, DE; Hoes, AW; Kelder, JC; Plokker, HW; Rutten, FH, 2011) |
| "Tachycardia-induced heart failure is associated with depletion of intracellular calcium." | ( Bøtker, HE; Gross, GJ; Hjortdal, VE; Khambadkone, S; Redington, AN; Schmidt, MR; Sørensen, KE; Vogel, M; White, PA, 2011) |
| "Heart failure is one of the major causes of death in the Western world because cardiac muscle loss is largely irreversible and can lead to a relentless decline in cardiac function." | ( Cashman, J; Forte, E; Lanier, M; Lo, F; Mercola, M; Willems, E, 2011) |
| "Chronic heart failure is one of the most common causes of death in western countries." | ( Hoppe, UC, 2011) |
| "Heart failure is a common antecedent to atrial fibrillation; both heart failure and atrial fibrillation are associated with increased myocardial oxidative stress." | ( Bonilla, I; Cardounel, AJ; Carnes, CA; Elton, TS; Györke, S; Khan, M; Kuppusamy, P; Li, C; Nishijima, Y; Sridhar, A; Terentyev, D; Terentyeva, R; Velayutham, M; Zweier, JL, 2011) |
| "Heart failure is associated with deficient endothelial nitric oxide (NO) production as well as increased oxidative stress and accelerated NO degradation." | ( Ferro, A; Gkaliagkousi, E; Passacquale, G; Ritter, J; Shah, A, 2011) |
| "End-stage heart failure is associated with the heterogeneous remodeling of excitation-contraction coupling and calcium handling." | ( Efimov, IR; Fast, VG; Fedorov, VV; Glukhov, AV; Lou, Q; Moazami, N, 2011) |
| "Anemia in heart failure is both common and associated with worse symptoms and increased mortality." | ( Flather, MD; Kotecha, D; Manzano, L; Ngo, K; Palazzuoli, A; Walters, JA, 2011) |
| "Congestive heart failure is associated with impaired renal function." | ( Abassi, Z; Abu-Saleh, N; Awad, H; Bishara, B; Goltsman, I; Khamaysi, I; Ramadan, R, 2011) |
| "Heart failure is a major cause of morbidity and mortality in society." | ( Abozguia, K; Beadle, RM; Frenneaux, MP; Leon, FL; Patel, K; Wagenmakers, A; Williams, LK; Yousef, Z, 2011) |
| "Heart failure is the final consequence of the majority of cardiovascular diseases, and resveratrol has been shown to directly attenuate heart contraction." | ( Li, JJ; Qian, HY; Wang, H; Xu, H; Yang, YJ; Zhang, Q, 2012) |
| "Heart failure is a frequent complication of myocardial infarction." | ( Azevedo, PS; Minicucci, MF; Paiva, SA; Polegato, BF; Zornoff, LA, 2011) |
| "Heart failure is characterized by a great number of metabolic and histological defects, however, previous studies did not provide strong evidence of a correlation between the antioxidant status of myocardial tissue itself and cardiac function." | ( Brenot, R; Cottin, Y; David, M; Girard, C; Jazayeri, S; Maupoil, V; Rochette, L; Tatou, E; Vergely, C; Zeller, M, 2011) |
| "Chronic heart failure is often complicated by the development of cachexia with the loss of fat mass." | ( Cabassi, A; Coghi, P; Fiaccadori, E; Montanari, A; Parenti, E; Pilotti, E; Regolisti, G; Tedeschi, S; Vicini, V, 2012) |
| "Heart failure is a major public health problem because of its high prevalence and impact on mortality, morbidity, quality of life, and social costs." | ( Brasolin, B; Bruno, N; Caira, C; D'Ambrosi, A; Fedele, F; Mancone, M, 2011) |
| "Heart failure is a major cause of morbidity and mortality worldwide." | ( Dai, G; Gao, X; Luo, J; Peng, L; Sun, H, 2011) |
| "Heart failure is a chronic clinical syndrome with very poor prognosis." | ( Aaronson, A; Agarwal, M; Morrissey, RP; Nguyen, CT; Schwarz, ER; Willix, RD, 2011) |
| "Diastolic heart failure is a major cause of mortality in the elderly population." | ( Dudley, SC; Jeong, EM; Liu, H; Reed, AL; Sorescu, D; Sturdy, M; Sutliff, RL; Tanaka, A; Walp, ER, 2011) |
| "End-stage heart failure is associated with impaired cardiac output (CO) and organ blood flow." | ( Boesgaard, S; Brassard, P; Gustafsson, F; Hansen, PB; Hassager, C; Jensen, AS; Madsen, PL; Møller, JE; Nordsborg, N; Olsen, PS; Sander, K; Secher, NH, 2011) |
| "Heart failure is a progressive disease characterized by high prevalence in society, significantly reducing physical and mental health, frequent hospitalization and high mortality (50% of the patients survive up to 4 years after the diagnosis, the annual mortality varying from 5% to 75%)." | ( Axente, L; Bazacliu, G; Sinescu, C, 2011) |
| "Heart failure is a frequent and life-threatening syndrome which is not only the result of myocardial injury or hemodynamic overload as commonly perceived, but appears to be the result of an interplay among genetic, neurohormonal, inflammatory, and biochemical factors, collectively referred to as biomarkers." | ( Böhm, M; Bramlage, P; Ketelslegers, JM; Schirmer, SH; Turgonyi, E; Voors, AA; Zannad, F, 2011) |
| "Congestive heart failure is a very real public health issue not only in the United States, but worldwide." | ( Dohadwala, M; Estes, NA; Link, MS, 2011) |
| "Heart failure is a major cause of death in developed countries, and the development of an epoch-making cure is desired from the viewpoint for improving the quality of life and reducing the medical cost of the patient." | ( Nishida, M, 2011) |
| "Heart failure is the most frequent cause of hospitalization in elderly population." | ( Caglayan, E; Er, F; Erdmann, E; Gassanov, N, 2011) |
| "The associated heart failure is less common; it can be reversible but must be actively monitored and managed." | ( Gupta, R; Maitland, ML, 2011) |
| "Heart failure is a progressive, heterogeneous form of cardiovascular disease that requires treatment to be individualized depending on the presenting symptoms." | ( Currie, GM; Iqbal, B; Jelinek, HF; Kiat, H; Trifunovic, M; Wang, L; Wheat, JM, 2011) |
| "Heart failure is a serious, progressive and chronic illness that affects an ever-growing part of the population." | ( De Loof, H; De Meyer, G; Gysen, C, 2011) |
| "Heart failure is associated with significant morbidity and mortality despite significant advances in therapies developed for it." | ( Caballero, R; Delpón, E; Duarte, J; Tamargo, J, 2011) |
| "Heart failure is a growing epidemic, and a typical aspect of heart failure pathophysiology is altered calcium transients." | ( Chi, NC; Chu, KY; Colecraft, H; Fang, K; Fong, TS; Halushka, MK; Hong, TT; Hoopes, CW; Jensen, BC; Ocorr, K; Russell, SD; Shaw, RM; Smyth, JW; Vogan, JM, 2012) |
| "Heart failure is a growing global epidemic that involves in its pathophysiology a proinflammatory state." | ( Basile, E; Bellocci, F; Cialdella, P; Giglio, AF; Gustapane, M; Narducci, ML; Pazzano, V; Pedicino, D; Pelargonio, G; Santangeli, P; Vitulano, N, 2013) |
| "Congestive heart failure is common in patients with chronic kidney disease, but the association of serum sodium concentration with mortality in such patients is not well characterized." | ( Kalantar-Zadeh, K; Kovesdy, CP; Lott, EH; Lu, JL; Ma, JZ; Malakauskas, SM; Molnar, MZ, 2012) |
| "Chronic heart failure is associated with endothelial dysfunction and insulin resistance." | ( Christiansen, B; Dominguez, H; Falskov, B; Hermann, TS; Køber, L; Major-Pedersen, A; Rask-Madsen, C; Raunsø, J; Torp-Pedersen, C, 2011) |
| "Heart failure is extremely prevalent and is associated with significant mortality, morbidity and cost." | ( Gopal, D; Maisel, AS; Saremi, A, 2012) |
| "Heart failure is characterized by several abnormalities of sympathetic cardiac activity that can be assessed by 123I metaiodobenzylguanidine single photon emission computed tomography (MIBG SPECT)." | ( Bologna, A; Casaretti, L; Conte, S; Formisano, R; Losco, T; Mattiello, G; Mosca, S; Musella, F; Parente, A; Perrone-Filardi, P; Pirozzi, E; Savarese, G, 2012) |
| "In women, heart failure is associated with a higher frequency of hypertension, nonischemic cardiomyopathy and left bundle branch block than in men." | ( Barsheshet, A; Brenyo, A; Goldenberg, I; Moss, AJ, 2012) |
| "Heart failure is an age-related disease, as the incidence increases with age." | ( Otsu, K; Yamaguchi, O, 2012) |
| "Because advanced heart failure is associated with reduction of regulatory proteins of fatty acid oxidation, we hypothesized that failing myocardium may not be able to adapt to increased fatty acid intake and therefore undergo lipid accumulation, potentially aggravating myocardial dysfunction." | ( Lerch, R; Montessuit, C; Papageorgiou, I; Pedrazzini, T; Pellieux, C, 2012) |
| "Heart failure is a leading cause of morbidity and mortality in Western society." | ( Chin, MT; Korte, FS; Liu, Y; Moussavi-Harami, F; Razumova, M; Regnier, M; Yu, M, 2012) |
| "The hallmark of heart failure is the progressive dilatation of the left ventricle, thinning of the left ventricular wall leading to increased wall stress and increased myocardial oxygen consumption." | ( Bauernschmitt, R; Helgerson, S; Hinson, A; Lee, RJ; Sabbah, HN, 2013) |
| "Chronic heart failure is an important cause for morbidity and mortality in adults with congenital heart disease (ACHD)." | ( Bauersachs, J; Bode-Böger, SM; Denecke, A; Kielstein, JT; Lovric, S; Martens-Lobenhoffer, J; Schieffer, B; Tutarel, O; Westhoff-Bleck, M, 2012) |
| "Chronic heart failure is associated with decreased FEV 1 , and FEV 1 improves after heart transplantation." | ( Kanoh, S; Moskowitz, WB; Rubin, BK; Tanabe, T, 2012) |
| "Congestive heart failure is an inexorable disease associated with unacceptably high morbidity and mortality." | ( Gao, MH; Hammond, HK; Tang, T, 2012) |
| "Heart failure is characterized by disturbed energy metabolism and impaired mitochondrial function." | ( Askevold, ET; Aukrust, P; Berge, RK; Bjørndal, B; Dahl, CP; Gullestad, L; Nymoen, SH; Svardal, A; Ueland, T; Øie, E, 2013) |
| "Heart failure is a heterogeneous syndrome." | ( Frenneaux, M; Singh, S, 2012) |
| "Heart failure is associated with neurological deficits, including cognitive dysfunction." | ( Bolz, SS; Foltz, W; Henkelman, RM; Heximer, SP; Husain, M; Jaffray, D; Kapoor, A; Kroetsch, JT; Lidington, D; Matthews, SG; Meissner, A; Momen, A; Noyan-Ashraf, MH; van Eede, M; Voigtlaender-Bolz, J; Yang, J; Zhang, H, 2012) |
| "Heart failure is likely to be particularly prevalent in the nursing home population, but reliable data about the prevalence of heart failure in nursing homes are lacking." | ( Brunner-la Rocca, HP; Daamen, MA; Gorgels, AP; Hamers, JP; Schols, JM; Tan, FE; van Dieijen-Visser, MP, 2012) |
| "Heart failure is a common condition in the Western world, particularly among elderly persons and with an ever-aging population, the incidence is expected to increase." | ( Harbinson, MT; McKeag, NA; McKeown, PP; McKinley, MC; Woodside, JV, 2012) |
| "Heart failure is usually a relentless condition associated with a poor prognosis." | ( Channer, KS; Morris, PD; Robinson, T, 2012) |
| "Acute heart failure is one of the most common condition leading to hospital admission and is burdened by important mortality and readmission rates." | ( Arques, S, 2012) |
| "Heart failure is a common consequence of CKD, and it portends high risk for mortality." | ( Anderson, A; Chen, J; Dries, D; Go, AS; He, J; Hsu, CY; Keane, M; Li, Y; Mishra, RK; Park, M; Rosas, SE; Shlipak, MG; Xie, D, 2012) |
| "Heart failure is a major cause of morbidity and mortality in the world." | ( Fillmore, N; Lopaschuk, GD, 2013) |
| "Heart failure is a chronic and progressive pathology." | ( Duquet, N, 2012) |
| "Heart failure is a growing cause of morbidity and mortality." | ( Aiba, T; Begley, MJ; Boström, P; Cantley, LC; Das, S; del Monte, F; Ellinor, PT; Graham, EL; Hessler, K; Knight, AC; Morissette, MR; Ottaviano, FG; Quintero, PA; Rosenberg, M; Rosenzweig, A; Tomaselli, GF; Xiao, C, 2012) |
| "Heart failure is a multifaceted pathophysiologic syndrome, with prevalent dysfunction of other vital organs and systems." | ( Anker, SD; Doehner, W; Murín, J; Sandek, A; Valentová, M; von Haehling, S, 2013) |
| "Cardiac cells with heart failure are usually characterized by impairment of Ca(2+) handling with smaller SR Ca(2+) store and high risk of triggered activities." | ( Lu, L; Xia, L; Zhu, X, 2012) |
| "Heart failure is a major cause of mortality and morbidity." | ( Barton, PM; Cowie, MR; Deeks, JJ; Derit, M; Hobbs, FD; Iles, R; Mant, J; Roalfe, AK; Tait, L; Taylor, CJ, 2012) |
| "Severe heart failure is highly associated with chronic kidney disease (CKD)." | ( Daher, Ede F; Libório, A; Mejia, J; Neto, J; Uchoa, R; Valdivia, J, 2012) |
| "Heart failure is a leading cause of death and disability." | ( Merali, S; Sherwi, N; Wong, K, 2012) |
| "Heart failure is a pressing public health problem with no curative treatment currently available." | ( Ardehali, H; Bayeva, M; Gheorghiade, M, 2013) |
| "Heart failure is becoming a global epidemic." | ( Buckley, CL; Horton, JS; Stokes, AJ, 2013) |
| "Development of heart failure is known to be associated with changes in energy substrate metabolism." | ( Basu, R; Clanachan, A; Gandhi, M; Kassiri, Z; Lopaschuk, GD; Mori, J; Oudit, GY; Zhabyeyev, P, 2013) |
| "Heart failure is a major health problem with significant morbidity and mortality." | ( Dwivedi, G; Haddad, T; Liu, Y, 2013) |
| "Heart failure is an important public health problem that is increasing in prevalence throughout the world." | ( Greenberg, BH; Zamani, P, 2013) |
| "Heart failure is one of the leading causes of death throughout the world." | ( Hasegawa, K; Katanasaka, Y; Morimoto, T; Sunagawa, Y, 2013) |
| "Acute heart failure is a public health issue with morbidity and mortality exceeding that of myocardial infarction." | ( Ezekowitz, JA, 2013) |
| "Heart failure is one of the leading causes of death in developed countries, and its prevalence is expected to increase further in the coming years." | ( Echizen, H; Ogawa, R; Stachnik, JM, 2013) |
| "Anemia in heart failure is considered to develop due to a complex interaction of iron deficiency, kidney disease, and cytokine production, although micronutrient insufficiency and blood loss may contribute." | ( Agarwal, AK; Shah, R, 2013) |
| "Heart failure is a serious public health issue with a growing prevalence, and it is related with the aging of the population." | ( de Assis, LV; Isoldi, MC; Locatelli, J, 2014) |
| "Right heart failure is a major cause of morbidity and mortality after left ventricular assist device (LVAD) implantation." | ( Hellgren, L; Johansson, J; Schiller, P; Vikholm, P, 2014) |
| "Heart failure is a common disease with high levels of morbidity and mortality." | ( Doney, AS; Lang, CC; Palmer, CN; Parry, HM, 2013) |
| "Its effect on heart failure is proven, but its benefit for patients with chronic kidney disease (CKD) has not been not confirmed." | ( Murasawa, T; Ohno, D; Otsuka, T; Sakai, Y; Sato, N; Tsuruoka, S, 2013) |
| "Heart failure is the leading cause of morbidity and mortality in the aged and the intake of phytochemicals from fruits and vegetables decreases with age." | ( Bennink, MR; Bolling, SF; Seymour, EM, 2013) |
| "Heart failure is a highly prevalent disorder associated with increased mortality, repeated and lengthy hospitalization, and disability." | ( Komajda, M, 2012) |
| "Heart failure is a major burden to the health care system in terms of not only cost, but also morbidity and mortality." | ( Choudhary, R; Chowdhury, P; Kehl, D; Maisel, A, 2013) |
| "Heart failure is characterised by the inability of the heart to ensure sufficient blood flow to meet the metabolic needs of the body's tissues." | ( Juillière, Y, 2013) |
| "Heart failure is one of the leading causes of sudden death in developed countries." | ( Oh, JG; Park, WJ, 2013) |
| "As heart failure is an important risk factor for thromboembolism and increased platelet activation is common in heart failure, we investigated the potential effect of Rivaroxaban treatment on platelets in an experimental CHF model." | ( Bauersachs, J; Flierl, U; Fraccarollo, D; Micka, J; Schäfer, A, 2013) |
| "Heart failure is a global problem, with an estimated prevalence of 2% in developed countries." | ( Martins da Silva, MI; Morão Moreira, AP; Vidigal Ferreira, MJ, 2013) |
| "Chronic heart failure is associated with sympathetic activation characterised by elevated circulating norepinephrine levels linked to cardiovascular morbidity and mortality." | ( Böhm, M; Ewen, S; Linz, D; Mahfoud, F; Reil, JC; Schirmer, SH; Ukena, C, 2013) |
| "Patients with heart failure are at higher risk for thromboembolic events, even in the absence of atrial fibrillation, but the effect of anticoagulation therapy on outcomes is uncertain." | ( Curtis, LH; Eapen, ZJ; Fonarow, GC; Hammill, BG; Hernandez, AF; Klaskala, W; Kociol, RD; Mills, RM, 2013) |
| "Its role in heart failure is discussed controversially." | ( Amann-Zalan, I; Azizi Ghanbari, A; Britz, A; Dörr, R; Lodwig, V; Lohmann, T; Schnell, O; Spitzer, S; Stumpf, J; Ulm, B, 2013) |
| "Chronic heart failure is an important cause for morbidity and mortality in adults with congenital heart disease (ACHD)." | ( Bauersachs, J; Beutel, G; Denecke, A; Kielstein, JT; Kümpers, P; Lukasz, A; Schieffer, B; Tutarel, O; Westhoff-Bleck, M, 2013) |
| "Heart failure is a complex disease in which a careful clinical examination and the measurement of cardiac function may not always be sufficient for making a correct diagnosis." | ( Buga, L; Joseph, AC; Pellicori, P; Sherwi, N, 2013) |
| "Human congestive heart failure is accompanied by structural and electrical alterations leading to the development of an arrhythmogenic substrate." | ( Müller, FU; Schulte, JS; Seidl, MD, 2014) |
| "Heart failure is accompanied by significant perturbations in cardiac energy metabolism that can both decrease cardiac energy supply and decrease cardiac efficiency." | ( Lopaschuk, GD; Mori, J; Oudit, GY; Zhang, L, 2013) |
| "Heart failure is currently one of the most common hospitalization causes." | ( Agreli, G; Braile, DM; Breda, JR; Buffolo, E; Caputi, G; Gaia, DF; Palma, JH, 2013) |
| "Heart failure is a common cardiac disease in elderly patients." | ( Falgenhauer, M; Fruhwald, F; Hayn, D; Riedel, A; Schreier, G, 2013) |
| "Heart failure is a common disorder associated with high morbidity and mortality as well as increasing socio-economic costs." | ( Eriksson, U; Müller-Edenborn, B, 2013) |
| "Heart failure is a growing health and economic problem in America, and outcomes continue to remain dismal, particularly for those presenting with acute heart failure syndrome (AHFS)." | ( Goldsmith, SR; Kalra, A; Maharaj, V, 2014) |
| "The progression of heart failure is affected by several factors, including chronic stimulation of the β-adrenoceptor." | ( Li, QS; Liu, FQ, 2013) |
| "Acute heart failure is a common reason for admission, and outcome is often poor." | ( Chiswell, K; Cleland, JG; Cotter, G; Davison, BA; Fiuzat, M; Givertz, MM; Mansoor, GA; Massie, BM; Metra, M; O'Connor, CM; Ponikowski, P; Stevens, S; Teerlink, JR; Voors, AA, 2014) |
| "Heart failure is a costly and difficult disease to treat." | ( Eisen, HJ; Feitell, S; Hankins, SR, 2014) |
| "The syndrome of heart failure is prevalent and a cause of significant morbidity and mortality." | ( Plein, S; Swoboda, PP, 2014) |
| "Congestive heart failure is underdiagnosed in patients with chronic obstructive pulmonary disease (COPD)." | ( Brekke, PH; Høiseth, AD; Karlsson, BD; Omland, T; Søyseth, V, 2013) |
| "Congestive heart failure is an important cause of endotoxin resorption from the intestine, which significantly increases PCT expression in noninfected patients with heart failure." | ( Ge, N; Liu, J; Liu, W; Wang, W; Wen, D; Yuan, H; Zhang, P; Zhang, X, 2014) |
| "Most patients with heart failure are diagnosed and managed in primary care, however, underdiagnosis and undertreatment are common." | ( Hoes, AW; Landman, MA; Limburg, A; Rutten, FH; van der Hoeven, H; van Riet, EE, 2014) |
| "Since heart failure is a major cause of mortality in obesity, we investigated the effects of heme-oxygenase (HO) on heart failure and cardiometabolic complications in obese normoglycemic Zucker-fatty rats (ZFs)." | ( Gerger, C; Jadhav, A; Lee, P; Mishra, M; Ndisang, JF; Tiwari, S; Weber, L, 2013) |
| "Chronic heart failure is a costly epidemic that affects up to 2% of people in developed countries." | ( Balshaw, R; Chen, V; Cohen Freue, GV; Dyck, JR; Hollander, Z; Ignaszewski, A; Keown, PA; Lam, KK; Lazárová, M; McManus, BM; McMaster, RW; Ng, RT; Oudit, GY; Pauwels, J; Schreiner, G; Tebbutt, SJ; Wilson-McManus, JE, 2014) |
| "Heart failure is characterized by a debilitating decline in cardiac function, and recent clinical trial results indicate that improving the contractility of heart muscle cells by boosting intracellular calcium handling might be an effective therapy." | ( Doevendans, PA; Hajjar, RJ; Jeong, D; Kho, C; Lee, A; Mercola, M; Mitsuyama, S; Park, WJ; Rojas-Muñoz, A; Sluijter, JP; van Mil, A; Wahlquist, C, 2014) |
| "End-stage heart failure is not a specific additional phenomenon observed in patients with HCM, but is the natural course of the disease in most of those patients." | ( Hamada, M; Ikeda, S; Shigematsu, Y, 2014) |
| "In this review, heart failure is confined to etiologies not due to rhythm disturbances or valvular heart disease." | ( Dörr, M; Empen, K; Felix, SB; Hummel, A, 2014) |
| "Chronic heart failure is a common disease with a high morbidity and mortality." | ( Hoffmann, JJ; Keyzer, JM; Nabbe, KC; Pop, VJ; Ringoir, L; Widdershoven, JW, 2014) |
| "Heart failure is an established predictor of primary cardiac events during pregnancy." | ( Ascoop, AK; De Backer, J; De Pauw, M; Gevaert, S; Roelens, K; Tromp, F, 2014) |
| "Heart failure is one of the most common cardiovascular complications of diabetes and the most disabling and deadly complication too." | ( Boesgaard, TW; Flyvbjerg, A; Gustafsson, I; Holmager, P; Jorsal, A; Kistorp, C; Kumme, A; Møller, JE; Nielsen, R; Nilsson, B; Tarnow, L; Videbæk, L; Wiggers, H, 2014) |
| "heart failure is a major risk factor for cardiovascular mortality, for which n-3 fatty acids may have beneficial effects." | ( Geleijnse, JM; Gemen, EF; Giltay, EJ; Hoogeveen, EK; Kromhout, D; Kusters, R; van't Sant, P, 2015) |
| "A hallmark of heart failure is impaired cytoplasmic Ca(2+) handling of cardiomyocytes." | ( Bers, DM; Bisping, E; Bossuyt, J; Holzer, M; Kockskämper, J; Leitinger, G; Ljubojevic, S; Marsche, G; Mittler, T; Pieske, B; Post, H; Pritz, E; Radulovic, S; Sacherer, M; Schmidt, A; Sedej, S; Sereinigg, M; Wakula, P; Winkler, C; Zissimopoulos, S, 2014) |
| "Heart failure is a complex syndrome that affects almost all organs and systems of the body." | ( Casado Cerrada, J; Pérez Calvo, JI, 2014) |
| "Heart failure is accompanied by a loss of the orderly disposition of transverse (T)-tubules and a decrease of their associations with the junctional sarcoplasmic reticulum (jSR)." | ( Chen, B; Franzini-Armstrong, C; Guo, A; Iyer, VR; Kutschke, WJ; Song, LS; Weiss, RM; Zhang, C; Zhang, X, 2014) |
| "Acute heart failure is a major cause of emergency hospital admission, with significant impact on health resources and patient outcomes." | ( McDonagh, T; Piper, S, 2014) |
| "Heart failure is a common complication of diabetes characterized by an elevation in left ventricular filling pressures (LVF) that often develops in the absence of clinical symptoms." | ( Baranchuk, A; Farias, J; Ferrer, M; Gysel, M; Lombardero, M; Tinetti, M, 2015) |
| "Heart failure is a final common pathway or descriptor for various cardiac pathologies." | ( Cardona, K; Ferrero, JM; Gomez, JF; Romero, L; Trenor, B, 2014) |
| "As complex disease, heart failure is associated with various pathophysiological and biochemical disorders." | ( Birner, C; Block, D; Buesing, M; Jungbauer, CG; König, W; Luchner, A; Maier, L; Riedlinger, J; Riegger, G; Stadler, S, 2014) |
| "Heart failure is a multi-factorial progressive disease in which eventually the contractile performance of the heart is insufficient to meet the demands of the body, even at rest." | ( Stienen, GJ, 2015) |
| "Heart failure is a global problem with an estimated prevalence of 38 million patients worldwide, a number that is increasing with the ageing of the population." | ( Braunwald, E, 2015) |
| "Chronic heart failure is characterized by decreased exercise capacity with early exacerbation of fatigue and dyspnea." | ( Bonomo, C; Cezar, MD; Damatto, RL; Fernandes, DC; Guizoni, DM; Junior, SA; Laurindo, FR; Lima, AR; Martinez, PF; Matsubara, LS; Novelli, EL; Okoshi, K; Okoshi, MP; Pagan, LU; Seiva, FR; Zornoff, LA, 2015) |
| "Acute heart failure is a common condition associated with considerable morbidity, mortality, and cost." | ( Maisel, AS; Storrow, AB; Teichman, SL, 2015) |
| "Advanced heart failure is associated with end-organ damage." | ( Bergerone, S; Botta, M; Bovolo, V; Canavosio, FG; Frea, S; Gaita, F; Pidello, S, 2015) |
| "Heart failure is often complicated by arrhythmias that can adversely affect the quality of life and increase the risk for sudden cardiac death." | ( Borgquist, R; Singh, JP, 2015) |
| "Heart failure is a common syndrome caused by different abnormalities of the cardiovascular system that result in impairment of the ventricles in filling or ejecting blood." | ( Bozorgnia, B; Mather, PJ, 2015) |
| "Heart failure is not simply a single organ disease; rather it is a complex multi-system clinical syndrome, with impairment of endocrine, haematological, musculoskeletal, renal, respiratory and vascular systems, which influence morbidity and mortality." | ( Lawford, P; Sheridan, P; Warriner, D, 2015) |
| "Acute heart failure is globally one of most frequent reasons for hospitalization and still represents a challenge for the choice of the best treatment to improve patient outcome." | ( Di Somma, S; Magrini, L, 2015) |
| "Heart failure is associated with disrupted t-tubule structure, but its effect on t-tubule function is less clear." | ( Bryant, SM; Cannell, MB; James, AF; Kong, CH; Orchard, CH; Watson, J, 2015) |
| "Prevalence of heart failure is increasing, especially in the elderly population." | ( Chong, VH; Chowdhury, F; Lang, CC; Mancini, DM; Parry, H; Saunders, J; Singh, J, 2015) |
| "Multifactor heart failure is a common life-threatening event in elderly patients and often complicated by concomitant hypertension and diabetes mellitus (DM)." | ( Chen, XM; Fu, Y; Guo, JC; Hua, Q; Qin, J; Qin, S; Yang, W; Zhou, YJ, 2015) |
| "Acute heart failure is a symptom complex of heterogeneous etiology." | ( Dörr, R; Simonis, G; Spitzer, SG; Stumpf, J, 2015) |
| "Heart failure is a leading cause of death worldwide." | ( Lee, CF; Tian, R, 2015) |
| "Advanced heart failure is a malignant disease characterized by a debilitating late course, with increasingly frequent hospitalisations and high rate of mortality." | ( Nieminen, MS; Silvetti, S, 2016) |
| "Heart failure is a common cause of hospitalization and can be divided into types with preserved and reduced ejection fraction (HFpEF and HFrEF, respectively)." | ( Azer, M; Barnard, D; Clopton, P; Frivold, G; Greenberg, B; Iqbal, N; Jaski, B; Kelsay, D; Kupfer, K; Lee, E; Lombardo, D; Maisel, AS; Marais, J; Miyamoto, MI; Shah, KS; Taub, PR; Zile, M, 2016) |
| "Heart failure is a disease predominantly caused by an energy metabolic disorder in cardiomyocytes." | ( Cheng, X; Li, P; Luo, S; Pan, C, 2015) |
| "Despite this, heart failure is still related to increasing rates of morbidity, repeated hospitalizations, and mortality." | ( Pereira-Barretto, AC, 2015) |
| "Heart failure is a common disease with high levels of morbidity and mortality." | ( Anwar, MS; Doney, AS; Iskandar, MZ; Lang, CC; Palmer, CN; Parry, HM, 2015) |
| "Heart failure is associated with disrupted t-tubular structure, but its effect on t-tubular function is less clear." | ( Bryant, SM; Gadeberg, HC; James, AF; Orchard, CH, 2016) |
| "Heart failure is a systemic and multiorgan syndrome with metabolic failure as a fundamental mechanism." | ( Fragasso, G; Gowdak, LH; Hamid, MA; Jourdain, P; Lopaschuk, GD; Lopatin, YM; Ponikowski, P; Rosano, GM; Seferovic, PM; Vinereanu, D, 2016) |
| "Heart failure is a highly morbid syndrome generating enormous socio-economic costs." | ( Mericskay, M, 2016) |
| "Heart failure is a highly prevalent cardiovascular complication among patients receiving long-term hemodialysis, but the benefits of carvedilol, bisoprolol, and metoprolol controlled release/extended release on the outcomes of these patients remain unclear." | ( Chen, TH; Hong, CY; Sue, YM; Tang, CH; Wang, CC, 2016) |
| "Heart failure is accompanied by up-regulation of transforming growth factor beta signaling, accumulation of collagen and dysregulation of sarcoplasmic reticulum calcium adenosine triphosphatase cardiac isoform 2a (SERCA2a)." | ( Brandon-Warner, E; Bridges, CR; Fargnoli, AS; Hajjar, RJ; Katz, MG; Kendle, AP; Schrum, LW; Williams, RD, 2016) |
| "Heart failure is a serious complication that can occur in patients with a variety of congenital and acquired disorders including congenital heart disease, cardiomyopathy, and myocarditis." | ( Cabrera, AG; Humlicek, T; Jefferies, JL; Naim, MP; Rossano, JW, 2016) |
| "Heart failure is often preceded by cardiac hypertrophy, which is characterized by increased cell size, altered protein abundance, and actin cytoskeletal reorganization." | ( Bernstein, SI; Cammarato, A; Harding, SE; Kass, DA; Kooij, V; Kronert, WA; Lee, DI; Rainer, PP; Schmidt, W; Van Eyk, JE; Viswanathan, MC, 2016) |
| "Heart failure is a significant global health problem, which is becoming worse as the population ages, and remains one of the biggest burdens on our economy." | ( Bernardo, BC; Blaxall, BC, 2016) |
| "Clinical status in heart failure is conventionally assessed by the physician's evaluation, patients' own perception of their symptoms, quality of life (QoL) tools, and a measure of functional capacity." | ( Anker, SD; Comin-Colet, J; Cooper, TJ; Dickstein, K; Filippatos, G; Johnson, P; Lainscak, M; Lüscher, TF; Mori, C; Ponikowski, P, 2016) |
| "Heart failure is associated with generalized insulin resistance." | ( Abel, ED; Riehle, C, 2016) |
| "Heart failure is common and results in substantial morbidity and mortality." | ( Fonarow, GC; Gordin, JS, 2016) |
| "Heart failure is a clinical syndrome that manifests from various cardiac and noncardiac abnormalities." | ( Ambrosy, AP; Butler, J; Chioncel, O; Collins, SP; Gheorghiade, M; Greene, SJ; Macarie, C; Vaduganathan, M, 2016) |
| "As heart failure is a great problem of clinical practice and diabetes is a strong risk factor of heart failure, we are looking also for prevention of heart failure and for its treatment also by using antidiabetic drug." | ( Murín, J, 2016) |
| "Heart failure is a major source of cardiovascular morbidity and mortality worldwide." | ( Oliveira, GH; Robinson, MR, 2016) |
| "Heart failure is a growing global public health problem." | ( Greenberg, B; Hsiao, R, 2016) |
| "Heart failure is a global problem with elevated prevalence, and it is associated with substantial cardiovascular morbidity and mortality." | ( Vilela-Martin, JF, 2016) |
| "Heart failure is the consequence of sustained, abnormal neurohormonal and mechanical stress and remains a leading cause of death worldwide." | ( Chen, Q; Liu, Y; Yu, M; Yu, Y; Zhang, W; Zhang, Z; Zhao, X, 2016) |
| "Acute heart failure is a common condition among adults presenting with dyspnea in the Emergency Department (ED), still the diagnosis is challenging as objective standardized criteria are lacking." | ( Borselli, M; Bruni, F; Cevenini, G; Frizzi, J; Gialli, V; Gonnelli, S; Granai, C; Guazzi, G; Pastorelli, M; Sarcoli, E; Sartini, S, 2017) |
| "Chronic heart failure is one of the leading causes for hospitalization in the United States and Europe, and is accompanied by high mortality." | ( Hein, L; Lother, A, 2016) |
| "Advanced systolic heart failure is associated with myocardial and systemic metabolic abnormalities, including low levels of total cholesterol and low-density lipoprotein." | ( Colombo, PC; Kennel, PJ; Maldonado, D; Mancini, DM; Mountis, MM; Naka, Y; Schulze, PC; Starling, RC; Vest, AR; Young, JB, 2016) |
| "Heart failure is one of the major public health challenges facing the Western world." | ( Chaggar, PS; Orsborne, C; Shaw, SM; Williams, SG, 2017) |
| "Heart failure is the commonest cause of hospitalization and of rehospitalization This review paper is a comprehensive review of current treatment of heart failure in 2016." | ( Aronow, WS, 2016) |
| "Acute heart failure is a common condition that leads to hospital admission, with important mortality and readmission rates." | ( Arques, S; Roux, E, 2016) |
| "Heart failure is a clinical syndrome that evolves from either functional or structural changes to the ventricles that lead to filling or ejection abnormalities." | ( Adhyaru, B; Raj, L, 2016) |
| "The later stages of heart failure are characterized by a steady decline in quality of life." | ( Fruhwald, F; Fruhwald, S; Pollesello, P, 2016) |
| "Chronic heart failure is a common clinical syndrome associated with high healthcare system use." | ( Bayram, C; Britt, H; Henderson, J; Hobbs, FR; Miller, GC; Taylor, CJ; Valenti, L, 2016) |
| "Chronic heart failure is a significant burden in general practice." | ( Bayram, C; Britt, H; Henderson, J; Hobbs, FR; Miller, GC; Taylor, CJ; Valenti, L, 2016) |
| "Acute heart failure is a common cause of hospitalization among older patients." | ( Ammirati, E; Frigerio, M; Guida, P; Lagioia, R; Oliva, F; Passantino, A; Scrutinio, D, 2017) |
| "Chronic heart failure is a common consequence of various heart diseases." | ( Ma, L, 2016) |
| "Heart failure is a disease characterized by high prevalence and mortality, and frequent rehospitalizations." | ( Avanzi, GC; Castello, LM; Codognotto, M; de Araújo Porto, PB; De Berardinis, B; Di Somma, S; Lalle, I; Magrini, L; Navarin, S; Piccoli, A; Precht, BLC; Russo, V; Santarelli, S; Villacorta, AS; Villacorta, H, 2017) |
| "Heart failure is a global disease with increasing prevalence due to an aging worldwide population with increasing co-morbidities." | ( Bauersachs, J; Butler, J; Lewis, KS; Sandner, P, 2017) |
| "Heart Failure is a global epidemic, affecting approximately 5 million adults in the U." | ( Butler, J; Hamo, CE; Papadimitriou, L, 2017) |
| "Heart failure is also characterized by an elevated rate of morbidity and mortality and represents one of the leading causes of hospitalization." | ( Agabiti Rosei, C; Bertacchini, F; Muiesan, ML; Paini, A; Salvetti, M; Stassaldi, D, 2017) |
| "Heart failure is a complex clinical syndrome characterized by insufficient cardiac function." | ( Fujiu, K; Iwami, S; Komuro, I; Manabe, I; Matsumoto, S; Nagai, R; Nakae, S; Nakayama, Y; Noshita, K; Ogata, F; Shibata, M, 2017) |
| "Heart failure is well recognized as a major public health concern not only due to severe and frequent adverse health outcomes but also related to the major financial burden this syndrome presents with advancing age in Western societies." | ( Adams, KF; Giblin, EM; Patterson, JH; Pearce, N, 2017) |
| "Heart failure is an important community health problem." | ( Altay, H; Çavuşoğlu, Y; Çetiner, M; Güvenç, TS; Temizhan, A; Ural, D; Yeşilbursa, D; Yıldırım, N; Yılmaz, MB, 2017) |
| "Heart failure is a major cause of disease burden in sub-Saharan Africa (SSA)." | ( Achan, J; Bukhman, G; Carlson, S; Duber, HC; Ikilezi, G; Mokdad, AH; Roth, GA; Stergachis, A; Wollum, A, 2017) |
| "Heart failure is a major medical and economic burden throughout the world." | ( Gan, XT; Karmazyn, M, 2017) |
| "Considering that heart failure is a potential side effect of current PC treatments, especially in elderly patients, istaroxime might combine beneficial cardiac and anti-cancer properties." | ( Curcic, P; Eaton, DM; Khafaga, M; Knez, I; Kolesnik, E; Köstenberger, M; Lewinski, DV; Pichler, M; Pieske, B; Rainer, PP; Schwantzer, G; Vafiadis, A; Wallner, M, 2017) |
| "Heart failure is common in patients with chronic kidney disease." | ( Anderson, A; Feldman, HI; Hamm, L; He, J; Kallem, RR; Kanthety, R; Kusek, JW; Ojo, A; Rahman, M; Raj, D; Ricardo, AC; Roy, JA; Shlipak, M; Soliman, EZ; Wolf, M; Zhang, X, 2017) |
| "Heart failure is associated with altered myocardial substrate metabolism and impaired cardiac energetics." | ( Abdurrachim, D; Bovenkamp, P; Ciapaite, J; Coumans, W; Faber, C; Geraets, IME; Glatz, JFC; Hermann, S; Hoerr, V; Kuhlmann, MT; Luiken, JJFP; Nabben, M; Nicolay, K; Prompers, JJ; Schäfers, M, 2017) |
| "Heart failure is a chronic, progressive illness that is increasing in prevalence in the USA." | ( McPherson, ML; Stewart, D, 2017) |
| "Heart failure is a disease with a high prevalence and incidence." | ( Bauersachs, J; Bavendiek, U; Kempf, T, 2017) |
| "Pediatric heart failure is a complex disease occurring when cardiac output is unable to meet the metabolic demands of the body." | ( Conway, J; Cunningham, C; Larsen, BMK; Lewis, KD, 2018) |
| "Heart failure is associated with mitochondrial dysfunction so that restoring or improving mitochondrial health is of therapeutic importance." | ( Fujioka, H; Liao, X; Sangwung, P; Shen, Y; Zhang, L; Zhang, R; Zhou, L, 2017) |
| "ACF-induced heart failure is associated with light microscopic signs of apparent congestion of blood vessels, increased apoptosis and breakdown of hepatocytes and inflammatory cell inifltration were observed." | ( Aboryag, NB; Bedewi, L; Dehe, L; Mohamed, DM; Mousa, SA; Schäfer, M; Shakibaei, M; Shaqura, M; Treskatsch, S, 2017) |
| "Heart failure is characterized by the inability of the cardiovascular system to maintain oxygen (O2) delivery (i." | ( Almeida, DR; Barroco, AC; Neder, JA; Reis, M; Sperandio, PA, 2017) |
| "Heart failure is characterized by excess fluid accumulation, in both the vascular compartment and interstitial space, yet many heart failure patients have arterial underfilling because of low cardiac output, which may be aggravated by conventional diuretic treatment." | ( Boulton, DW; Greasley, PJ; Hallow, KM; Helmlinger, G; McMurray, JJV, 2018) |
| "Objective Heart failure is currently the most serious complication of muscular dystrophy." | ( Asakura, M; Fujimura, H; Iwata, Y; Matsui, M; Matsumura, T; Saito, T; Sakoda, S, 2018) |
| "Heart failure is a leading cause of cardiovascular disease among patients with chronic kidney disease." | ( Abdel-Kader, K; Bansal, N; Eden, SK; Fly, J; Greevy, RA; Himmelfarb, J; Hung, AM; Ikizler, TA; Matheny, ME; Parr, SK; Perkins, AM; Siew, ED; Speroff, T, 2018) |
| "Anemia and chronic heart failure are frequent comorbidities in geriatric patients." | ( Singler, K, 2018) |
| "Heart failure is a common and serious cardiovascular complication of type 2 diabetes." | ( Packer, M, 2018) |
| "Heart failure is a term used to define a constellation of symptoms and signs that are commonly attributed to the inability of the heart to produce a cardiac output that meets the demands of the body." | ( Lang, CC; Zaid Iskandar, M, 2017) |
| "Heart failure is a leading cause of mortality and morbidity, and the search for novel therapeutic approaches continues." | ( Ackers-Johnson, M; Chen, C; Ding, T; Fawcett, JW; Foo, RSY; Li, PY; Ng, SL; Rudd, PM; Stenzig, J; Teo, G; Wang, P; Zhao, RR; Zhou, Y, 2018) |
| "Heart failure is a chronic, burdensome condition with higher re-hospitalization rates in African Americans than Whites." | ( Lennie, TA; Moser, DK; Song, EK; Wu, JR, 2018) |
| "Heart failure is complex but mitochondrial dysfunction seems to be an important target to improve cardiac function directly." | ( Dabkowski, ER; Hecker, PA; Murphy, MP; O Connell, KA; Ribeiro Junior, RF; Shekar, KC, 2018) |
| "All patients with heart failure are suggested to be enrolled in a structured program (e." | ( Edelmann, F; Knosalla, C; Mörike, K; Muth, C; Prien, P; Störk, S, 2018) |
| "Heart failure is a major public health concern and one of the most common reasons for a cardiac hospital admission." | ( Atkin, SL; Bagheri, RK; Butler, AE; Keihanian, F; Saeidinia, A; Sahebkar, A, 2018) |
| "Acute heart failure is associated with high morbidity and mortality." | ( Knoll, K; Kurowski, V; Sager, HB; Schunkert, H, 2018) |
| "Dogs with advanced heart failure are a clinical challenge for veterinarians but there are no studies reporting clinical features and outcome of this population." | ( Beaumier, A; Freeman, LM; Rush, JE; Yang, VK, 2018) |
| "Heart failure is a leading cause of death and the development of effective and safe therapeutic agents for heart failure has been proven challenging." | ( Guo, SY; Li, CQ; Li, P; Wu, SQ; Xia, B; Yang, H; Zhu, XY, 2018) |
| "Renal failure after heart failure is attributed to hemodynamic derangement including reduced renal perfusion and increased venous pressure." | ( Aşgün, F; Bakar, C; Ercan, E; Ercan, F; Güven Bağla, A; Içkin Gülen, M, 2018) |
| "Heart failure is a common adverse effect associated with doxorubicin treatment." | ( El-Gowilly, SM; El-Naggar, AE; Sharabi, FM, 2018) |
| "The concept that heart failure is "an engine out of fuel" has been generally accepted and metabolic remodeling has been recognized as an important aspect of this condition; it is characterized by defects in energy production and changes in metabolic pathways involved in the regulation of essential cellular functions such as the process of substrate utilization, the tricarboxylic acid cycle, oxidative phosphorylation, and high-energy phosphate metabolism." | ( Chen, L; Hu, S; Song, J, 2019) |
| "Heart failure is associated with altered gene expression and DNA methylation." | ( Eschenhagen, T; Foo, RS; Geertz, B; Hirt, MN; Höppner, G; Löser, A; Ng, SL; Peters, BS; Reichenspurner, H; Schaefer, A; Schneeberger, Y; Stenzig, J; Tan, W; Wong, E; Zhao, RR, 2018) |
| "Heart failure is a condition that is increasing in prevalence in the UK, with high patient mortality rates and frequent hospital admissions." | ( Brennan, EJ, 2018) |
| "Heart failure is a multifactorial clinical syndrome characterized by the inability of the heart to pump sufficient blood to the body." | ( Maarman, GJ; Nduhirabandi, F, 2018) |
| "Anaemia in heart failure is overwhelmingly characterized by impaired erythropoietin production, which is exacerbated with age, female sex, left ventricular ejection fraction, inflammation and disease severity." | ( Flammer, AJ; Haider, T; Montero, D, 2019) |
| "Heart failure is associated with activation of thrombin-related pathways, which predicts a poor prognosis." | ( Anker, SD; Byra, WM; Cleland, JGF; Fu, M; Gheorghiade, M; Greenberg, B; Lam, CSP; Mehra, MR; Neaton, JD; Nessel, CC; Spiro, TE; van Veldhuisen, DJ; Zannad, F, 2018) |
| "Patients with heart failure are at increased risk of hyperkalemia, particularly when treated with renin-angiotensin-aldosterone system inhibitor (RAASi) agents." | ( Bakhai, A; Bennett, H; Evans, M; Furuland, H; Linde, C; McEwan, P; Palaka, E; Qin, L, 2018) |
| "Heart failure is a chronic disease requiring careful attention to self-care." | ( Bonderski, V; Chin, J; Morrow, DG; Murray, MD, 2018) |
| "The burden of heart failure is projected to increase over the next decade; it is predicted that 1 in every 33 Americans will be affected by heart failure." | ( Baliga, RR, 2018) |
| "Heart failure is a common, costly, and potentially fatal condition." | ( Gan, Y; Liu, J; Liu, L; Tian, J; Zhao, W, 2018) |
| "Heart failure is a widespread condition in the United States that is predicted to significantly increase in prevalence in the next decade." | ( Chaparro, SV; Pham, BN, 2019) |
| "Heart failure is a major public health problem with rising prevalence and accounts for a substantial number of OPD and emergency visits." | ( Chatterjee, S; Ghosh, S; Guharay, T; Gupta, S; Majumder, B; Tandel, V, 2018) |
| "Heart failure is the leading cause of combined morbidity and mortality in the USA with 50% of cases being diastolic heart failure." | ( Angulski, ABB; Cohen, H; Metzger, JM; Thompson, BR, 2019) |
| "Heart Failure is one of the major public health problems and the leading cause of hospitalisation in people older than 65 years of age." | ( Anand, J; Seetharaman, B; Sumathy, J, 2015) |
| "Heart failure is the main cause of poor outcome following open heart surgery and experimental studies have demonstrated that glucose-insulin-potassium (GIK) infusion exerts cardioprotective effects by reducing myocardial ischemia-reperfusion injuries." | ( Diaper, J; Ellenberger, C; Garofano, N; Licker, M; Reynaud, T; Sologashvili, T, 2020) |
| "The development of heart failure is accompanied by complex changes in cardiac electrophysiology and functional properties of cardiomyocytes and fibroblasts." | ( Eckardt, L; Freundt, JK; Frommeyer, G; Grotthoff, JS; Hempel, G; Jacobs, AH; Lange, PS; Schäfers, M; Spieker, T; Stypmann, J; Wötzel, F, 2019) |
| "Heart failure is the end stage of various heart diseases such as ischemic heart disease, dilated cardiomyopathy, valvular heart disease, congenital heart disease, and hypertensive myocardial damage." | ( An, J; Deng, Y; Guo, Y; Wang, J; Wu, L; Xu, J, 2019) |
| "Heart failure is a major public health issue with a current prevalence of over 23 million worldwide." | ( Chowdhury, MS; Debnath, RC; Islam, MN; Paul, GK; Shakil, SS, 2019) |
| "Heart failure is a leading cause for hospital readmission." | ( Abdelmawgoud, A; Ahmed, A; Allman, RM; Bayoumi, E; Fonarow, GC; Kanonidis, IE; Lam, PH; Malik, A; Morgan, CJ; Packer, M; Qamer, SZ; Singh, S, 2019) |
| "Heart failure is a leading cause of mortality, yet our understanding of the genetic interactions underlying this disease remains incomplete." | ( Ashley, EA; Bernstein, D; Brandimarto, J; Cappola, T; Chang, AC; Chin, ET; Connolly, A; Cordero, P; Depaoli-Roach, AA; Dewey, F; Erbilgin, A; Glazer, N; Gloudemans, MJ; Hakonarson, H; Hannenhalli, S; Huang, Y; Li, H; Li, M; Lusis, AJ; Malloy, C; Margulies, KB; Montgomery, SB; Moravec, CS; Morley, M; Parikh, VN; Pavlovic, A; Ritter, S; Shang, C; Skreen, J; Smith, KS; Tang, WHW; Waggott, D; Wheeler, MT; Zaleta, K; Zhao, M, 2019) |
| "Heart failure is an important cause of morbidity and mortality in adults with congenital heart disease (ACHD)." | ( Ewert, P; Hager, A; Maurer, SJ; Pujol Salvador, C; Schiele, S; Tutarel, O, 2020) |
| "Heart failure is associated with a major burden for patients and the health care system in terms of health care resource utilization, costs, and mortality." | ( Altevers, J; Barck, I; Braun, S; Greiner, W; Hardt, T; Jacob, C, 2019) |
| "Heart failure is a complex syndrome whose phenotypic presentation and disease progression depends on a complex network of adaptive and maladaptive responses." | ( Belenkov, YN; Brink, M; De Keulenaer, GW; Dugaucquier, L; Feyen, E; Segers, VFM; Shakeri, H; Shchendrygina, A; Vermeulen, Z, 2019) |
| "Concomitant heart failure is associated with poor clinical outcome in dialysis patients." | ( Hirata, Y; Isagawa, T; Kido, Y; Komuro, I; Manabe, I; Nakagama, Y; Okamura, K; Ono, M; Sakamoto, M; Sato, T; Soma, K; Takeda, N, 2019) |
| "Heart failure is one of the major cardiovascular complications in patients with type 2 diabetes mellitus (T2DM) and increases the risk of morbidity and mortality." | ( Iwakura, K, 2019) |
| "Acute heart failure is a common cause of hospital admission." | ( Chan, JSK; Harky, A; Kot, TKM; Ng, M, 2020) |
| "Heart failure is a class of cardiovascular diseases that remains the number one cause of death worldwide with a substantial economic burden of around $18 billion incurred by the healthcare sector in 2017 due to heart failure hospitalization and disease management." | ( Alam, S; Alawieh, H; Chemaly, TE; Khraiche, M, 2019) |
| "Heart failure is a major cause of morbidity and mortality worldwide." | ( Chen, Y; Duan, Y; Han, J; Liang, Y; Liao, C; Wang, D; Wang, Y; Xie, Z; Xu, S; Yang, X; Yu, M; Zhao, B, 2020) |
| "Iron deficiency in heart failure is common, and with improvements in diagnosis and management, it has led to a better understanding of the importance of iron deficiency in cardiac failure and function." | ( Lavoie, AJ, 2020) |
| "Early postoperative heart failure is common after cardiac surgery, and inotrope treatment may impact renal perfusion and oxygenation." | ( Bragadottir, G; Lannemyr, L; Redfors, B; Ricksten, SE, 2020) |
| "Chronic heart failure is frequently misdiagnosed in old patients with chronic peripheral oedema, and B-type natriuretic peptide plasma concentration helped to improve the diagnosis of this condition and identify chronic heart failure." | ( Belmin, J; Donadio, C; Genranmayeh, K; Jarzebowski, W; Lafuente-Lafuente, C; Valembois, L, 2020) |
| "Heart failure is a progressive and debilitating disease." | ( Hu, G; Yang, S; Zhang, J, 2020) |
| "Heart failure is often undiagnosed or misdiagnosed in this population and therefore remains untreated." | ( Homar, V; Lainscak, M; Mirosevic, S; Svab, I, 2021) |
| "Chronic heart failure is the final stage of such heart diseases as hypertension, cardiomyopathy, and myocardial infarction." | ( Sunagawa, Y, 2020) |
| "Heart failure is among the leading causes for hospitalization in Europe." | ( Burden, AM; Curkovic, I; Egbring, M; Jödicke, AM; Kullak-Ublick, GA; Neuer, T; Roos, M; Tomka, IT; Zellweger, U, 2020) |
| "Heart failure is associated with ventricular dyssynchrony and energetic inefficiency, which can be alleviated by cardiac resynchronization therapy (CRT) with approximately one-third of non-response rate." | ( Chen, X; Ge, J; Gong, X; Huang, Z; Liang, Y; Qin, S; Shao, W; Su, Y; Sun, Z; Yu, Z; Zheng, Y; Zhou, Q, 2020) |
| "Heart failure is a clinical diagnosis characterised by non-specific symptoms such as dyspnoea, fatigue and oedema." | ( O'Brien, J; O'Halloran, L, 2020) |
| "The incidence of heart failure is increasing within the Fontan population." | ( Buber, J; Dolgner, SJ; Li, S; Nguyen, VP; Steinberg, ZL, 2020) |
| "Heart failure is a common cause of death in industrialized countries with aging populations." | ( Derzsi, L; Dobrowolski, L; Gawrys-Kopczynska, M; Holyst, R; Jaworska, K; Konop, M; Kraszewska, K; Maksymiuk, K; Mogilnicka, I; Pilz, M; Samborowska, E; Sozanski, K; Ufnal, M, 2020) |
| "Heart failure is a complex clinical syndrome, represented as an impairment in ventricular filling and myocardial blood ejection." | ( McConnell, BK; Qasim, H, 2020) |
| "Heart failure is the leading cause of morbidity and mortality worldwide." | ( Ang, BT; Chai, CS; Chee, KH; Lim, MA; Ng, DL; Tan, KL; Tan, SB; Teo, WJ; Tung, YZ; Wai, SY, 2021) |
| "Heart failure is one of the most common disorders after malignant diseases." | ( Gyoda, Y; Kawauchi, J; Oikawa, Y; Sakuma, E; Watanabe, J, 2020) |
| "Heart failure is associated with increased neurohormonal activation that results in changes in body composition including volume overload and the loss of skeletal muscle, body fat, and bone density." | ( Gottlieb, SS; Hankinson, SJ; Hong, CC; Ton, VK; Williams, CH, 2020) |
| "Hyperkalemia in heart failure is a condition that can occur with relative frequency because it is related to pathophysiological aspects of the disease, and favored by drugs that form the basis of chronic cardiac failure therapy." | ( Ajello, L; Clemenza, F; Falletta, C; Gesaro, GD; Minà, C, 2020) |
| "Congestive heart failure is characterized by suppressed cardiac output and arterial filling pressure, leading to renal retention of salt and water, contributing to further volume overload." | ( Basu, S; Hallow, KM; Yu, H, 2020) |
| "Heart failure is also accompanied by an upregulation of xanthine oxidase, the enzyme that catalyzes the formation of uric acid and a purported source of reactive oxygen species." | ( Packer, M, 2020) |
| "Refractory heart failure is a major cause of mortality and hospitalization, and peritoneal dialysis (PD) is one of the options for controlling volume overload." | ( Iwaki, R; Komiya, T; Oishi, K; Takasu, Y; Toda, N, 2021) |
| "Heart failure is a fatal complication of type 2 diabetes but little is known about its incidence in people with impaired glucose tolerance (IGT)." | ( Coleman, RL; Holman, RR; McMurray, JJV; Rydén, L; Scott, CAB; Standl, E; Sun, Y; Wamil, M, 2020) |
| "Heart failure is often accompanied by titin-dependent myocardial stiffness." | ( Abeßer, M; Baba, HA; Dabral, S; Hamdani, N; Herwig, M; Kuhn, M; Michel, K; Mügge, A; Schuh, K; Skryabin, BV; Špiranec Spes, K; Werner, F, 2020) |
| "Chronic heart failure is one of the most common medical conditions, affecting more than 23 million people worldwide." | ( Benstoem, C; Brandenburg, V; Breuer, T; Heussen, N; Kalvelage, C; Marx, G; Stoppe, C, 2020) |
| "Finally, heart failure is also observed in long-duration, aging patients with type 1 diabetes, but this clinical issue has not been as extensively explored as in patients with type 2 diabetes and warrants further clinical investigation." | ( Cooper, ME; Shaw, JA, 2020) |
| "Heart failure is associated with an impaired NO-soluble guanylyl cyclase (sGC)-cGMP pathway and its augmentation is thought to be beneficial for its therapy." | ( Benkner, A; Eckstein, G; Felix, SB; Fielitz, J; Fleuch, L; Grube, K; Kaderali, L; Klingel, K; Meitinger, T; Nath, N; Rüdebusch, J, 2022) |
| "Heart failure is one of the most serious diseases worldwide." | ( Liu, L; Liu, Y; Ren, YK; Sui, YB; Zhang, KK, 2020) |
| "Heart failure is the terminal stage of many cardiovascular diseases and is considered to be closely related to oxidative stress." | ( Cao, Y; Leng, X; Li, J; Liu, P; She, M; Yan, Y; Yao, W; Zhang, S, 2021) |
| "Heart failure is a major cause of morbidity and mortality, resulting in millions of deaths and hospitalizations annually." | ( Al-Tabatabaee, S; Erley, J; Florian, A; Giusca, S; Götze, C; Katus, HA; Kelle, S; Korosoglou, G; Lapinskas, T; Montenbruck, M; Patel, AR; Pieske, B; Steen, H; Zieschang, V, 2021) |
| "In octogenarians, heart failure is associated with high rates of cardiovascular and non-cardiovascular events, and is one of the main causes of hospitalization and disability." | ( Belmin, J; Benetos, A; Chassagne, P; De Decker, L; Hanon, O; Jeandel, C; Krolak-Salmon, P; Nourhashemi, F; Paccalin, M, 2021) |
| "Heart failure is a major public health problem, and abnormal iron metabolism is common in patients with heart failure." | ( Abe, H; Asahi, M; Ito, J; Murakawa, T; Nakahara, K; Nishida, K; Omiya, S; Otsu, K; Rusu, MC; Shah, AM; Tanada, Y; Taneike, M; Ueda, H, 2021) |
| "Heart failure is a heterogeneous disease with multiple risk factors and various pathophysiological types, which makes it difficult to understand the molecular mechanisms involved." | ( Hamano, M; Iida, M; Komuro, I; Nomura, S; Yamanishi, Y, 2021) |
| "Heart failure is a complex clinical syndrome that usually presents with breathlessness, leg edema, and fatigue." | ( , 2021) |
| "Heart failure is a worldwide health condition that currently has limited noninvasive treatments." | ( Azarcon, P; Bia, R; Davis, K; Franklin, S; Hickenlooper, S; Horiuchi, E; Szulik, MW, 2021) |
| "Heart failure is a common and deadly complication in patients receiving hemodialysis and is difficult to diagnose and treat." | ( Anker, SD; Bhandari, S; Connolly, E; Farrington, K; Ford, I; Jhund, PS; Kalra, PA; MacDonald, MR; Macdougall, IC; Mark, PB; McMurray, JJV; Petrie, MC; Robertson, M; Tomson, CRV; Wheeler, DC, 2021) |
| "Patients with heart failure are likely to be frail, irrespective of their age." | ( Fujiki, S; Kashimura, T; Minamino, T; Mitsuma, W; Obata, H; Ozaki, K; Sakai, K; Shimizu, I; Suda, M; Tomii, A; Uehara, A; Watanabe, H, 2021) |
| "Heart failure is a debilitating disease process, so this finding has important policy implications in low-income countries and poor communities with less-stringent health policies because they are known to have the highest levels of exposure." | ( Skipina, TM; Soliman, EZ; Upadhya, B, 2021) |
| "Heart failure is associated with many comorbidities and among them, cancer has stood out as a contributor of death in these patients." | ( Cambrón-Mora, D; Garcia-Garduño, TC; Padilla-Gutierrez, JR; Valle, Y, 2021) |
| "Heart failure is a major cause of morbidity and mortality globally." | ( Deoker, A; Lehker, A; Mares, A; Mukherjee, D; Rodriguez, T, 2022) |
| "Heart failure is the final pathway for a wide spectrum of myocardial stress, including hypertension and myocardial infarction." | ( Funamoto, M; Hasegawa, K; Katanasaka, Y; Katayama, A; Miyazaki, Y; Morimoto, T; Nurmila, S; Shimizu, K; Shimizu, S; Sunagawa, Y, 2021) |
| "The development of heart failure is associated with fluid balance, including that of extracellular water (ECW) and intracellular water (ICW)." | ( Asai, K; Hoshika, Y; Iwasaki, YK; Kodani, E; Kubota, Y; Maruyama, M; Miyamoto, M; Miyauchi, Y; Mozawa, K; Shimizu, W; Takano, H; Tanabe, J; Tara, S; Tokita, Y; Tsukada, Y; Yamamoto, T; Yodogawa, K, 2022) |
| "Heart failure is one of the leading healthcare problems in the world." | ( Al-Sadawi, M; Ayyadurai, P; Bhandari, M; Saad, M; Shah, NN; Vittorio, TJ, 2022) |
| "Right-sided heart failure is a common consequence of pulmonary arterial hypertension." | ( Crossman, DJ; Han, JC; Howe, K; Loiselle, DS; Ross, JM, 2021) |
| "Heart failure is poorly documented in general practice records and may be contributing to untoward downstream effects, such as low documentation of echocardiography, poor use of guideline recommended therapies and frequent use of medications that may worsen HF." | ( Audehm, RG; Haikerwal, D; Liew, D; Lim, K; Neville, AM; Parsons, RW; Piazza, P; Sindone, AP, 2021) |
| "Chronic heart failure is a condition associated with ageing, affecting 1-2% of the adult population, raising to 70% of the adult population over 70 years of age." | ( Payne, D, 2021) |
| "Heart failure is a medical condition in which the heart cannot pump enough blood." | ( Rao, S, 2022) |
| "Heart failure is the end-stage phenotype of several cardiac diseases." | ( Minatoguchi, S, 2022) |
| "Chronic heart failure is a debilitating condition that accounts for an annual NHS spend of £2." | ( Beresford, L; Claxton, L; Cubbon, R; Dayer, M; Gottlieb, SS; Hartshorne-Evans, N; Kilroy, B; Llewellyn, A; Rothery, C; Sharif, S; Simmonds, M; Stewart, LA; Tierney, JF; Witte, KK; Wright, K, 2022) |
| "Heart failure is characterized by activation of the renin-angiotensin-aldosterone system, which is involved in the regulation of cardiac hypertrophy and hypertension." | ( Jeong, MH; Kee, HJ; Kee, SJ; Zhao, T, 2022) |
| "Heart failure is associated with notable morbidity and mortality, and therefore, novel therapies are needed." | ( Grimm, D; Norre, T; Simonsen, U, 2022) |
| "Heart failure is a devastating clinical syndrome, but current therapies are unable to abolish the disease burden." | ( Bomer, N; Cleland, JGF; Grote Beverborg, N; Pavez-Giani, MG; van der Meer, P; van Veldhuisen, DJ, 2022) |
| "Heart failure is often underdiagnosed and undertreated in COPD; better care could improve outcome." | ( Bourke, S; Hesse, K; Steer, J, 2022) |
| "Heart failure is an important mortality and morbidity." | ( Arslan, Ş; Genç, A; Yılmaz Öztekin, GM, 2022) |
| "Heart failure is a condition caused by a variety of pathophysiological factors." | ( Guo, S; Qian, W; Shen, L; Yang, Y; Yao, Y; Zhou, G; Zhou, J, 2022) |
| "Chronic heart failure is a major health concern affecting millions of Americans annually and remains a significant burden on the healthcare system." | ( Meier, ML; Pierce, KN, 2022) |
| "Acute decompensated heart failure is often treated with a combination of loop and thiazide-like diuretics." | ( Ahlschwede, KM; Andey, T; Ofori, E; Osei, A; Somberg, JS, 2022) |
| "Heart failure is one of the most common but complicated end-stage syndromes in clinical practice." | ( Li, WM; Liu, J; Liu, Z; Ni, J; Yin, Y; Zhang, P, 2022) |
| "Heart failure is a major contributor to morbidity and mortality in the geriatric population, with no promising therapy currently available with considerable benefit." | ( Bahurupi, Y; Bhat, NK; Dhar, M; Kalra, S; Mittal, K; Parchani, A; Sharma, M, 2022) |
| "Heart failure is a fairly common outcome of hypertension." | ( Han, X; Li, G; Liang, G; Liang, S; Long, X; Luo, W; Sun, J; Wang, M; Yu, T; Zhang, Y, 2022) |
| "Heart failure is one of the cardiovascular diseases that impacts the geriatric population." | ( Adams, J; Mosler, C, 2022) |
| "SIGNIFICANCE: Heart failure is the terminal stage of cardiac hypertrophy, which imposes an enormous clinical and economic burden worldwide." | ( Cao, JM; Gao, LJ; Liu, QH; Shen, J; Wang, DP; Wu, LF; Zhou, Y, 2022) |
| "Heart failure is a common event in the course of hypertension." | ( Li, G; Liang, G; Liang, S; Luo, W; Sun, J; Wang, M; Yu, T; Zou, C, 2022) |
| "Heart failure is a growing public health problem, especially in the elderly, often occurring due to ischemia and coronary artery disease." | ( Deng, H; Li, Q; Zhu, D, 2022) |
| "Heart failure is the leading cause of mortality, morbidity, and health care expenditures worldwide." | ( Anderson, JC; Lal, H; Singh, AP; Tallquist, MD; Tousif, S; Umbarkar, P; Woodgett, J; Zhang, Q, 2022) |
| "Heart failure is the final stage of the development of heart disease, with a high mortality and disability rate." | ( Dong, L; Feng, Y; Lin, Q; Lin, T, 2022) |
| "Acute heart failure is a syndrome defined as the new onset de novo heart failure or worsening [acutely decompensated heart failure (ADHF)] leading to symptoms and signs of HF, mostly related to systemic congestion as based on the European Society of Cardiology (ESC) definition." | ( Attri, R; Bhatia, MS; Dahiya, N; Pannu, AK; Sharda, SC, 2022) |
| "Heart failure is a worldwide health problem and is the leading cause of hospitalization in older patients." | ( Hu, T; Huang, J; Lou, Y, 2023) |
| "Heart failure is a prevalent disorder whose prognosis remains poor despite advances in treatment." | ( Ambale-Venkatesh, B; Anastos, K; Kaplan, RC; Kato, Y; Kizer, JR; Lazar, JM; Lima, JAC; Naveed, M; Qi, Q; Shitole, SG; Tien, PC; Wang, T; Wang, Z, 2023) |
| "Heart failure is currently one of the leading causes of death worldwide, and the inflammatory factors play an important role in its development." | ( Gong, T; Hou, M; Liu, Y; Wang, Y; Zhang, Y, 2022) |
| "Congestive heart failure is a serious chronic condition when the heart's muscles become too damaged and a condition in which one or both ventricles cannot pump sufficient blood to meet the metabolic needs of the body." | ( Biresaw, HB; Hussen, NM; Workie, DL, 2022) |
| "Heart failure is one of the diseases with the highest mortality in the world, and inflammation is the main cause for its occurrence and development." | ( Chen, Y; Duan, Y; Fang, M; Han, J; Li, Q; Liu, Z; Meng, H; Wang, T; Wei, L; Yang, X; Zhang, Z; Zou, T, 2022) |
| "TAC-induced chronic heart failure is associated with bone mass loss, and the sympathetic nerve plays a significant role in heart failure-related bone mass loss." | ( Fan, D; Guan, Z; Huang, J; Jia, J; Leng, H; Li, Z; Song, C; Xu, Y; Yuan, W; Zhang, C; Zhang, W; Zhu, J, 2023) |
| "Background Acute heart failure is the most frequent cause of unplanned hospital admission in elderly patients." | ( Aissani, M; Kehl, J; Pfister, O; Schöbi, D; Strahm, M; van Haelst, P; Zhang, YP; Zhou, Q, 2022) |
| "Prevalence of heart failure is increasing worldwide mainly due to the ageing of the population and the improvement in diagnosis and treatment." | ( Adamo, M; Cimino, G; Lombardi, CM; Metra, M; Pancaldi, E; Tomasoni, D, 2022) |
| "Heart failure is often accompanied by systemic inflammation, which activates hepcidin, thus impairing the duodenal absorption of iron and the release of iron from macrophages and hepatocytes, leading to a decline in circulating iron." | ( Packer, M, 2022) |
| "Heart failure is associated with profound alterations in cardiac intermediary metabolism." | ( Kuhn, AR; van Bilsen, M, 2022) |
| "Heart failure is associated with profound alterations in cardiac intermediary metabolism." | ( Kuhn, AR; van Bilsen, M, 2022) |
| "Heart failure is associated with profound alterations in cardiac intermediary metabolism." | ( Kuhn, AR; van Bilsen, M, 2022) |
| "Heart failure is associated with an increased risk of atrial fibrillation (AF), but the effects of adrenomedullin on atrial arrhythmogenesis remain unclear." | ( Chen, SA; Chen, YC; Chen, YJ; Chin, CG; Elimam, AM; Higa, S; Hsieh, MH; Lin, FJ; Lin, YK; Lu, YY, 2022) |
| "Heart failure is associated with an increased risk of atrial fibrillation (AF), but the effects of adrenomedullin on atrial arrhythmogenesis remain unclear." | ( Chen, SA; Chen, YC; Chen, YJ; Chin, CG; Elimam, AM; Higa, S; Hsieh, MH; Lin, FJ; Lin, YK; Lu, YY, 2022) |
| "Heart failure is associated with an increased risk of atrial fibrillation (AF), but the effects of adrenomedullin on atrial arrhythmogenesis remain unclear." | ( Chen, SA; Chen, YC; Chen, YJ; Chin, CG; Elimam, AM; Higa, S; Hsieh, MH; Lin, FJ; Lin, YK; Lu, YY, 2022) |
| "Mouse models of heart failure are extensively used to research human cardiovascular diseases." | ( Asfaw, TN; Bondarenko, VE, 2023) |
| "Mouse models of heart failure are extensively used to research human cardiovascular diseases." | ( Asfaw, TN; Bondarenko, VE, 2023) |
| "Heart failure is one of the major fatal diseases and mitochondrial biogenesis is an important compensatory mechanism in the process of heart failure." | ( Chen, M; Jin, J; Wang, X; Xia, G; Xu, J; Ye, Y, 2023) |
| "Heart failure is a major cause of morbidity and mortality worldwide, and can result from pressure overload, where cardiac remodelling is characterized by cardiomyocyte hypertrophy and death, fibrosis, and inflammation." | ( Andreassen, K; Apte, SS; Christensen, G; Clark, C; Dahl, CP; González, A; Heymans, S; Li, J; López, B; Louch, WE; Lunde, IG; Martin, D; Olav Melleby, A; Palmero, S; Robinson, EL; Rypdal, KB; Seifert, DE; Sjaastad, I; Stokke, MK; Tønnessen, T, 2022) |
| "Heart failure is a growing global health concern with high mortality and morbidity." | ( Ahmed, SH; Asghar, MS; Irfan, M; Jawed, S; Rahmat, ZS; Shaikh, TG; Ullah, I; Waseem, S, 2023) |
| "Acute heart failure is a frequent cause of hospital admission in Portugal, and has an increasing tendency given the aging population." | ( Araújo, I; Bonifácio, D; Branco, P; Costa, R; Fernandes, J; Fonseca, C; Guerreiro, R; Henriques, C; Rodrigues, A, 2023) |
| "Heart failure is one of the common cardiovascular diseases, and digoxin is required in the list of drug treatments." | ( Li, Q; Lu, P; Wu, G, 2022) |
| "Heart failure is characterized by episodes of congestion with need for hospitalization." | ( Meekers, E; Mullens, W, 2023) |
| "Heart failure is associated with aging." | ( Ayesta, A; Datino, T; Díez-Villanueva, P; Esteban-Fernández, A; Jimenez-Mendez, C; Martínez-Sellés, M; Pérez, Á, 2023) |
| "Doxorubicin-induced heart failure is a clinical problem that needs to be solved urgently." | ( Hu, Y; Qu, H; Zhou, H, 2023) |
| "Heart failure is one of the major causes of death worldwide and continues to increase despite therapeutics and pharmacology advances." | ( Drosatos, K; Mia, S; Mylonas, N, 2023) |
| "Heart failure is a condition with high mortality rates, and there is a lack of therapies that directly target maladaptive changes in the extracellular matrix (ECM), such as fibrosis." | ( Aronsen, JM; Bergo, KK; Carlson, CR; Christensen, G; Dahl, CP; Erusappan, PM; Espe, E; Fiane, AE; Hauge-Iversen, IM; Lunde, IG; Melleby, AO; Nordén, ES; Olsen, MB; Riise, J; Romaine, A; Sasi, A; Sjaastad, I; Tønnessen, T; Vistnes, M; Wang, CH; Zhang, L; Øgaard, J, 2023) |
| "Heart failure is a critical and ultimate phase of cardiovascular ailment that leads to a considerable incidence of disability and mortality." | ( Cao, S; Chen, J; Chen, P; Chen, Y; Deng, Q; Dong, Q; Guo, Y; Hu, B; Hu, Y; Huang, X; Jiang, R; Pan, J; Tan, T; Wang, H; Wang, Y; Zhou, Q; Zhou, Y, 2023) |
| "Once a diagnosis of heart failure is established, several treatments can be beneficial, from diuretics to relieve congestion to various aspects of guideline-directed medical therapy, some of which vary according to the ejection fraction of the patient." | ( Arnold, SV, 2023) |
| "Heart failure is a severe condition that is associated with a high risk of complications." | ( Casado-Cerrada, J; Ceresuela-Eito, LM; Dávila-Ramos, MF; Escobar-Cervantes, C; Formiga, F; González-Franco, A; Montero-Pérez-Barquero, M; Muela-Molinero, A; Pérez-Silvestre, J; Quesada-Simón, MA; Suárez-Pedreira, I, 2023) |
| "Heart failure is a leading cause of morbidity and mortality worldwide, which is closely related to enhanced oxidative stress and inflammation." | ( Chen, Y; Duan, Y; Fang, M; Li, Q; Liu, Z; Meng, H; Meng, X; Wang, T; Yang, X; Zhang, Z; Zou, T, 2023) |
| "Heart failure is a leading cause of mortality in developed countries." | ( Akazawa, Y; Aoki, J; Arita, M; Hioki, A; Ikeda, K; Kitazume-Taneike, R; Mine, K; Murakawa, T; Nishida, H; Nishida, K; Oka, T; Omi, J; Omiya, S; Otsu, K; Sakata, Y; Sugihara, R; Tamai, T; Taneike, M; Ueda, H; Yamaguchi, O, 2023) |
| "Heart failure is the leading cardiovascular comorbidity in chronic kidney disease (CKD) patients." | ( Dong, Z; Ge, J; Liu, B; Liu, L; Luo, W; Pei, Z; Qu, Y; Shalamu, A; Song, S; Wei, Z; Weng, X, 2023) |
| "Heart failure is a major side effect of doxorubicin (DOX) treatment in patients with cancer." | ( Angelini, A; D'Ambrosio, L; Di Bona, A; Fedrigo, M; Forte, M; Frati, G; Frati, L; Ghigo, A; Mangione, E; Marchitti, S; Miglietta, S; Petrozza, V; Relucenti, M; Rubattu, S; Sadoshima, J; Sarto, G; Schiavon, S; Schirone, L; Sciarretta, S; Stanzione, R; Valenti, V; Vecchio, D; Versaci, F; Volpe, M; Zaglia, T, 2023) |
| "Heart failure is the main causes of morbidity and mortality." | ( Alcalai, R; Arad, M; Guetta, T; Hochhauser, E; Kornowski, R; Ofek, E; Petrover, Z; Seidman, CE; Seidman, J; Yadin, D, 2023) |
| "Right heart failure is the leading cause of death in pulmonary hypertension (PH), and echocardiography is a commonly used tool for evaluating the risk hierarchy of PH." | ( Chen, Y; Du, M; Feng, H; Fu, X; Hong, W; Jiang, Q; Kuang, M; Lai, N; Li, X; Lin, Z; Liu, S; Lu, W; Wang, J; Wen, D; Xing, Y; Yang, K; Yang, Q; Zhao, T; Zhou, D, 2023) |
| "Heart failure is a clinical syndrome that requires frequent rehospitalization and has a high mortality." | ( Atici, A; Barman, HA; Dogan, O; Dogan, SM; Ebeoglu, AO; Enar, R; Ikitimur, B; Mirzayev, K; Ozyıldırım, S; Yumuk, MT, 2023) |
| "Heart failure is a significant disease, and its high readmission rate is a big concern." | ( Fujimori, K; Fushimi, K; Miyazaki, D; Tarasawa, K, 2023) |
| "Heart failure is a chronic progressive condition, with considerable burden on patients' quality of life and economic burden for the healthcare systems." | ( Bellanca, L; Gaultney, J; Groyer, H; Kolovos, S; Linden, S; Rosano, GMC; Solé, A, 2023) |
| "Heart failure is a serious global health challenge, affecting more than 6." | ( Bahlouli, L; Dridi, H; Marks, AR; Miotto, MC; Santulli, G; Weninger, G, 2023) |
| "Heart Failure is a leading cause of mortality among older adults." | ( de la Colina, AN; Kaushal, N; Mann-Krzisnik, D; Nemati, D, 2023) |
| "Chronic heart failure is the end stage of heart diseases caused by multiple causes." | ( Hu, SY; Hu, ZX; Lian, K; Wang, F, 2023) |
| "Heart failure is a complex clinical syndrome with a detrimental impact on mortality and morbidity." | ( Goliopoulou, A; Kalogeras, K; Katsarou, O; Katsioupa, M; Kourampi, I; Marinos, G; Oikonomou, E; Siasos, G; Theofilis, P; Tousoulis, D; Tsatsaragkou, A; Tsigkou, V; Vavuranakis, M, 2023) |
| "Acute heart failure is a leading cause of hospitalisations with an increasing economic and public health burden." | ( Carballo, D; Carballo, S; Darbellay Farhoumand, P; Jolti, M, 2023) |
| "Heart failure is an increasing public health issue with substantial morbidity and mortality rates." | ( Alibaşiç, H; Aydin, S; Çiçek, M; Ekici, B; Koçak, A, 2023) |
| "Heart failure is caused by acute or chronic cardiovascular diseases with limited treatments and unclear pathogenesis." | ( Qi, P; Zhai, Q; Zhang, X, 2023) |
| Excerpt | Reference |
|---|
| "Vasodilative treatment of severe heart failure with infusions of phentolamine leads to ventricular unloading and in many cases brings about a dramatic improvement of the patient's condition." | ( Imhof, P, 1977) |
| "In untreated rats, heart failure increased (P < ." | ( Deck, CC; Gaballa, MA; Goldman, S; Raya, TE, 1992) |
| "After treatment for the heart failure plasma atrial natriuretic peptide fell considerably and there were associated increases in plasma aldosterone and plasma renin activity." | ( Adesanya, CO; Anjorin, FI; MacGregor, GA; Parry, EH; Sada, IA; Sagnella, GA, 1991) |
| "Digoxin is commonly used to treat congestive heart failure." | ( Coletta, D; Forman, DE; Kenny, D; Kosowsky, BD; Pastore, JO; Rohrer, M; Stoukides, J, 1991) |
| "The first attempts at treating heart failure with beta-blockers were made almost 15 years ago." | ( Grosgogeat, Y; Komajda, M; Lechat, P; Salloum, J, 1990) |
| "Patients receiving conventional treatment for heart failure were randomly assigned to receive either placebo (n = 1284) or enalapril (n = 1285) at doses of 2." | ( Cohn, JN; Davis, CE; Hood, WB; Pitt, B; Yusuf, S, 1991) |
| "The ideal treatment of heart failure would include a drug acting on its cause, another drug to restore a degree of contraction and relaxation adjusted to the amount of load, a third drug bringing back to normal a perturbed peripheral circulation and a fourth drug to relieve the symptoms due to sodium retention." | ( Castaigne, A; Dubois-Randé, JL; Dutoit, C; Duval-Moulin, AM; Merlet, P; Perchet, H; Saal, JP, 1990) |
| "Apparent diuretic resistance in the treatment of heart failure is usually caused by iatrogenic vascular compromise or by the use of a single diuretic rather than an appropriate combination." | ( Gross, P; Hensen, J; Ketteler, M; Schömig, A; Wichmann, A, 1989) |
| "Chronic treatment of heart failure patients with beta-adrenoceptor antagonists leads to an up-regulation of cardiac beta-adrenoceptors, but in a subtype-selective fashion: beta 1-selective antagonists increase only cardiac beta 1-adrenoceptors, whereas non-selective antagonists increase both beta 1- and beta 2-adrenoceptors." | ( Borst, HG; Brodde, OE; Maier, W; Michel, MC; Zerkowski, HR, 1989) |
| "Alifedrine may have a place in the treatment of heart failure as an oral by active, positive inotropic agent." | ( Anand, IS; Hughes, LO; Raftery, EB; Whittington, JR, 1989) |
| "Conventional treatment for heart failure, including the use of other vasodilators, was continued in both groups." | ( , 1987) |
| "In nine patients with severe, treatment-resistant heart failure (stages IV in the NYHA classification) the acute and long-term effect of captopril were studied." | ( Esser, H; Heck, I; Kikis, D; Stumpe, KO, 1985) |
| "Efficacy in treating congestive heart failure and hypertension secondary to renal artery stenosis has also been demonstrated for both angiotensin converting enzyme inhibitors." | ( Cleary, JD; Taylor, JW, 1986) |
| "The use of digoxin in the treatment of heart failure is now indicated almost solely for the control of a fast heart rate in patients with atrial fibrillation." | ( Poole-Wilson, PA, 1988) |
| "Though originally designed for treating heart failure, diuretics are more commonly prescribed, worldwide, in hypertension than for relief of oedema." | ( Lant, A, 1986) |
| "The main approaches to treating heart failure are reviewed against the same framework of reference." | ( Henderson, AH, 1983) |
| "The evaluation of the long-term treatment of heart failure is complicated by many biological, clinical and technical problems." | ( Storstein, L; Taylor, SH, 1983) |
| "The use of digoxin in the treatment of mild heart failure is questionable since the drug has serious side-effects and the efficacy in patients already taking diuretics has not been established." | ( Poole-Wilson, PA, 1984) |
| "The history of the treatment of heart failure may be divided into three stages, the consequences of different conceptions of the physiopathology of the disease, with diuretics to counteract salt and water retention, vasodilators to improve conditions of cardiac load, angiotensin converting enzyme inhibitors to limit the effect of neurotumoral and sympathetic activation." | ( Lanfranchi, J, 1995) |
| "The potential benefits of treating heart failure patients with an angiotensin II receptor antagonist instead of or in addition to an ACE-inhibitor are discussed." | ( Chang, PI; Pitt, B, 1994) |
| "For many years the pharmacological treatment of heart failure patients was based on the increase in inotropism through the digitalis and on the reduction in sodium-water retention through diuretics, while less importance was given to the improvement of the afterload." | ( Dessì-Fulgheri, P; Paci, MV; Rappelli, A, 1994) |
| "Thus pharmacological treatment of heart failure should be aimed not only at improving systemic haemodynamics but also at reversing neurohumoral activation and baroreflex impairment." | ( Grassi, G; Mancia, G, 1994) |
| "This review of the pharmacologic treatment of heart failure due to left ventricular systolic dysfunction summarizes the recommendations of the expert panel for the Agency for Health Care Policy and Research Heart Failure Guideline." | ( Baker, DW; Bottorff, M; Konstam, MA; Pitt, B, 1994) |
| "This agent holds great promise for the treatment of heart failure patients." | ( Eichhorn, EJ, 1993) |
| "Patients requiring treatment for heart failure were entered to the treatment trial (n = 2,569) while those patients not receiving pharmacological treatment for heart failure were entered in the prevention trial (n = 4,228)." | ( Yusuf, S, 1993) |
| "Twenty-two patients with chronic treated heart failure (12 with secondary pulmonary hypertension, Group I; 10 with normal pulmonary artery pressure, Group II) and 8 control patients constituted the study groups." | ( Bagley, CW; Cycan, A; Fields, J; Mohanty, PK; Pandian, NG; Porter, TR; Taylor, DO, 1993) |
| "In patients treated for heart failure during the acute phase of myocardial infarction, the lowest 18-month event rate was seen in the verapamil group (21." | ( Jespersen, CM, 1993) |
| "Integral to optimal treatment of heart failure is maximization of both pharmacologic and nonpharmacologic therapy." | ( Moser, DK, 1996) |
| "In untreated congestive heart failure, aldosterone plasma concentrations are elevated in proportion to the severity of the disease and are further increased by the use of diuretic treatment." | ( Zannad, F, 1995) |
| "However, long-term medical treatment of severe heart failure is only palliative." | ( Felix, SB, 1996) |
| "It is still unclear how treatment of heart failure influences the relationship between hemodynamic parameters and plasma levels of N-terminal proANF." | ( Dickstein, K; Hall, C; Klinge, R; Polis, A, 1997) |
| "The use of nitrates for treatment of heart failure is encumbered by tolerance, caused by whatever mechanism, which has been reported only in a few instances with sydnonimines." | ( Beyerle, A; Hähnel, I; Lampen, M; Lehmann, G; Reiniger, G; Schömig, A, 1998) |
| "Although the treatment of heart failure has traditionally focused on drugs to improve ventricular function, there is increasing evidence that therapeutic modulation of neurohumoral activation is a key to successful treatment of heart failure." | ( Mark, AL; Middlekauff, HR, 1998) |
| "To compare digoxin and enalapril in the treatment of heart failure due to mitral insufficiency." | ( Díaz, M; Eggers, G; Gamboa, C; Garcés, E; Lanas, F; Montecinos, A; Stockins, B, 1998) |
| "After treatment of right heart failure cardiac catheterization indicated moderate precapillary pulmonary hypertension (PH) with a mean pulmonary artery pressure (PAPm) of 24 mm Hg and pulmonary vascular resistance (PVR) of 470 dyn." | ( Halank, M; Höffken, G; Horstkotte, D; Poller, W; Schwimmbeck, P; Tschöpe, C; Wiemer, M, 1998) |
| "Positive inotropic agents are used to treat severe heart failure due to myocarditis." | ( Matsumori, A; Nishio, R; Ono, K; Sasayama, S; Shioi, T; Wang, W; Yamada, T, 1998) |
| "Endocardial cells from amiodarone-treated heart failure patients displayed longer (p < 0." | ( Charpentier, F; Drouin, E; Lande, G, 1998) |
| "In chronically treated heart failure patients with full angiotensin-converting enzyme-inhibition and diuretics, there is decreased compliance of the aorta and its major branches, which is inversely correlated with the aldosterone escape phenomenon." | ( Clement, DL; Cohn, JN; De Buyzere, ML; Duprez, DA; Morgan, D; Rietzschel, ER; Taes, Y, 1998) |
| "Clinicians should no longer attempt to treat chronic heart failure with pharmacologic growth and remodeling process." | ( Eichhorn, EJ, 1998) |
| "When digitoxin is used in the treatment of heart failure in the very elderly patients, one should be aware of the possibility of digitoxin intoxication, even at a low dose." | ( Bøhmer, T; Røseth, A, 1999) |
| "Enalapril is a cost-effective treatment in heart failure that would be expected to yield considerable cost savings in this therapeutic area." | ( Bryson, HM; Goa, KL; Wilde, MI, 1994) |
| "Adding ramipril to conventional treatment for heart failure after acute myocardial infarction is therefore cost effective, and compares favourably with the cost effectiveness of other common medical therapies in the cardiovascular field." | ( Andersson, F; Ball, S; Bergentoft, P; Erhardt, L; Martinez, C, 1997) |
| "Carvedilol's place in the treatment of heart failure is not yet precisely documented." | ( , 1999) |
| "The effectiveness of this drug in the treatment of heart failure occurring immediately after extracorporeal circulation (ECC) in cardiac surgery was investigated." | ( Akamatsu, T; Hirata, T; Horinokuchi, N; Kuro, M; Uchida, O, 1999) |
| "In patients undergoing intensive treatment for heart failure, ARD is common and clinically significant." | ( Chertow, GM; Stevenson, LW; Weinfeld, MS, 1999) |
| "The aims of the treatment of heart failure are to improve the quality of life and slow the progression of cardiac disease." | ( Cohn, JN, 1999) |
| "Other drugs may be helpful in the treatment of heart failure." | ( Parmley, WW, 2000) |
| "The medical treatment of heart failure has improved significantly in the last decade, yet despite the reduction of morbidity and mortality, heart attacks and stroke cause 15 million deaths each year." | ( Schwartz, A, 1999) |
| "Coenzyme Q10 is commonly used to treat congestive heart failure on the basis of data from several unblinded, subjective studies." | ( Alexander, BS; Fisher, ML; Freudenberger, R; Gottlieb, SS; Khatta, M; Krichten, CM; Robinson, SW, 2000) |
| "N-BNP-guided treatment of heart failure reduced total cardiovascular events, and delayed time to first event compared with intensive clinically guided treatment." | ( Espiner, EA; Frampton, CM; Nicholls, MG; Richards, AM; Troughton, RW; Yandle, TG, 2000) |
| "However, the principal trials about the treatment of heart failure were mainly addressed to patients with significant left ventricular systolic dysfunction, whereas the optimal therapy for diastolic dysfunction is not well known." | ( di Lenarda, A; Pinamonti, B; Sinagra, G, 2000) |
| "New developments in the drug treatment of heart failure include the possible addition of beta-blockers or spironolactone to diuretic and ACE inhibitor therapy." | ( , 2000) |
| "Drugs for the treatment of heart failure can be classified as follows: 1." | ( Just, H, 2000) |
| "Diuretics remain the mainstay in treating congestive heart failure." | ( Fidelman, Z; Korshun, Z, 2000) |
| "Although digoxin has been used to treat heart failure for more than 200 years, its role in patients with congestive heart failure and sinus rhythm is still debatable." | ( Haji, SA; Movahed, A, 2000) |
| "The ATLAS Study showed that the treatment of heart failure with high-doses of lisinopril has a high probability of being more cost-effective than low-dose therapy." | ( Armstrong, PW; Cleland, J; Drummond, M; Horowitz, JD; Massie, BM; Poole, L; Poole-Wilson, PA; Ryden, L; Sculpher, MJ, 2000) |
| "Recommendations for the treatment of heart failure were carried out by a systematic review of the available evidence of the different pharmacologic treatments." | ( Agustí Escasany, A; Arnau De Bolós, JM; Casas Rodríguez, J; Diogène Fadini, E; Durán Dalmau, M; Galve Basilio, E; Manito Lorite, N; Rodríguez Cumplido, D, 2001) |
| "The drug treatment of heart failure, once simple, has become complex." | ( Lainchbury, JG; Nicholls, MG; Richards, AM; Troughton, RW; Yandle, TG, 2001) |
| "In patients requiring treatment for heart failure, if possible, aspirin should be avoided and the integrity of prostaglandin metabolism respected; the severer the heart failure the more compelling." | ( Hall, D, 2001) |
| "This may be advantageous for the treatment of heart failure patients." | ( Brixius, K; Reicke, S; Schwinger, RH, 2002) |
| "The therapeutic mechanism of LJP in treating heart failure might be related with the lowering of angiotensin II in cardial tissue and plasma so as to reduce the left ventricular hypertrophy." | ( Cai, H; Dong, Y; Hu, W, 2000) |
| "For most patients, treating heart failure involves correcting underlying left ventricular dysfunction, thereby slowing the remodeling process." | ( Basile, JN, 2002) |
| "Advances in the treatment of heart failure may require manipulation of neurohumoral responses to cardiac impairment in addition to the established strategy of angiotensin-converting enzyme (ACE) inhibition." | ( Charles, CJ; Cooper, GJ; Coy, DH; Espiner, EA; Lewis, LK; Nicholls, MG; Rademaker, MT; Richards, AM, 2002) |
| "Among patients admitted for treatment of heart failure, we aimed to evaluate the value of B-type natriuretic peptide levels in predicting subsequent death or hospital readmission." | ( Azevedo, A; Bettencourt, P; Ferreira, A; Ferreira, S, 2002) |
| "Although a cornerstone in the treatment of heart failure, angiotensin-converting enzyme inhibitors are under-used, partly due to side effects." | ( Gordon, A; Helmers, C; Löfdahl, P; Pantev, E; Rydberg, E; Willenheimer, R, 2002) |
| "The utilization of b-blockers for the treatment of heart failure in the United States is inadequate despite the available data and the current guidelines that support their use." | ( Gattis, WA; Gheorghiade, M; O'Connor, CM, 2002) |
| "Nesiritide has beneficial actions for treatment of heart failure, including arterial and venous dilatation, enhanced sodium and urinary excretion, and suppression of the renin-angiotensin-aldosterone and sympathetic nervous systems." | ( Racine, E; Tran, A; Vichiendilokkul, A, 2003) |
| "The current treatment for heart failure, i." | ( Barnay, P; Gelisse, R; Levy, S; Maixent, JM; Paganelli, F; Saadjian, A; Sbragia, P, 2000) |
| "Valsartan was recently approved to treat heart failure in patients who cannot be maintained on an ACE inhibitor." | ( Manohar, P; Piña, IL, 2003) |
| "To assess pharmacological treatment of heart failure, in relation to the available evidence, it is important to take severity into account." | ( Haaijer-Ruskamp, FM; Kragten, HJ; Lok, DJ; Pont, LG; van Gilst, WH, 2003) |
| "To evaluate the impact of new medical treatments for heart failure between 1990 and 1998." | ( Bouvy, ML; Heerdink, ER; Hoes, AW; Leufkens, HG, 2003) |
| "Digoxin may be initiated after emergent treatment of heart failure has been completed in an effort to establish a long-term treatment strategy." | ( Dec, GW, 2003) |
| "During the course of treatment of heart failure patients, cardiotonic agents are inevitable for improvement of myocardial dysfunction." | ( Endoh, M, 2003) |
| "Levosimendan is a new agent for the treatment of acute heart failure." | ( Erhardt, L; Mebazaa, A, 2003) |
| "We report the successful treatment of severe heart failure in two patients with beta-thalassemia major with the combined therapy." | ( Chang, JS; Peng, CT; Tsai, CH; Wu, KH, 2004) |
| "The use of PPAR-gamma agonists in the treatment of heart failure is, however, controversial." | ( Thiemermann, C, 2004) |
| "Their role in the treatment of heart failure has not been studied." | ( Böhm, M; Heeschen, C; Laufs, U; Nickenig, G; Schackmann, S; Wassmann, S, 2004) |
| "Guidelines for the pharmacological treatment of heart failure (HF) are based on results from large clinical trials demonstrating benefit." | ( Bettencourt, P, 2004) |
| "The standard treatment for right heart failure includes aggressive fluid resuscitation, inotropic agents, and avoiding drugs, such as diuretics or nitrates, or maneuvers that decrease pre-load." | ( Flaker, G; Govindarajan, G; Reddy, HK; Wasson, S, 2004) |
| "Beneficial effects of anti-aldosterone treatment in heart failure may thus be secondary in part to blockade of cardiac aldosterone action." | ( Ambroisine, ML; Bendall, JK; Delcayre, C; Fuchs, S; Garnier, A; Heymes, C; Milliez, P; Nehme, J; Robidel, E; Swynghedauw, B, 2004) |
| "The use of beta-blockers for the treatment of heart failure in the United States is inadequate, despite available data and current guidelines that support their use." | ( Gattis, WA; O'Connor, CM, 2004) |
| "beta-blockers (BB) in the treatment of heart failure (HF) are frequently underprescribed and underdosed, perhaps because of recommendations for office visits at each dose change." | ( Mischke, L; Moyer-Knox, D; Mueller, TM; Vuckovic, K; Williams, RE, 2004) |
| "To compare patients treated for heart failure in relation to the management in general practices versus hospital admission." | ( Blue, L; Cowburn, P; Dargie, H; McDonagh, T; Nielsen, OW; Robb, SD, 2004) |
| "In addition, BNP-guided treatment of heart failure may reduce total cardiovascular events, and delayed time to first event combination with intensive clinically guided treatment." | ( Horie, M; Tsutamoto, T, 2004) |
| "Digoxin has been used to treat congestive heart failure (CHF) for more than two centuries." | ( Song, S; Wang, L, 2005) |
| "In the Resynchronisation Hemodynamic Treatment for Heart Failure Management (RHYTHM-ICD) study, patients randomised to cardiac resynchronisation therapy (CRT) showed an improvement in symptoms and functional capacity compared to the control group." | ( Clark, AL; Cleland, JG; Coletta, AP; Ingle, L; Lalukota, K, 2004) |
| "Digoxin is used to treat congestive heart failure and atrial fibrillation." | ( Aomar Millán, I; Carrillo Santos, JC; Puche Cañas, E, 2004) |
| "Because treatments for heart failure have changed since the benefits of spironolactone were reported, the prevalence of these complications may differ in current clinical practice." | ( Aaronson, KD; Koelling, TM; Tamirisa, KP, 2004) |
| "Eplerenone compared with placebo in the treatment of heart failure after acute myocardial infarction is effective in reducing mortality and is cost-effective in increasing years of life by commonly used criteria." | ( Caro, J; Goldberg, R; Ishak, J; Kolm, P; Mahoney, EM; Pitt, B; Spertus, JA; Tooley, J; Weintraub, WS; Willke, R; Zhang, Z, 2005) |
| "Medical treatment of heart failure is associated with 50% survival at 5 years." | ( Chachques, JC; Monnet, E, 2005) |
| "Costs for the treatment for heart failure within the National Health Service (NHS) in the United Kingdom (UK) were applied to resource utilisation data prospectively collected in all patients randomized into the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study." | ( Coats, AJ; Hebborn, A; McMurray, JJ; Packer, M; Stewart, S, 2005) |
| "The potential use of the combination treatment in heart failure might result in a synergistic effect through the different cardioprotective mechanisms of celiprolol and candesartan." | ( Hayashi, T; Kitaura, Y; Matsumura, Y; Mori, T; Ohkita, M; Okuda, N; Shimomura, H; Sohmiya, K; Yoshikawa, J; Yoshiyama, M, 2005) |
| "NCX is an attractive target for the treatment of heart failure and ischemia-reperfusion." | ( Kakefuda, A; Kuramochi, T; Sakamoto, S; Taguchi, T; Tsukamoto, I; Yamada, H, 2005) |
| "In the past, pharmacological treatment of heart failure was aimed only at relieving edema and improving hemodynamics." | ( Czuriga, I, 2005) |
| "In the treatment of heart failure, the effects of therapeutic agents on life prognosis remains unclear." | ( Lee, JD; Shimizu, H; Takeuchi, M; Ueda, T, 2006) |
| "It could thus prove useful in the treatment of heart failure: in fact it is the only drug that has been proven able to lower O2 consumption of dysfunctioning myocardium." | ( Abate, L; Biagi, P, 2005) |
| "Patients not responding to conventional treatment of heart failure received interferon beta1b (group C) or prednisolone (group B)." | ( Bienek-Ziolkowski, M; Hoher, M; Hombach, V; Kaya, Z; Kochs, M; Lepper, PM; Torzewski, J; Zimmermann, O; Zwaka, TP, 2005) |
| "There are important unmet needs in the treatment of acute heart failure syndromes (AHFS)." | ( Barraud, D; Mebazaa, A; Welschbillig, S, 2005) |
| "Patients are well treated for heart failure with 90% on loop or thiazide diuretics, 42% aldosterone antagonists, 91% ACE inhibitor or AT-I blocker, 75% beta-blockers, and 32% digitalis." | ( Blideskog, M; Dunselman, P; Eskilson, C; Hjalmarson, A; Kjekshus, J; McMurray, JV; Waagstein, F; Wedel, H; Wessman, P; Wikstrand, J, 2005) |
| "When digitoxin is used in the treatment for heart failure in the very elderly patients, one should be aware of the possibility of digitoxin intoxication, even on a low dose." | ( Bohmer, T; Røseth, A, 1998) |
| "The decision to use an agent to treat anemia in heart failure should be made on a case-by-case basis." | ( Abraham, WT; Iyengar, S, 2005) |
| "Patients with untreated heart failure (HF) exhibit a blunted hemodynamic and neuroendocrine response to a high sodium intake, leading to excessive sodium and water retention." | ( Bie, P; Christensen, NJ; Damgaard, M; Friberg, L; Gadsbøll, N; Gustafsson, F; Kanters, JK; Norsk, P, 2006) |
| "In the treatment of acute heart failure, rapidly working sublingual nitrates should be given first and foremost." | ( Goudswaard, AN; Rutten, FH; van Lieshout, J; Walma, EP; Wiersma, T, 2005) |
| "Concomitant treatment for heart failure and calcium supplementation was initiated." | ( Aessopos, A; Deftereos, S; Farmakis, D; Korovesis, K; Tsironi, M, 2004) |
| "Traditional medical treatment of acute heart failure has remained unchanged for many years." | ( Atar, D; Hodt, A; Steine, K, 2006) |
| "For perioperative treatment of acute heart failure, levosimendan, nesiritide and L-NAME constitute promising alternatives to conventional inotropic and vasodilatory drugs." | ( Böttiger, BW; Motsch, J; Rauch, H, 2006) |
| "The therapies developed to treat heart failure over the years have resulted in a significant improvement in clinical outcome." | ( McKelvie, RS, 2006) |
| "Thirteen metoprolol-treated heart failure patients were randomized to a 2-way crossover study of equal daily doses of metoprolol IR and metoprolol XL, each administered for 3 weeks." | ( Aquilante, CL; Binkley, PF; Hatton, PS; Johnson, JA; Pauly, DF; Schofield, RS; Terra, SG, 2006) |
| "Digoxin therapy has long been used to treat heart failure; however, its effectiveness was not completely known until recently." | ( Hatcher, HF; Morris, SA; Reddy, DK, 2006) |
| "Digoxin has been the cornerstone of the treatment of heart failure for more than 2 centuries." | ( Dickinson, MG; Pervaiz, MH; Yamani, M, 2006) |
| "Positive inotropes used for the treatment of heart failure have been arrhythmogenic." | ( Flevari, P; Kourea, K; Kremastinos, DT; Leftheriotis, D; Panou, F; Parissis, JT, 2006) |
| "Food and Drug Administration (FDA) for treating heart failure in black patients." | ( Bibbins-Domingo, K; Fernandez, A, 2007) |
| "Despite extensive research and novel treatments, chronic heart failure (CHF) remains a cause of high morbidity and mortality." | ( Gong, KZ; Kelso, EJ; Song, G; Spiers, JP; Zhang, ZG, 2007) |
| "This paper concerns the medical treatment of heart failure according to the recommendations of the European Society of Cardiology." | ( Schüpfer, CA, 2007) |
| "HO-1 and Bcl-2 protein levels in untreated heart failure rat's gastrocnemious muscle were reduced when compared with controls: 3." | ( Bertipaglia, L; Calò, LA; Corradini, R; Dalla Libera, L; Davis, PA; Naso, A; Pagnin, E; Piccoli, A; Savica, V; Spinello, M, 2008) |
| "When used in optimal doses to treat patients with heart failure, renin-angiotensin-aldosterone system (RAAS) inhibitors improve clinical outcomes but can cause hyperkalemia." | ( Desai, AS; Dunlap, ME; Granger, CB; Hainer, JW; McMurray, JJ; Michelson, EL; Olofsson, B; Pfeffer, MA; Solomon, SD; Swedberg, K; Young, JB; Yusuf, S, 2007) |
| "This study suggests that treating heart failure patients with ACE inhibitors may result in zinc deficiency." | ( Arroyo, M; Corbatón, A; González-Estecha, M; Lopez-Colón, JL; Olivan, P; Prats, P; Sánchez, JA; Trasobares, E, 2007) |
| "Thus, strategies for the treatment of heart failure have focused on agents that block the RAS." | ( Deswal, A; Mann, DL; Ramasubbu, K, 2007) |
| "Awareness and optimized treatment of heart failure and COPD may reduce the clinical burden of these patients." | ( Anand, IS; Barlera, S; Carretta, E; Cohn, JN; Latini, R; Maggioni, AP; Masson, S; Staszewsky, L; Tognoni, G; Wong, M, 2007) |
| "Several therapies commonly used for the treatment of acute heart failure syndromes (AHFS) present some well-known limitations and have been associated with an early increase in the risk of death." | ( Böhm, M; De Luca, L; Dickstein, K; El-Banayosy, A; Filippatos, G; Gheorghiade, M; Mebazaa, A; Nieminen, M; Parissis, JT; Rhodes, A; Voors, AA; Zannad, F, 2008) |
| "The URGENT study demonstrated that treatment of acute heart failure with standard therapy, including intravenous diuretics and nitrates, leads to a rapid resolution of breathlessness in the sitting position but that orthopnoea often persists." | ( Clark, AL; Cleland, JG; Coletta, AP; Cullington, D, 2008) |
| "In ARB-treated heart failure, venous responses to bradykinin are preserved but arterial responses are reduced compared with healthy controls." | ( Campbell, R; Frenneaux, M; Gunaruwan, P; Maher, A; Schmitt, M; Sharman, J; Williams, L, 2009) |
| "Its properties holds promise for the treatment of heart failure but further large-scale studies will be needed to determine its precise efficacy, safety, as well as the compound's long-term impact on mortality." | ( Economides, C; Kota, B; Prasad, AS; Singh, BN, 2008) |
| "After treatment of heart failure and calcium-vitamin D supplementation, signs and symptoms of heart failure improved rapidly." | ( Güngör, H; Nalbantgil, S; Ozerkan, F; Zoghi, M, 2009) |
| "Successful treatment of heart failure is demonstrated in a rat model of transaortic banding by RNAi targeting of phospholamban, a key regulator of cardiac Ca(2+) homeostasis." | ( Bisping, E; Chemaly, E; Chen, J; Erdmann, V; Fechner, H; Hadri, L; Hajjar, RJ; Kawase, Y; Kockskämper, J; Krohn, S; Kurreck, J; Lebeche, D; Liang, L; Ly, H; Pieske, B; Poller, WC; Schultheiss, HP; Sipo, I; Suckau, L; Tschope, C; Vetter, R; Wang, X; Weger, S; Westermann, D, 2009) |
| "Approaches for treatment of acute heart failure and heart failure with preserved ejection fraction are supported by little clinical evidence." | ( Abraham, WT; Krum, H, 2009) |
| "She received standard treatment for heart failure, including a beta-blocker, an angiotensin-converting enzyme inhibitor, and diuretics." | ( Jarkowski, A; Wong, MK, 2009) |
| "It may be an ideal drug for the treatment of acute heart failure syndromes and warrants further investigation in large clinical trials." | ( Filippatos, GS; Gheorghiade, M; Harinstein, ME, 2009) |
| "Standard treatment for heart failure consists of a diuretic, an ACE inhibitor (or angiotensin-receptor blocker if the ACE inhibitor is not well tolerated), a ss-blocker, and low-dose digoxin (if needed)." | ( Eichhorn, EJ, 2002) |
| "Vitamin D3 might serve as an adjunctive treatment for heart failure patients." | ( Garakyaraghi, M; Kerdegari, M; Siavash, M, 2010) |
| "Beta-blocker treatment of stable heart failure in primary care." | ( Barroso, A; Bernáldez, MJ; Domingo, M; Domíngueza, M; Pie, M; Sancho, F; Simó, M; Verdú Rotellar, JM, 2009) |
| "Drugs used for the treatment of heart failure were withheld at least 24 hours before the study." | ( Lage, SG; Lagudis, S; Mansur, AJ; Medeiros, CC; Vieira, ML; Yamada, AT, 2009) |
| "The patient had been treated for chronic heart failure and prescribed 100 mg/day of acetylsalicylic acid (aspirin) for its antiplatelet effect." | ( Ishihara, S; Iwano, S; Naganawa, S; Nakashima, T; Sone, M, 2009) |
| "Evidence-based treatment for heart failure (HF) comprises beta-blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone receptor antagonists (ARA)." | ( Celebi, O; Dietz, R; Habedank, D; Knaus, T; Krebs, A; Nitardy, A; Rauchhaus, M; Stockburger, M, 2011) |
| "Beta-blockers are mainstay of current treatment of heart failure (HF)." | ( Bettari, L; Bugatti, S; Covolo, L; Dei Cas, L; Donato, F; Gelatti, U; Giubbini, R; Lombardi, C; Metra, M; Pezzali, N; Romeo, A; Zacà, V, 2010) |
| "With aggressive treatment of the heart failure and hyperthyroid state, her dyspnea, pleural effusion, chylous ascites, and edema resolved completely within a few days." | ( Chang, CT; Chen, CC; Hsieh, MH; Wang, TY, 2010) |
| "Digoxin therapy is used to treat heart failure patients for more than 200 years." | ( Juillière, Y; Selton-Suty, C, 2010) |
| "Thus, ACE inhibitor treatment of heart failure symptoms in patients with a systemic right ventricle is safe and reduces NT-proBNP levels significantly as a marker for ventricular overload." | ( Bertram, H; Meyer, GP; Schieffer, B; Tutarel, O; Wessel, A; Westhoff-Bleck, M, 2012) |
| "Unlike the treatment of heart failure in adults, for which an extensive body of literature supports current treatment regimens, management of heart failure in children is largely guided by extrapolation from adult studies and expert opinion." | ( O'Connor, MJ; Rosenthal, DN; Shaddy, RE, 2010) |
| "It does not show promise in the treatment of acute heart failure with renal dysfunction." | ( Bloomfield, DM; Cleland, JG; Cotter, G; DeLucca, P; Dittrich, HC; Givertz, MM; Mansoor, GA; Massie, BM; Metra, M; O'Connor, CM; Ponikowski, P; Salerno, CM; Teerlink, JR; Voors, A; Weatherley, BD, 2010) |
| "Short-term ATV treatment in heart failure (HF) patients reduces oxidative stress and improves FDD and functional capacity." | ( Alcaino, H; Castro, PF; Chiong, M; Gabrielli, LA; Garcia, L; Godoy, I; Greig, D; Lavandero, S; López, R; Mellado, R; Navarro, M; Nogerol, C; Tapia, F; Verdejo, HE, 2011) |
| "The patient was started on treatment for acute heart failure based on the physical examination and the elevated brain natriuretic peptide level." | ( Bangalore, S; Grosu, H; Jean, R; Kumar, S; Kumari, R, 2012) |
| "The heart transplant is a treatment of the heart failure, which is not responding to medications." | ( Arpesella, G; Bombardini, T; Gherardi, S; La Falce, S; Picano, E, 2011) |
| "My focus is on the treatment of heart failure in patients with a low left ventricular ejection fraction." | ( McMurray, JJ, 2011) |
| "Among studies conducted on the treatment of heart failure, those based on the growth hormone axis are of particular interest." | ( Bakır, F; Berker, D; Cetin, M; Çetin, ZG; Ciçekçioğlu, H; Güler, S; Işık, S; Ozuğuz, U; Uçar, O, 2011) |
| "Loop diuretics are recommended to treat congestion in heart failure (HF), despite limited quality evidence." | ( Follath, F; Gayat, E; Laribi, S; Lassus, J; Mebazaa, A; Nikolaou, M; Parissis, J; Peacock, WF; Salem, R; Yilmaz, MB, 2011) |
| "Diuretic treatment for heart failure may lead to an increased urinary thiamine excretion and in long-term thiamine deficiency, which may further compromise cardiac function." | ( der Maur, CA; Erne, P; Schoenenberger, AW; Schoenenberger-Berzins, R; Suter, PM; Vergopoulos, A, 2012) |
| "On the contrary, established treatments of heart failure, including β-blockers, renin-angiotensin system antagonists, and aldosterone-receptor blockers seem able to act by modulating cytokine expression, suggesting a new role for these molecules in guiding heart failure therapy." | ( Basile, E; Bellocci, F; Cialdella, P; Giglio, AF; Gustapane, M; Narducci, ML; Pazzano, V; Pedicino, D; Pelargonio, G; Santangeli, P; Vitulano, N, 2013) |
| "With respect to medical therapies for treating right heart failure, there is evidence for the use of both nitric oxide and the phosphodiesterase type 5 inhibitor sildenafil in carefully selected patients with secondary pulmonary hypertension who undergo implantation of LVADs." | ( MacGowan, GA; Schueler, S, 2012) |
| "This compound may be promising for the treatment of heart failure of various etiologies." | ( Fujiwara, H; Fujiwara, T; Goto, K; Kanamori, H; Kawaguchi, T; Kawasaki, M; Maruyama, R; Minatoguchi, S; Morishita, K; Nikami, H; Ogino, A; Takemura, G; Takeyama, T; Tsujimoto, A; Ushikoshi, H; Watanabe, T; Yamada, K, 2012) |
| "Tolvaptan is potentially useful for treatment of heart failure patients with fluid overload who are refractory to conventional diuretic therapies." | ( Abe, H; Hasumi, E; Hirata, Y; Inajima, T; Iwata, H; Kinugawa, K; Nagai, R; Nishimura, G; Semba, H; Shiga, T; Takeda, N; Terada, Y; Uchino, Y; Yonenaga, A, 2012) |
| "β-blockers are an important treatment of heart failure (HF) and are useful in reducing the progression of the syndrome." | ( Francis, GS; Sarraf, M, 2012) |
| "Finally, new therapies for the treatment of heart failure complications, such as pulmonary hypertension and anemia, are discussed." | ( Aronson, D; Krum, H, 2012) |
| "While recent guidelines for the treatment of acute heart failure syndromes (AHFS) recommend pharmacotherapy with vasodilators in patients without excessively low blood pressure (BP), few reports have compared the relative efficiency of vasodilators on hemodynamics in AHFS patients." | ( Arashi, H; Hagiwara, N; Hattori, H; Higashitani, M; Hoshi, H; Minami, Y; Mizuno, M; Mori, F; Nuki, T; Sashida, Y; Serizawa, N; Shiga, T; Yamada, N; Yamaguchi, J; Yumino, D, 2013) |
| "Among patients undergoing treatment for heart failure, we observed positive associations between temperature and both BNP and CRP-predictors of heart failure prognosis and severity." | ( Davis, RB; Mittleman, MA; Phillips, RS; Wellenius, GA; Wilker, EH; Yeh, G, 2012) |
| "Underutilization of these treatments in heart failure patients were frequently reported, which could lead to increase morbidity and mortality." | ( Jung, SY; Kim, HJ; Kim, JY; Kim, KI; Lee, JY; Park, BJ; Seong, JM; Song, HJ, 2012) |
| "Many studies concerning treatment of acute heart failure are ongoing." | ( Nellessen, E; Piérard, L, 2012) |
| "Patients diagnosed with and treated for Acute Heart Failure Syndromes were prospectively enrolled in the Decision Making in Acute Decompensated Heart Failure multicenter trial." | ( Christenson, R; Collins, SP; Fermann, GJ; Hart, K; Lindsell, CJ; Maron, DJ; McPherson, JA; Miller, KF; Naftilan, AJ; Roll, S; Sawyer, DB; Sperling, M; Storrow, AB; Weintraub, NL, 2012) |
| "Our data showed that ISO treatment led to heart failure in OVX rats." | ( Hao, Y; Kang, S; Li, D; Liu, A; Liu, Y; Sun, D; Sun, H; Xu, C; Yan, C; Zhou, C, 2012) |
| "Novel compounds for the treatment of acute heart failure are clearly needed and fall into the general categories of inotropic, vasodilatory and other compounds in phase I to III of development." | ( Ezekowitz, JA, 2013) |
| "The effect of beta-blockers in treating Japanese heart failure (HF) patients with preserved left ventricular (LV) ejection fraction (EF) is unclear." | ( Hiramatsu, K; Kobayashi, F; Mori, Y; Nishikawa, Y, 2013) |
| "Previous studies have treated anemia in heart failure patients with either erythropoietin alone or combination of erythropoietin and intravenous (i." | ( Beck-da-Silva, L; Bocchi, E; Clausell, N; de Albuquerque, D; Montera, MW; Moura, LZ; Pereira-Barretto, AC; Piardi, D; Rassi, S; Rohde, LE; Soder, S; Vilas-Boas, F, 2013) |
| "Despite major advances in the treatment of heart failure (HF), it remains the major cause of mortality and morbidity worldwide." | ( Chuo, W; Guo, S; Han, J; Li, C; Li, D; Liu, Z; Ouyang, Y; Wang, W; Wang, Y; Wu, Y, 2013) |
| "The base of treatment of heart failure is the blockade of the neuro-hormonal system, which includes the use of angiotensin converting enzyme inhibitors (angiotensin receptor blockers in case of angiotensin converting enzyme inhibitors intolerance), beta receptor blockers and mineralocorticoid receptor antagonists." | ( Nagy, V, 2013) |
| "Optimizing treatment of heart failure by monitoring natriuretic peptides, including management of diuretic doses, remains matter of controversies." | ( Berry, M; Delmas, C; Fournier, P; Galinier, M, 2013) |
| "Natriuretic peptide-guided (NP-guided) treatment of heart failure has been tested against standard clinically guided care in multiple studies, but findings have been limited by study size." | ( Berger, R; Brunner-La Rocca, HP; Dahlström, U; Erntell, H; Eurlings, LW; Frampton, CM; Gaggin, HK; Januzzi, JL; Karlström, P; Moertl, D; Nicholls, MG; O'Connor, CM; Persson, H; Pfisterer, M; Pinto, YM; Richards, AM; Troughton, RW, 2014) |
| "Natriuretic peptide-guided treatment of heart failure reduces all-cause mortality in patients aged <75 years and overall reduces heart failure and cardiovascular hospitalization." | ( Berger, R; Brunner-La Rocca, HP; Dahlström, U; Erntell, H; Eurlings, LW; Frampton, CM; Gaggin, HK; Januzzi, JL; Karlström, P; Moertl, D; Nicholls, MG; O'Connor, CM; Persson, H; Pfisterer, M; Pinto, YM; Richards, AM; Troughton, RW, 2014) |
| "Although treatment of acute heart failure is based primarily on the administration of intravenous loop diuretics, evidence supporting this practice is still scarce and there is uncertainty about the optimal dose." | ( Formiga, F; Morales-Rull, JL; Trullàs, JC, 2014) |
| "The efficacy of tolvaptan for treating heart failure has already been shown." | ( Amaha, M; Matsumura, D; Nakamura, T; Nomura, M; Ono, Y; Sato, E; Ueda, Y; Yamagishi, H, 2014) |
| "Efforts are underway to treat heart failure by enhancing myofilament sensitivity to Ca(2+); transfer of the gene for SERCA2a, the protein that pumps calcium into the sarcoplasmic reticulum of the cardiomyocyte, seems promising in a phase 2 trial." | ( Braunwald, E, 2015) |
| "Improved treatments for heart failure patients will require the development of novel therapeutic strategies that target basal disease mechanisms." | ( Frisk, M; Louch, WE; Roe, AT, 2015) |
| "We are developing a novel treatment for heart failure by increasing myocardial 2 deoxy-ATP (dATP)." | ( Cheng, Y; Moussavi-Harami, F; Racca, AW; Razumova, MV; Regnier, M; Stempien-Otero, A, 2015) |
| "However, evidence-based data on treating heart failure in the acute setting are limited, and current individual treatment options have variable efficacy." | ( Maisel, AS; Storrow, AB; Teichman, SL, 2015) |
| "Digoxin is the oldest known treatment for heart failure (HF) and has been demonstrated to reduce admissions for worsening heart failure in a large randomized trial recruiting patients in sinus rhythm with heart failure and ejection fraction <45%." | ( Chaggar, PS; Shaw, SM; Williams, SG, 2015) |
| "It has been used to treat heart failure for over a thousand years." | ( Wei, H; Wu, H; Yan, X; Yu, W; Zhang, X, 2015) |
| "Early spironolactone treatment decreases heart failure development frequency by improving myocardial systolic and diastolic function and attenuating hypertrophy and fibrosis in spontaneously hypertensive rats." | ( Blotta, DA; Bonomo, C; Campos, DH; Cezar, MD; Cicogna, AC; Damatto, RL; Gomes, MJ; Lima, AR; Martinez, PF; Okoshi, K; Okoshi, MP; Oliveira, SA; Pagan, LU; Rosa, CM, 2015) |
| "Despite initial in-hospital treatment of acute heart failure (HF), some patients experience worsening HF (WHF)." | ( Armstrong, PW; Califf, RM; Ezekowitz, JA; Felker, GM; Hasselblad, V; Hernandez, AF; Kelly, JP; Mentz, RJ; O'Connor, CM; Zannad, F, 2015) |
| "There is no effective medical treatment for heart failure with preserved ejection fraction (HFpEF)." | ( Borlaug, BA; Koepp, KE; Melenovsky, V, 2015) |
| "Besides conventional treatment of heart failure, targeted therapies such as pharmacological prolactin blockade are under evaluation." | ( Bouabdallaoui, N; Demondion, P; Ennezat, PV; Le Jemtel, TH; Lebreton, G; Mouquet, F, 2017) |
| "Loop diuretics used in the treatment of heart failure often induce renal impairment." | ( Hasegawa, T; Ikeda, U; Izawa, A; Kimura, K; Misawa, T; Momose, T; Morita, T; Motoki, H, 2016) |
| "They are also beneficial for the treatment of heart failure, primarily due to effects in non-epithelial tissues." | ( Yang, J; Young, MJ, 2016) |
| "Digoxin is widely used as symptomatic treatment in heart failure (HF), but the role in contemporary treatment of HF with sinus rhythm (SR) is debatable." | ( Gislason, G; Gustafsson, F; Køber, L; Madelaire, C; Nelveg-Kristensen, KE; Schmiegelow, M; Schou, M; Torp-Pedersen, C, 2016) |
| "Given the increasing use of LVADs to treat end-stage heart failure, these issues are likely to become more frequently encountered in the future." | ( Chaggar, PS; Javed, W; Shaw, SM; Venkateswaran, R, 2016) |
| "For example, its use in the possible treatment of heart failure has received recent attention due to its unique therapeutic properties." | ( Bartberger, MD; Bianco, CL; Fukuto, JM; Toscano, JP, 2017) |
| "Incorporating to the treatment of heart failure drugs such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers has meant a great step forward in the treatment of patients with this condition that significantly has decreased mortality and morbidity." | ( Hernández García, S; Rivas Estany, E, 2016) |
| "This article also discusses treatment of heart failure with use of cardiac resynchronization therapy, implantable cardioverter-defibrillators, and surgical therapy, and management of end-stage heart failure." | ( Aronow, WS, 2016) |
| "Therefore, the NO-cGMP pathway is a treatment target in heart failure." | ( Breitenstein, S; Lewis, KS; Roessig, L; Sandner, P, 2017) |
| "GGF2 is now being developed for the treatment of heart failure in humans." | ( Button, DC; Caggiano, AO; Ganguly, A; Hackett, CS; Iaci, JF; Luis Guerrero, J; Parry, TJ; Sawyer, DB; Srinivas, M; Troy, EL; Vecchione, AM; Zolty, R, 2017) |
| "Thus, symptomatic treatment of heart failure requires significant improvement." | ( Bakuła, E; Balsam, P; Cacko, A; Filipiak, KJ; Fojt, A; Grabowski, M; Główczyńska, R; Huczek, Z; Kowalik, R; Markulis, M; Opolski, G; Ozierański, K; Peller, M; Sieradzki, B; Tymińska, A, 2017) |
| "Effective treatments in heart failure (HF) patients with ischemic etiology have not been fully established." | ( Kobayashi, A; Oikawa, M; Sato, T; Sato, Y; Suzuki, S; Takeishi, Y; Watanabe, S; Yokokawa, T; Yoshihisa, A, 2017) |
| "Less intensive treatment for heart failure with reduced ejection fraction (HFrEF) may be appropriate for patients in long-term care settings because of limited life expectancy, frailty, comorbidities, and emphasis on quality of life." | ( Adegbala, OM; Albright, KC; Blackburn, J; Brown, TM; Chen, L; Durant, RW; Kilgore, ML; Levitan, EB; Olubowale, O; Rhodes, JD; Safford, MM; Van Dyke, MK, 2017) |
| "After treating his heart failure, he was able to leave the intensive care unit." | ( Hirota, Y; Iwasaka, J; Kita, H; Maeba, H; Ohkita, A; Senoo, T; Tanaka, M; Uchitani, K, 2018) |
| "After providing supportive treatment, the heart failure symptoms disappeared and her anemia had improved." | ( Dodo, Y; Goto, Y; Gotoh, H; Inagaki, M; Kiuchi, Y; Nakamura, Y; Namba, H; Ohsawa, I; Tsuji, M, 2018) |
| "Clinical treatment of heart failure is still suffering from limited efficacy and unfavorable side effects." | ( Almassy, J; Gaburjakova, M; Komaromi, I; Nanasi, P, 2018) |
| "We started anti-thyroid agents and a treatment for heart failure with beta blockers and diuretics under anti-coagulation therapy." | ( Isogai, H; Kakihara, M; Kaneko, T; Kasuya, H; Kishida, C; Koyano, H; Miyazaki, T; Naito, R; Nakazato, Y; Odagiri, F; Ozaki, D; Shimai, R; Tokano, T; Yabe, K; Yasuda, Y; Yokoyama, K, 2018) |
| "There are no approved drugs for the treatment of heart failure with preserved ejection fraction (HFpEF), which is characterized by left ventricular (LV) diastolic dysfunction." | ( Ambardekar, AV; Cavasin, MA; Demos-Davies, KM; Dinarello, CA; Granzier, HL; Jeong, MY; Lin, YH; Mahaffey, JH; Mascagni, P; McKinsey, TA; Monzani, V; Reece, TB; Saripalli, C; Wennersten, SA, 2018) |
| "Carperitide is used to treat acute heart failure (AHF) in Japan." | ( Hata, R; Kadota, K; Katoh, H; Kawase, Y; Tada, T, 2018) |
| "As established treatments for heart failure with reduced ejection fraction (HFrEF) have proven ineffective for HFpEF, the contention that the intrinsic cardiomyocyte phenotype is distinct in these 2 conditions requires consideration." | ( Bell, JR; Chandramouli, C; Charchar, FJ; Crossman, DJ; Curl, CL; Danes, VR; Delbridge, LMD; Edgley, AJ; Erickson, JR; Harding, TW; Harrap, SB; Ip, WTK; Kalman, JM; Kompa, AR; Mellor, KM; Porrello, ER; Raaijmakers, AJA; Soeller, C, 2018) |
| "Pharmacological treatment for heart failure involves different drugs as: angiotensin-converting enzyme inhibitors, B-adrenergic blockers, digitalis glycosides and diuretics." | ( Baez, A; Bazán, C; Camino Willhuber, GO; Fretes, R; Guzman Mentesana, G; Lo Presti, S; Paglini-Oliva, PA; Rivarola, HW; Strauss, M, 2017) |
| "In 32 treated heart failure patients aged 69." | ( Cuspidi, C; Dell'Oro, R; Facchetti, R; Grassi, G; Gronda, E; Mancia, G; Quarti-Trevano, F; Seravalle, G; Spaziani, D, 2019) |
| "There are few effective treatments for heart failure with preserved ejection fraction (HFpEF)." | ( Anstrom, KJ; Borlaug, BA; Braunwald, E; Chen, HH; Davila-Roman, VG; Desvigne-Nickens, P; Felker, GM; Givertz, MM; Hernandez, AF; Koepp, GA; Levine, JA; LeWinter, MM; Lewis, GD; Mann, DL; Margulies, KB; McNulty, S; Redfield, MM; Shah, SJ; Smith, AL; Tang, WHW; Whellan, DJ, 2018) |
| "This could be an effective strategy for treating heart failure through regulation of mitochondrial dynamics." | ( Iwasa, M; Kanamori, H; Kawaguchi, T; Kawasaki, M; Mikami, A; Minatoguchi, S; Naruse, G; Nishigaki, K; Yamada, Y; Yoshida, A, 2019) |
| "To date, there is no established treatment for heart failure with preserved ejection fraction (HFpEF)." | ( Asakura, M; Asanuma, H; Fu, HY; Fukuda, H; Hitsumoto, T; Imazu, M; Ito, S; Kitakaze, M; Min, KD; Nakajima, Y; Shindo, K; Takahama, H; Yamazaki, S, 2019) |
| "Chronic ISO treatment led to heart failure (HF) characterized by significant reduction of systolic blood pressure (SBP) accompanied by an increase in left ventricular weight (LVW) along with increased collagen content in the LV." | ( Adamcova, M; Aziriova, S; Baka, T; Dolezelova, E; Karesova, I; Krajcirovicova, K; Repova, K; Simko, F; Stanko, P, 2019) |
| "Advances in the treatment of heart failure with reduced ejection fraction due to systolic dysfunction are engaging an ever-expanding compendium of molecular signaling targets." | ( Hahn, VS; Kass, DA; Pinilla-Vera, M, 2019) |
| "Background The treatment of heart failure with reduced ejection fraction has been the subject of numerous randomized controlled trials involving medications and cardiac implantable electronic device therapies." | ( Almader-Douglas, D; Amin, M; Asirvatham, SJ; Cha, YM; Friedman, PA; Gersh, BJ; Killu, AM; Kunze, KL; Lee, JZ; Madhavan, M; Mulpuru, SK; Neville, MR; Tseng, AS, 2019) |
| "Sacubitril/valsartan is an established treatment for heart failure with reduced ejection fraction due to acquired cardiovascular disease." | ( Ewert, P; Hager, A; Maurer, SJ; Pujol Salvador, C; Schiele, S; Tutarel, O, 2020) |
| "Diuretics are a cornerstone in treatment of heart failure (HF)." | ( Al-Habbaa, A; Eid, PS; Elkady, AH; Elsayed, GG; Elshafay, A; Hirayama, K; Huy, NT; Kien, ND; Minh, LHN; Mohammed, AT; Morra, ME; Nghia, TLB; Sherif, NA; Thanh, LV; Turk, T; Y, MN, 2020) |
| "180 patients who have been treated for chronic heart failure were selected as research objects and divided into control group and research group." | ( Li, X; Qu, W; Yu, Z, 2019) |
| "Oxygen therapy remains a cornerstone of treatment for acute heart failure in patients with pulmonary congestion." | ( Aissaoui, N; Augy, JL; Bailleul, C; Danchin, N; Diehl, JL; Guerot, E; Nael, J; Ortuno, S; Puymirat, E; Ruggiu, M; Vimpère, D, 2019) |
| "The efficacy of liraglutide to treat heart failure remains controversial." | ( Chen, Q; Huang, G; Wang, L; Zhang, Y, 2019) |
| "In recent years, new medications for treating chronic heart failure have been clinically applied, but there is controversy surrounding drug selection and whether patients with HFrEF benefit from these medications." | ( Chen, B; Duan, Y; Li, H; Lu, L; Su, W; Wang, S; Wu, J; Zhao, Y, 2020) |
| "Sacubitril/Valsartan is a treatment for heart failure with reduced ejection fraction (HFrEF) which has a spectacular effect on the reduction of cardiovascular events (major adverse cardiovascular events [MACEs])." | ( Bidaut, A; Bouali, Y; Donal, E; Gallard, A; Galli, E; Hubert, A; Laurin, C; Leclercq, C, 2020) |
| "MRAs are a recognized treatment for heart failure and hypertension." | ( Mohammadpour, AH; Omidkhoda, N; Sahebkar, A; Sathyapalan, T; Vakilian, F, 2020) |
| "TMAO-treated rats with heart failure had lower blood pressure and urinated more than untreated rats with the condition." | ( Derzsi, L; Dobrowolski, L; Gawrys-Kopczynska, M; Holyst, R; Jaworska, K; Konop, M; Kraszewska, K; Maksymiuk, K; Mogilnicka, I; Pilz, M; Samborowska, E; Sozanski, K; Ufnal, M, 2020) |
| "Among the analysed 3288, doxorubicin-treated patients, heart failure cumulative incidence was 6." | ( Fogarassy, G; Fogarassyné Vathy, Á; Forster, T; Hornyák, L; Kenessey, I; Kováts, T; Polgár, C; Veress, G, 2020) |
| "Standard treatment for heart failure includes pharmacotherapy and cardiac device implants." | ( Ang, BT; Chai, CS; Chee, KH; Lim, MA; Ng, DL; Tan, KL; Tan, SB; Teo, WJ; Tung, YZ; Wai, SY, 2021) |
| "Although bisoprolol is used widely to treat patients with heart failure (HF), little information is available regarding the association between the dose of bisoprolol administered and the bisoprolol plasma concentration (Bis-PC) in real-world clinical practice." | ( Arita, T; Kano, H; Kato, Y; Matsuno, S; Nagashima, K; Oikawa, Y; Otsuka, T; Sagara, K; Semba, H; Suzuki, S; Tanabe, G; Uejima, T; Yagi, N; Yajima, J; Yamashita, T, 2020) |
| "It is recommended for the treatment of heart failure reduced ejection fraction in the presence of beta-blocker therapy for the further reduction of the heart rate." | ( Beak, YS; Choi, SH; Jang, JH; Kim, DH; Ko, KY; Kwan, J; Kwon, SW; Lee, MJ; Park, JH; Park, SD; Shin, SH; Woo, SI; Yoon, GS, 2020) |
| "PD was started to treat refractory heart failure." | ( Iwaki, R; Komiya, T; Oishi, K; Takasu, Y; Toda, N, 2021) |
| "Sacubitril/valsartan is an effective treatment for heart failure with reduced ejection fraction (HFrEF) based on clinical trial data." | ( Elsayed, H; Ganesananthan, S; Morgan, A; Parkes, A; Phillips, J; Shah, N; Shah, P; Yousef, Z, 2020) |
| "The use of MSS may be promising for the treatment of heart failure in patients with CHF and AF." | ( Amanatova, VA; Grishin, IR; Nazarov, BM; Nikolaeva, OA; Safiullina, AA; Sapel'nikov, OV; Tereshchenko, SN; Uskach, TM, 2020) |
| "Despite the progress in the treatment of heart failure with reduced ejection fraction (HFrEF), the prognosis remains unfavorable." | ( Lelonek, M; Nowakowska, I; Pawlak, A; Rubiś, P; Wiśniowska-Śmiałek, S, 2021) |
| "Shenfu injection has advantages in the treatment of heart failure in patients with coronary heart disease, but there is a lack of standard clinical study to verify this." | ( Gao, Y; Tan, X; Zhu, R, 2021) |
| "Although recommended for the treatment of acute heart failure (AHF), the use of intravenous (IV) nitroglycerin (NTG) is supported by scarce and contradicting evidence." | ( Alquézar-Arbé, A; Cotter, G; Davison, B; Freund, Y; Gil, V; Herrero-Puente, P; Jacob, J; Jiménez-Fábrega, FX; Llorens, P; Martín-Sánchez, FJ; Masip, J; Mebazaa, A; Miró, Ò; Rosselló, X; Takagi, K, 2021) |
| "Intravenous morphine is a controversial treatment for acute heart failure (AHF)." | ( Chen, Q; Chen, Y; Dong, S; Lin, Y; Liu, H; Pang, X; Yuan, J, 2021) |
| "Despite the progress made in the treatment of heart failure with reduced ejection fraction (HFrEF) in recent years, the prognosis of the disease remains poor, with ventricular arrhythmias (VA) contributing significantly to increased mortality." | ( Giannakoulas, G; Kotsa, K; Koufakis, T; Zebekakis, P, 2022) |
| "Despite the availability of established treatments, heart failure (HF) is associated with a poor prognosis and its management is suboptimal, highlighting the need for new options for treatment and prevention." | ( Rao, S, 2022) |
| "That is why new drugs are needed to treat and prevent heart failure." | ( Rao, S, 2022) |
| "New strategies to treat or prevent heart failure are urgently needed." | ( Bomer, N; Cleland, JGF; Grote Beverborg, N; Pavez-Giani, MG; van der Meer, P; van Veldhuisen, DJ, 2022) |
| "Despite considerable advances in the treatment of heart failure with reduced ejection fraction (HFrEF) over the last 60 years, mortality and morbidity remains high." | ( Hellenkamp, K; Nolte, K; von Haehling, S, 2022) |
| "In recent years, with improvements in treatments for heart failure (HF), the survival period of patients has been extended." | ( Hui, N; Liang, C; Liu, J; Ren, X; Tian, L; Wang, J; Wang, K; Xia, J; Xie, X; Zhang, J, 2022) |
| "Despite advances in its treatment, heart failure remains a major cause of morbidity and mortality, evidencing an urgent need for novel mechanism-based targets and strategies." | ( Aluja, D; Barrabés, JA; Delgado-Tomás, S; Inserte, J; Ruiz-Meana, M, 2022) |
| "Current treatments for heart failure with reduced ejection fraction, defined by an LVEF of less than 40%, involve a variety of agents with established morbidity and mortality benefits." | ( Meier, ML; Pierce, KN, 2022) |
| "After treatment for heart failure, a significant reduction was found in PDW (average value before treatment: 14." | ( Asagai, S; Harada, G; Inai, K; Sato, M; Shimada, E, 2022) |
| "In the treatment of heart failure with reduced ejection fraction (with or without diabetes), dapagliflozin and empagliflozin have been recommended by cardiologists since 2021 to prevent hospitalizations for heart failure and to reduce mortality with the strongest class and level of evidence." | ( Prázný, M, 2022) |
| "The efficacy of nitrite therapy for the treatment of heart failure remains controversial." | ( Xu, H; Zhang, Q; Zhou, Q, 2022) |
| "Sacubitril/valsartan has changed the treatment of heart failure with reduced ejection fraction (HFrEF), due to the positive effects on morbidity and mortality, partly mediated by left ventricular (LV) reverse remodelling (LVRR)." | ( Benfari, G; Brunetti, ND; Cameli, M; Canepa, M; Carluccio, E; Ciccarelli, M; Cicoira, M; Citro, R; Corrado, E; Correale, M; De Carli, G; Degiovanni, A; Dini, FL; Emdin, M; Giannoni, A; Guaricci, AI; Loria, V; Malagoli, A; Mandoli, GE; Mazzeo, P; Mengoni, A; Moderato, L; Novo, G; Pasquini, A; Pastore, MC; Patti, G; Piscitelli, L; Pugliese, NR; Rosa, G; Santoro, C; Taddei, C, 2023) |
| "Sacubitril/valsartan has changed the treatment of heart failure with reduced ejection fraction (HFrEF), due to the positive effects on morbidity and mortality, partly mediated by left ventricular (LV) reverse remodelling (LVRR)." | ( Benfari, G; Brunetti, ND; Cameli, M; Canepa, M; Carluccio, E; Ciccarelli, M; Cicoira, M; Citro, R; Corrado, E; Correale, M; De Carli, G; Degiovanni, A; Dini, FL; Emdin, M; Giannoni, A; Guaricci, AI; Loria, V; Malagoli, A; Mandoli, GE; Mazzeo, P; Mengoni, A; Moderato, L; Novo, G; Pasquini, A; Pastore, MC; Patti, G; Piscitelli, L; Pugliese, NR; Rosa, G; Santoro, C; Taddei, C, 2023) |
| "Despite advances in the treatment of heart failure in recent years, options for patients are still limited and the disease is associated with considerable morbidity and mortality." | ( Andreevski, AL; Anlauf, S; Bogner, P; Dieskau, AP; Dreher, J; Eitner, F; Fliegner, D; Follmann, M; Gericke, KM; Maassen, S; Meibom, D; Meyer, J; Micus, S; Schlemmer, KH; Steuber, H; Tersteegen, A; von Buehler, CJ; Wunder, F, 2022) |
| "Despite advances in the treatment of heart failure in recent years, options for patients are still limited and the disease is associated with considerable morbidity and mortality." | ( Andreevski, AL; Anlauf, S; Bogner, P; Dieskau, AP; Dreher, J; Eitner, F; Fliegner, D; Follmann, M; Gericke, KM; Maassen, S; Meibom, D; Meyer, J; Micus, S; Schlemmer, KH; Steuber, H; Tersteegen, A; von Buehler, CJ; Wunder, F, 2022) |
| "With modern treatments for heart failure with reduced ejection fraction (EF), indicative of impaired cardiac systolic function, patients may exhibit an increase in EF." | ( Chiang, CE; Claggett, B; Comin-Colet, J; de Boer, RA; DeMets, D; Desai, AS; Drozdz, J; Fang, JC; Hernandez, AF; Inzucchi, SE; Jhund, PS; Kitakaze, M; Kosiborod, MN; Lam, CSP; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; O'Meara, E; Petersson, M; Solomon, SD; Vaduganathan, M; Vardeny, O; Zieroth, S, 2022) |
| "With modern treatments for heart failure with reduced ejection fraction (EF), indicative of impaired cardiac systolic function, patients may exhibit an increase in EF." | ( Chiang, CE; Claggett, B; Comin-Colet, J; de Boer, RA; DeMets, D; Desai, AS; Drozdz, J; Fang, JC; Hernandez, AF; Inzucchi, SE; Jhund, PS; Kitakaze, M; Kosiborod, MN; Lam, CSP; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; O'Meara, E; Petersson, M; Solomon, SD; Vaduganathan, M; Vardeny, O; Zieroth, S, 2022) |
| "Vericiguat is approved for treating worsening heart failure with reduced ejection fraction." | ( Aliprantis, AO; Becker, C; Besche, N; Böttcher, M; Coenen, M; Corcea, V; Donath, F; Düngen, HD; Fuhr, R; Gal, P; Maschke, C; Mikus, G; Pires, PV; Trenk, D, 2023) |
| "It is suitable for the treatment of acute heart failure (HF) and acute cardiac insufficiency after cardiac surgery." | ( Fu, Y; Pan, Y; Wang, X; Zhang, H, 2023) |
| "Preventing or treating heart failure (HF) by blocking cardiomyocyte apoptosis is an effective strategy that improves survival and reduces ventricular remodelling and dysfunction in the chronic stage." | ( Bian, M; Jiang, M; Li, Y; Lian, N; Meng, Q; Tong, J; Zhu, W, 2023) |
| "Current drugs for treating heart failure (HF), for example, angiotensin II receptor blockers and β-blockers, possess specific target molecules involved in the regulation of the cardiac circulatory system." | ( Duangrat, R; Kurose, H; Mangmool, S; Parichatikanond, W, 2023) |
| "Using SGLT2i to treat heart failure is cost-effective, with more certainty in LVEF ≤ 40% compared to LVEF > 40%." | ( Kan, YM; Ong, SC; Tan, YJ, 2023) |
| "The burden from medication costs for treating heart failure can be financially toxic for uninsured/underinsured patients and their families." | ( Dong, A; Hauptman, PJ; Heidel, RE; Pleines, KM; Wheeler, JS, 2023) |